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blood. Figure from [22]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
4.1 Maturity scheme for mathematical model. Stem cells are the most immature
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4.2 Proliferation and death rates of di!erentiating cells depend on cell ma-
turity. The functional forms presented in Equations 4.6 are plotted versus cell
maturity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
4.3 The generation of hierarchical tissue from stem cells. (A) A log plot of
stem (blue) and non-stem (red) cells in the tissue versus time. Starting at stem-
cell homeostasis, the stem-cell population remains constant over time, while the
non-stem cell population expands until it reaches homeostasis. (B) The maturity
distribution of non-stem cells at steady state demonstrates the majority of cells are
fully mature. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
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4.4 Schematic diagram of mutation acquisition in hierarchical tissues. Stem
cells with zero, one, two, or three mutations may self-renew or di!erentiate to form
progenitors, which in turn continue dividing and maturing. Each time cells divide,
there is a small probability they will acquire a mutation. Cells can accumulate up
to three mutations, at which point they are classified as cancer cells. . . . . . . . . 57
4.5 Genetic instability determines the fastest path when all mutations are
advantageous. (A) Cancer stem cells for each pathway versus time. The order
in which genetic instability is acquired has the greatest influence on determining
tumor growth. Pathways in which G is acquired first are the fastest, while those
that acquire G last are slowest. (B) Cancer non-stem cells reflect the behavior of
cancer stem cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.6 The emergence of cancer is slowed when all mutations are not advanta-
geous. The emergence of cancer is delayed in pathways in which the D mutation
is not acquired first. Case A is plotted with dashed lines while case B is plotted
with solid lines. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
4.7 Comparison of tissue composition for fastest paths when all mutations
are advantageous versus when some are lethal. (A) The changing tissue
composition in the GDR pathway, fastest for Case A in which all mutations are
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4.9 Progenitor and di!erentiated cells accumulate due to extra progenitor
divisions. (A) The total non-stem cell population for each pathway. The DRG
pathway generates hypercellularity the fastest. However, most of these cells only
have 2 mutations. (B) The percentage of progenitor and di!erentiated cells that
have one mutation. DGR is the only pathway dominated by cells with one mutation.
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over time. Tissues following the DRG and RDG pathways are mainly composed
of cells with both the D and R mutations. (D) The percentage of progenitor and
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5.1 Growth dynamics of GFP+ cells in 7F2 and OP9. (A) GFP+ and GFP-
cells in 7F2 versus time. (B) Asymmetric division is favored in 7F2. (C) GFP+
and GFP- cells in OP9 versus time. (D) Symmetric self-renewal is favored in OP9. 92
5.2 Sensitivity Analysis. The ratio of the number GFP+ cells to GFP- cells (green)
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Cancer is a disease caused by the accumulation of phenotype-altering genetic mu-
tations in somatic cells. Malignancies exhibit di!erent characteristics based on the
specific types of mutations they have acquired, but there are commonalities found in
most forms of cancer. In particular, deregulation of cell proliferation, evasion of pro-
grammed cell death, independence of growth or control signals, and increased genetic
instability endow a fitness advantage in cancer cells over their normal counterparts,
resulting in tumor formation.
Due to various regulatory mechanisms that preserve genomic integrity, the rate at
which genetic mutations arise is very low. Furthermore, it is believed that a single
mutation is not su"cient to initiate malignant growth, and thus the probability of
acquiring enough mutations to initiate tumorigenesis is small. Mammalian tissues
are organized in a hierarchical structure of stem, progenitor, and di!erentiated cells
that is believed to o!er additional protection against cancer. Stem cells are a small
percentage of tissue cells and are long-lived with substantial proliferative potential.
They often have the ability to generate all of the other cells in the tissue. In contrast,
progenitors mature and lose proliferative capability as they divide, and eventually
form di!erentiated cells that are generally short-lived and compose the majority of
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the tissue. Consequently, it has been suggested stem and early progenitor cells are
the only tissue cells that persist long enough to accumulate enough mutations to
initiate malignancy.
Just as not every cell is capable of dividing, not all tumor cells have an equal
capacity for forming new tumors. Tumor-initiating cells have qualities similar to
those of stem cells, including longevity and the ability to self-renew or di!erentiate,
albeit abnormally. Due to these parallels, tumor-initiating cells are called cancer
stem cells. Cancer stem cells form as the result of mutation accumulation in stem
cells or in progenitors or di!erentiated cells that have acquired the ability to self-
renew. The cancer stem cell hypothesis suggests this population generates mutated
progeny and drives tumor growth, meaning that their eradication is required to cure
cancer.
In order to characterize cancer stem cells, it is necessary to know what mutations
deregulate normal cell behavior. Much research has focused on identifying specific
genetic transformations that initiate particular types of cancer in order to better
understand the causes and driving mechanisms of these tumors. Some mutations are
disease-specific, for example, the BCR-ABL fusion gene found in Chronic Myeloge-
nous Leukemia, while others, such as the tumor suppressor, p53, have been detected
in a wide variety of malignancies. In addition, investigation seeks to determine the
order in which mutations are acquired, because this may influence tumor growth
dynamics.
There are several challenges in cancer research, and mathematical modeling may
be helpful in addressing issues that are di"cult to conclude experimentally. The
goal of this dissertation is to address, with the assistance of mathematical modeling,
several unanswered questions surrounding the cancer stem cell hypothesis. In partic-
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ular, focus is directed towards (1) investigating the sequential order of mutations that
causes the most rapid tumor initiation in hierarchical tissues, (2) identifying which
cellular mechanisms instigate aggressive malignancies when deregulated, and (3) ex-
amining tumor heterogeneity and composition, with specific attention to the cancer
stem cell population. This will be accomplished by developing a maturity-structured
mathematical model of mutation acquisition in hiearchical tissue.
Pertinent biological background information is presented in Chapter II to famil-
iarize the reader with the biology. Specifically, hierarchical tissue, cancer stem cells,
and the pathology of Chronic Myelogenous Leukemia are discussed. Chapter III re-
views previously developed mathematical models that were used to simulate tissue
of both normal homeostasis and cancer. In addition to highlighting the insightful
conclusions derived from these models, attention is drawn to the lack of cancer mod-
els that explicitly incorporate the maturity structure of hierarchical tissue, which
motivates this dissertation.
In Chapter IV, a maturity-structured model is developed and used to examine
mutation acquisition in hierarchical tissue. This model has many novel features that
have not previously been integrated. For instance, symmetric self-renewal, asymmet-
ric self-renewal, and symmetric di!erentiation divisions are incorporated, enabling
investigation of the e!ects on tissue homeostasis due to imbalance of the stem-cell
division pattern. In addition, sequential acquisition of genetic mutations in stem, pro-
genitor, and di!erentiated cells is explored. Evolving tumor composition is discussed,
and the significance of genetic instability and increased symmetric self-renewal are
emphasized.
Various factors influence the pattern of stem-cell division but these are not in-
corporated in the modeling in Chapter IV. In Chapter V, an ordinary di!erential
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equations model is presented that incorporates regulatory mechanisms governing
stem-cell division and quiescence. The model is used to simulate tissue generation
and achieve homeostasis. A sensitivity analysis is conducted in Chapter VI to de-
termine which model parameters impart the most e!ect on healthy tissue formation
and equilibrium. Specifically, the analysis suggests that tissue equilibrium is most
altered due to increased stem-cell proliferation, decreased stem-cell apoptosis, and
increased symmetric self-renewal.
Chapter VII explores the deregulation of stem-cell governing mechanisms as a
result of mutation acquisition. In particular, mutations increasing symmetric self-
renewal in stem cells are found to cause the most aggressive forms of cancer. Further-
more, it is demonstrated that regulatory mechanisms prevent significant expansion
of stem cells, but complete loss of governance can result in exponential growth.
Finally, in Chapter VIII, all of the model features from previous chapters are
incorporated into one comprehensive framework. Specifically, a maturity-structured
model of hierarchical tissue that incorporates stem-cell regulatory mechanisms is
used to investigate mutation acquisition initiating cancer. The model structure is
general enough to simulate tumorigenesis in various tissues, but as an example,
the dynamics of Chronic Myelogenous Leukemia are simulated to demonstrate the
model’s capabilities. To conclude, the relevance and significant contributions of




This year, the National Cancer Institute estimates that nearly one-and-a-half
million Americans will be diagnosed with cancer [93]. Although medical advances
have prolonged patient survival, cures remain elusive for many forms of cancer when
surgery is not enough, resulting in approximately half a million American deaths a
year [93]. Based on trends established in the last five years, forty percent of people
born today will develop some form of cancer in their lifetime [93]. The rate of
mortality in combination with the rate of incidence makes cancer a deadly disease
that a!ects the entire population. As a result, much research has been devoted to
understanding the causes of cancer in order to develop new therapeutic treatment
strategies.
The cancer stem cell hypothesis proposes that a small subpopulation of mutated
cells drives malignant growth [110]. These tumor-initiating cells are called cancer
stem cells because they share similar qualities with normal somatic stem cells, in
particular, the ability to self-renew. Furthermore, cancer stem cells are sometimes
more resistant to current methods of treatment, and their survival promotes malig-
nant regeneration and prevents complete eradication of the tumor. In this chapter,
biological background information is presented pertaining to cancer stem cells and
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their contribution towards cancer development in hierarchically structured tissues.
2.1 Hierarchical Tissue Structure
Mammalian tissues are complex and composed of heterogeneous cell populations
that di!er in functional abilities as well as state of maturation. In many human
tissues, rare and immature stem cells have been identified that are ultimately re-
sponsible for generating all tissue cells [4, 98]. Stem cells proliferate and di!erentiate
to form progenitor cells, which are slightly more mature than stem cells. Progenitors
are not fully di!erentiated, but they expand through several rounds of cell division
and become more di!erentiated as they divide. When all rounds of division are com-
pleted, terminal di!erentiation ensures that cells reach full maturity, after which they
are generally incapable of additional proliferation. Tissues often consist of several
types of di!erentiated cells; each is necessary to perform specialized tasks. Many hu-
man tissues are formed and maintained through this hierarchical structure in which
stem cells give rise to progenitor cells, which in turn give rise to di!erentiated cells [4].
Stem cells have several characteristics that make them unique. First, because they
are näıve and multipotent, stem cells are capable of forming progeny of various lin-
eages [63]. In contrast, as non-stem cells divide, they also become more di!erentiated
and committed in lineage. Second, stem cells are rare within a tissue [4, 110]. Third,
stem cells may enter long periods of quiescence between divisions [39, 79, 89, 104].
While it is true that a few types of di!erentiated cells, such as lymphocytes, can
remain quiescent for an extended time between divisions, most progenitor and dif-
ferentiated cells do not have a significant G0 phase while retaining the ability to
divide intermittently [61]. Fourth, stem cells have the ability to self-renew, which
means that they can form daughter cells that are also stem cells [4, 110]. When non-
7
stem cells divide, they lose some of their proliferative potential and become more
di!erentiated, but self-renewal allows daughter cells to retain stemness. It is this
final quality that allows stem cells to live longer than other types of cells without
exhausting their proliferative potential or depleting the stem-cell pool.
2.1.1 Stem-Cell Division
Stem cells are capable of both self-renewal and di!erentiation, which they ac-
complish through three di!erent types of cell division. In a symmetric self-renewal
division, the two daughter cells are also stem cells, which increases the stem-cell pool
by one. Asymmetric division creates one daughter stem cell and one daughter pro-
genitor cell that is fated to di!erentiate, which does not change the stem-cell pool,
but increases the progenitor pool by one. Symmetric commitment occurs when both
daughter cells are progenitors, which depletes the stem-cell pool by one and increases
the progenitor pool by two. The three outcomes of stem cell division are depicted
in Figure 2.1. In order to regulate tissue homeostasis, a balance of divisions and
stem-cell apoptosis is necessary to maintain a constant number of stem cells while
also generating progenitor cells [34].
Although all three types of division have been observed in various experimental
settings, it is unknown which types of division occur in human tissues in vivo [97, 107,
125]. It is believed that stem cells possess the mechanisms to permit both symmetric
and asymmetric divisions, and can switch division type based on the demands of the
tissue [89, 104]. For instance, in time of injury or tissue generation, symmetric self-
renewal expands the stem-cell pool to speed cell production [89]. Some hypothesize
that under homeostatic conditions, asymmetric divisions occur in order to preserve
stem cell numbers, but a healthy steady state could also be maintained through
balanced symmetric self-renewal and di!erentiation divisions [34, 89].
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Figure 2.1: Stem cells are capable of three kinds of division. Stem cells may symmetri-
cally self-renew to form two daughter stem cells (A), asymmetrically self-renew to form
one stem cell and one progenitor cell (B), or symmetrically di!erentiate to form two
progenitor cells (C).
The immortal strand hypothesis suggests that stem cells have internal mechanisms
that asymmetrically cosegregate chromosomes at division ensuring the production
of one stem cell and one progenitor cell [81, 107]. According to this hypothesis,
the same set of chromosomes is always passed on to daughter stem cells, while the
newly synthesized set is passed on to daughter progenitor cells. Thus, the immortal
strand is a mechanism that assists stem cells in maintaining genetic integrity and
avoiding mutation during DNA replication. Chromosomal cosegregation has been
reported in a variety of mammalian adult stem cells, but experimental evidence
demonstrates that murine hematopoietic stem cells do not asymmetrically segregate
chromosomes [25, 64, 65, 106, 114, 115]. This finding suggests that chromosomal
cosegregation is not a characteristic of all stem cells and cannot be used as a method
of identifying and isolating stem cells within a tissue.
2.1.2 The Stem-Cell Niche
Because stem cells are rare and need to replenish tissue cells, they reside in niches
that both protect and regulate [42]. Niches have been identified in various tissues,
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including bone marrow, colon, testes, skin, hair follicle, and brain [42, 63, 97]. The
stem-cell niche is defined as the microenvironment of supporting cells and chemical
signals that regulates stem-cell maintenance and function [76, 97, 126]. It is believed
that the niche plays a crucial role in maintaining stem-cell qualities and regulating
the proliferation and di!erentiation of stem cells [42].
Physical interactions between stem cells and supporting cells in the niche are an
important aspect of niche control [42, 97]. Adherens junctions, integrins, and contact
with the extracellular matrix have all been implicated in rooting stem cells in the
niche [42, 97]. Because stem cells are usually in a quiescent state, it is thought
that signals in the niche inhibit di!erentiation [42]. Thus when a stem cell loses
interaction with the niche, it may lose its stem cell characteristics and di!erentiate.
In addition, the stem-cell niche may promote asymmetric divisions as a means of
mediating homeostasis [75].
Not only are stem cells di"cult to isolate from mammalian tissues, but the inabil-
ity to artificially reconstruct the stem-cell niche is an additional obstacle preventing
long term observation of stem cells in vitro [75, 95]. Consequently, it is evident
that the stem-cell niche provides necessary signals to support stem cells. As more
is discovered about the stem cell niche, it may be possible to more successfully ob-
serve stem cells in vitro, which would foster additional understanding. Furthermore,
knowledge of the niche may also assist investigation regarding abnormal growth or
degeneration of hierarchically structured tissues [75].
2.1.3 The Hematopoietic System
Hematopoietic stem, progenitor, and di!erentiated cells compose what is arguably
the most understood hierarchical system. Due to the availability of data regarding
blood cell production, this dissertation uses the hematopoietic system to model hi-
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erarchical tissue, both in normal and cancerous situations. In order to further un-
derstand characteristics of hematopoiesis, detailed information of the hematopoietic
system is now presented. Particular attention is given to cells of the granulocyte
lineage as aberrant white blood cell production contributing to leukemia is discussed
in Section 2.3.
Hematopoietic stem cells are responsible for generating various cell types that cir-
culate in the blood and lymph. Di!erentiation of hematopoietic stem cells produces
progenitor cells of either the myeloid or lymphoid lineages. Myeloid progenitors are
precursors for erythrocytes, macrophages, platelets, and granulocytes, which include
neutrophils, eosinophils, and basophils. Lymphoid progenitors are precursors for
lymphocytes, including the T-cells and B-cells that are necessary for adaptive im-
munity [61, 99]. A schematic of the hierarchy of hematopoietic cells is shown in
Figure 2.2.
In accordance with other types of hierarchical tissue, hematopoietic stem cells
are a very small percentage of all hematopoietic cells. In murine models, stem cells
comprise less than 0.01% of bone marrow cells [35, 32, 68, 80, 94]. It is di"cult to
purify immature cell populations and isolate stem cells, but several markers have
been identified. Human hematopoietic stem cells are enriched in populations with
the phenotype of CD34+, CD38!, Lin!, where Lin refers to a collection of “lin-
eage markers” that can be used to exclude di!erentiated cells [94]. Recently, it was
demonstrated that SLAM family receptors CD150, CD244, and CD48 could be used
to isolate stem and progenitor cells. Hematopoietic stem cells are purified in the pop-
ulation expressing CD150+ CD244! CD48!, transiently reconstituting multipotent
myeloid progenitors express CD244+ CD150! CD48!, and more committed progen-
itors express CD48+ CD244+ CD150! [68]. Even with the most current isolation
11
[Thy1.1low, Flk-2neg], ST-HSC [Thy1.1low, Flk-2!], and MPP
[Thy1.1", Flk-2!] in combination with the [Linneg/low, c-Kithigh,
and Sca-1!] markers (10). Morphologically, HSCs and MPPs
resemble lymphocytes.
Differentiation Potential. Whereas LT-HSCs self-renew for the life
of the host, the derivative ST-HSCs retain self-renewal capacity
for #8 weeks (2) and give rise to the briefly self-renewing MPPs
(11), which then differentiate into oligolineage-restricted pro-
genitors through functionally irreversible maturation steps (see
Fig. 1). Two kinds of oligolineage-restricted progenitors have
been identified so far in the mouse: the common lymphoid
progenitors (CLPs), which at a clonal level are restricted to give
rise to T lymphocytes, B lymphocytes, and natural killer cells
(12), and the common myeloid progenitors (CMPs), which are
progenitors for the myelo-erythroid lineages (13). CMPs give
rise to myelomonocytic progenitors (GMPs), which in turn
produce monocytes!macrophages and granulocytes, and to
megakaryotic!erythroid progenitors, which differentiate into
megakaryocytes!platelets and erythrocyte, but still maintain the
potential for B cell lineage differentiation at an extremely low
frequency (13). Interestingly, both CMPs and CLPs can give rise
to dendritic cells (14, 15), suggesting the existence of alternative
commitment pathways to the mutually exclusive developmental
pathways for myeloid and lymphoid lineages. All of these
progenitor populations are separable as pure populations by
using cell surface markers and have been shown to be devoid of
detectable self-renewal activity after transplantation (16).
In parallel to the clarification of the developmental hierarchy
between HSCs and committed progenitors, considerable
progress has been made toward the identification of molecular
mechanisms regulating lineage commitment within the hema-
topoietic system. Although it is largely beyond the scope of this
review to describe these mechanisms in detail, they appear to
represent a stepwise process characterized by the alternate
expression of specific transcriptional regulators, growth factors,
and growth factor receptors, whose combination determines
lineage commitment and maturation (17, 18). With the recent
use of DNA microarrays to investigate the gene expression
profile of HSCs, progress has also been made toward the
identification of the downstream effectors genes of the tran-
scription factors (19, 20). Future gene expression profiling of
defined HSCs and progenitor populations should rapidly ad-
vance our understanding of the molecular regulatory networks
that control the development of all blood cells.
Proliferation, Apoptosis, and Self-Renewal. As HSCs mature from
the long-term self-renewing pool to MPPs, they progressively
lose their potential to self-renew but become more mitotically
active. In young mice, the frequency of HSCs in hematopoietic
tissues is relatively constant (21–23) and HSCs have long been
considered to be a resting cell population, with only a few stem
cells contributing to steady-state hematopoiesis. In fact, recent
studies have shown that in young adult mice #8–10% of
LT-HSCs randomly enter the cell cycle per day, with all HSCs
entering the cell cycle in 1–3 months (24, 25). Although the rate
Fig. 1. Hematopoietic and progenitor cell lineages. HSCs can be divided into LT-HSCs, highly self-renewing cells that reconstitute an animal for its entire life
span, or ST-HSCs, which reconstitute the animal for a limited period. ST-HSCs differentiate into MPPs, which do not or briefly self-renew, and have the ability
to differentiate into oligolineage-restricted progenitors that ultimately give rise to differentiated progeny through functionally irreversible maturation steps.
The CLPs give rise to T lymphocytes, B lymphocytes, and natural killer (NK) cells. The CMPs give rise to GMPs, which then differentiate into monocytes!
macrophages and granulocytes, and to megakaryotic!erythroid progenitors (MEP), which produce megakaryocytes!platelets and erythrocytes. Both CMPs and
CLPs can give rise to dendritic cells. All of these stem and progenitor populations are separable as pure populations by using cell surface markers.
Passegué et al. PNAS " September 30, 2003 " vol. 100 " suppl. 1 " 11843
Figure 2.2: Hierarchical structure of the hematopoietic system. Hematopoietic stem cells
form common myeloid and lymphoid progenitors, which in turn produce cells of the
myeloid and lymphoid li eages. Figure from [103].
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techniques, less than 50% of cells labeled as stem cells yield long-term reconstitu-
tion when transplanted into irradiated mice, implying that additional markers are
needed to truly distinguish long-term reconstituting hematopoietic stem cells from
the earliest progenitor cells [68].
Although there is a small number circulating in the blood, hematopoietic stem
cells mainly reside in the bone marrow, where most of blood cell production takes
place [103]. Progenitors expand and continue further maturation in the soft marrow
in the inner bone cavity [126]. It is believed that the hard outer bone surface o!ers
protection for immature cells while also creating a pressure gradient that pushes
fully di!erentiated cells into the bloodstream [39, 76]. Once myeloid cells complete
terminal di!erentiation, they no longer proliferate and are released into the blood.
Within the bone marrow, specialized niches maintain and regulate hematopoi-
etic stem cells. It is believed that endosteal and vascular or perivascular cells each
have roles in governing stem-cell behavior, as portrayed in Figure 2.3 [66]. The en-
dosteum is the vascularized inner lining of the bone surface, including osteoblasts
and osteoclasts that mediate bone formation and remodeling, respectively [66]. Al-
though hematopoietic stem cells home near the endosteal surface, it is uncertain if
endosteal cells compose the niche or instead produce signals that influence stem cells
nearby [66, 68]. Recently, it was observed that nearly all hematopoietic stem cells
reside within five cell diameters of sinusoids, which are specialized areas of the vascu-
lature specially constructed to permit cells to enter the blood [67, 68]. When taken
into account with the fact that hematopoietic stem cells can be mobilized quickly, this
provides compelling evidence for a vascular niche [66, 72]. Experimental evidence has
shown the importance of both endosteal and vascular cells in hematopoiesis, demon-
strating the significance of each for blood cell production [39, 87]. Consequently,
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it is likely that endosteal and vascular or perivascular cells are each significant in
hematopoietic stem cell maintenance, though more detailed information regarding
the contributions of these cells is needed [66].
Hematopoietic stem and progenitor cells must have high proliferative potential
in order to produce the vast number of di!erentiated blood cells that are needed
daily. The estimated blood cell daily turnover in humans includes approximately one
hundred billion granulocytes, two hundred billion erythrocytes, and one hundred and
fifty billion platelets [39, 78]. Most of the cell population expansion takes place in
the progenitor pool, which proliferates rapidly [109]. In contrast, hematopoietic stem
cells cycle less frequently, and the vast majority are in the G0 quiescent phase [89].
In fact, approximately 70-90% of hematopoietic stem cells are quiescent at any one
time [21, 39, 104]. In mice, 99% of hematopoietic stem cells have divided within 57
days [21]. Although the average division rate has not been explicitly experimentally
observed in humans, it has been hypothesized that cells divide may even divide more
infrequently in larger mammals, with a human hematopoietic stem cell cycling once
every 25-50 weeks, on average [1, 113].
Several factors influence hematopoietic stem cell proliferation and mediate the bal-
ance between quiescence, self-renewal and di!erentiation. It is believed that these
decisions are regulated through extrinsic and intrinsic signals, though the participat-
ing mechanisms are not fully understood [98, 108, 125]. For example, it is hypothe-
sized that osteoblasts secrete factors that maintain quiescence, namely angiopoietin
and thromboipoietin, while other factors, such as CXCL12, promote migration and
localization in the bone marrow [66]. The Bmi-1, Wnt, and Sonic hedgehog (Shh)
signaling pathways are involved in self-renewal [4, 57, 62, 63, 97, 108, 123]. Wnt-
signaling promotes self-renewal of hematopoietic stem cells, may encourage quies-
14
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HSCs also reside and undergo haematopoiesis in asso-
ciation with blood vessels in the placenta59,60. These data 
suggest that HSCs probably reside primarily in vascular 
and/or perivascular niches during embryonic and fetal 
development. Nonetheless, these niches remain to be 
characterized and could depend on critical contributions 
by non-vascular cells. It is also possible that embryonic 
and fetal HSCs behave differently from adult HSCs in part 
because the niches in which they reside are different.
Do perivascular cells regulate adult HSCs?
Vascular cells probably contribute to the creation of 
HSC niches in extramedullary tissues. HSCs are present 
throughout adult life in extramedullary tissues, such as 
the liver and spleen61, and extramedullary haematopoiesis 
can flourish in these tissues for long periods of time, 
despite the absence of bone or endosteum62,63. This 
implies that there are cells other than osteoblasts and 
osteoclasts that can create environments capable of 
sustaining adult HSCs. Most HSCs mobilized to the 
adult spleen localize adjacent to sinusoids6, suggesting 
that HSCs in extramedullary tissues may reside within 
perivascular niches. Sinusoids are specialized blood 
vessels that are present in haematopoietic tissues and 
through which venous circulation occurs. The walls of 
sinusoids are composed of fenestrated endothelial cells 
through which haematopoietic cells can enter and exit 
the circulation. The case for extramedullary vascular 
niches remains circumstantial as no data directly dem-
onstrate that perivascular cells in extramedullary tissues 
can promote the maintenance of HSCs.
Many HSCs in adult bone marrow can also be found 
around sinusoids. When the localization of HSCs in bone 
marrow has been studied using signalling lymphocyte 
activation molecule (SLAM) family markers, which give 
very high levels of HSC purity using a simple combination 
of markers, about 60% of bone-marrow HSCs were found 
adjacent to sinusoids and up to 20% of HSCs localized 
to the endosteum6,7. The remaining HSCs were scattered 
throughout the bone marrow, and were not located 
adjacent to sinusoids or the endosteum. HSCs were thus 
significantly more likely than other bone-marrow cells to 
localize to sinusoids or the endosteal surface, consistent 
with the idea that there might be niches in these loca-
tions7. Virtually all HSCs were within 5 cell diameters 
of a sinusoid in the bone marrow7, raising the possibility 
that even HSCs near the endosteum may be influenced 
by vascular or perivascular cells.
The observation that substantial numbers of HSCs 
localize to sinusoids in the bone marrow is reasonable, 
given that HSCs can be mobilized into circulation within 
minutes of administering interleukin-8 (IL-8) to mice64. 
Furthermore, HSCs deficient for Rac1 and Rac2 (genes 
encoding proteins that control cell migration) are defec-
tive in their ability to migrate (as assessed by in vitro 
migration assays) and yet conditional deletion of Rac1 and 
Rac2 from adult haematopoietic cells65 or administration 
of a RAC inhibitor leads to the entry of HSCs into circula-
tion within hours66. This rapid mobilization of HSCs that 
seem impaired in their migratory capacity suggests that 
many HSCs might not have to migrate very far to enter the 
circulation, such as would be the case if these cells were 
in perivascular niches, poised to enter circulation. All of 
these data raise the question of whether endothelial cells 
or perivascular cells actually create a perivascular niche 
that helps to maintain HSCs6,67 (FIG. 4a,c), or whether HSCs 
transiently migrate through perivascular sites on their way 
in and out of the circulation68 (FIG. 4b).
Similar to osteoblasts, endothelial cells can promote 
the maintenance of HSCs in culture69,70, and normal 
endothelial-cell function is required for haematopoiesis 
Figure 3 | Many different cell types may contribute to formation of HSC niches 
near the endosteum and around sinusoids. a | Osteoblasts and osteoclasts secrete a 
variety of factors that have been implicated in the regulation of haematopoietic stem 
cells (HSCs)2,43. Furthermore, bone remodelling by these cell types elevates the 
concentration of Ca2+ ions locally and in circulation, influencing HSC localization and 
maintenance through the Ca2+-sensing receptor44. Sympathetic-nervous-system activity 
also regulates HSC localization in the bone marrow85. The endosteal surface is also 
heavily vascularized. Vascular and perivascular cells, such as reticular cells8 and 
mesenchymal progenitors9, might contribute to the formation of HSC niches at or near 
the endosteum8,46. As-yet-unidentified cells could also contribute. b | Perivascular sites 
are likely to maintain fetal HSCs in the placenta, spleen and liver. During adulthood, the 
presence of HSCs around sinusoids in haematopoietic tissues6, the ability of endothelial 
cells to promote HSC maintenance in culture69,70, and the secretion of HSC regulatory 
factors by perivascular reticular cells and mesenchymal progenitors8,9,34, raises the 
possibility of perivascular niches for HSCs67 in the bone marrow and in extramedullary 
tissues such as the spleen. If such niches exist, a wide variety of vascular and 
perivascular cells could conceivably contribute to such niches, including endothelial 
cells, megakaryocytes, perivascular reticular cells, mesenchymal progenitors and other 
cell types.
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Figure 2.3: Hematopoietic stem cell niches in bone marrow. Hematopoietic ste cells are
governed by endosteal and vascular or perivascular cells in the bone marrow. Figure
from [66].
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cence, and influences cell fate decisions during development [42, 63, 87, 94, 98, 110].
In addition to chemical signals influencing stem-cell division, it is hypothesized that
cell-to-cell interaction and location within the niche may determine the mode of
stem-cell division as the niche size dictates the size of the stem-cell pool that can
be supported [33, 42, 76, 87, 97, 108]. Clearly, there are many influences governing
stem-cell proliferation, many of which are not yet fully understood; however, new
discoveries continue to be made.
The hematopoietic system is just one example of hiearchically structured tissue in
the human body. Composed of hematopoietic stem cells, common myeloid and lym-
phoid progenitors, and a variety of di!erentiated cell types, hematopoiesis is a prime
example of di!erentiated cell production that originates from the same population of
pluripotent precursors. Hematopoietic stem cells are the most studied mammalian
adult stem cells simply because of their accessibility. With new scientific advances
in experimental techniques, adult stem cells in other tissues are now being studied
in greater detail. Even though much has been learned, there are still many unknown
characteristics of adult stem cells. In particular, understanding the mechanisms gov-
erning stem-cell self-renewal and di!erentiation may shed light on abnormalities in
tissue regulation and maintenance.
2.2 Cancer Stem Cells
Cancer is a disease in which accumulated genetic mutations alter normal cellular
characteristics. It is thought that three to ten genetic mutations are required to
malignantly transform a cell [10, 50]. Although specific mutations vary from one
cancer to another, there are commonalities in the types of genes they a!ect. In their
review of cancer cells, Hanahan and Weinberg cite six characteristics that promote
16
aberrant growth: self-su"ciency in growth signals, insensitivity to antigrowth signals,
evasion of apoptosis, limitless replicative potential, promotion of angiogenesis, and
tissue invasion causing metastasis [50]. Ultimately, malignant growth requires a
combination of mutations that gain cellular function in addition to those that remove
tumor suppression [50].
Hierarchical tissues are not uniform in cellular composition, hence it is not sur-
prising that the tumors arising in them are heterogeneous as well. Most notably,
not all tumor cells are capable of initiating tumorigenesis [4, 12, 54, 57, 102, 110].
Tumor-initiating cells actually possess many of the same qualities as stem cells, in-
cluding the ability to self-renew and di!erentiate into diverse cell types, significant
replicative potential, and longevity [102, 110, 123]. The noted similarities between
tumor-initiating cells and stem cells has led to their labeling as cancer stem cells,
and the cancer stem cell hypothesis is a model explaining tumorigenesis. This hy-
pothesis states that malignant tumors are initiated and driven by a subpopulation
of cancer stem cells that promote unregulated growth [110]. It is uncertain whether
or not tumorigenic cells are a small minority in all types of malignancies, and it is
possible that the proportion cancer stem cells in the tumor may characterize disease
aggressiveness [4].
Sometimes cancer stem cells are mutated stem cells and sometimes they arise
from the mutations of progenitor or di!erentiated cells that have acquired the ability
to self-renew extensively [4, 56, 60, 62, 102, 103, 110]. Because stem cells are are
long-lived, they have more time to acquire mutations that contribute to transforma-
tion into a malignant state [28, 102, 123]. In addition, they already possess internal
mechanisms enabling self-renewal and inhibiting apoptosis, so fewer mutations may
be needed to initiate malignant growth [110]. In contrast, progenitors cannot limit-
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CD34+CD38+ leukaemia cells cannot transfer disease to mice in the
vast majority of cases, despite the fact that they exhibit a leukaemic
blast phenotype. This suggests that normal HSCs rather than 
committed progenitors are the target for leukaemic transformation.
The most frequent chromosomal abnormalities in AML involve
the 8;21 translocation, which results in AML1–ETO chimaeric 
transcripts in leukaemic cells. In work done on human HSCs from
patients in remission, AML1–ETO transcripts were found in a 
fraction of normal HSCs in the marrow32. These prospectively 
isolated HSCs and their progeny were not leukaemic, and could 
differentiate to normal myeloerythroid cells in vitro. This indicates
that the translocation occurred originally in normal HSCs and that
additional mutations in a subset of these HSCs or their progeny 
subsequently lead to leukaemia32. In this study, the normal HSCs
were CD34+CD38–Thy-1+, whereas the leukaemic blasts were
CD34+CD38–Thy-1–. Although the translocation must have
occurred in normal HSCs, subsequent transforming mutations
might have occurred either in downstream Thy-1– progenitors, or in
HSCs if one consequence of neoplastic proliferation was the loss of
Thy-1 expression. The idea that stem cells are a common target of
pre-leukaemic events or leukaemic transformation is also supported
by work in lymphoid33 and chronic myeloid leukaemias34 where
clonotypic leukaemia-associated chromosomal rearrangements
have also been found in CD34+CD38– cells, a population enriched for
HSCs. Thus, a variety of leukaemias may arise from mutations that
accumulate in HSCs to cause their malignant transformation at the
stage of stem cells or their progeny.
Progenitor cells as targets of transformation
Although stem cells are often the target of genetic events that are 
necessary or sufficient for malignant transformation, in other cases
restricted progenitors or even differentiated cells may become trans-
formed (Fig. 3). By targeting the expression of transgenes specifically
to restricted myeloid progenitors using the hMRP-8 promoter, it is
possible to create a mouse model in which myeloid leukaemia arises
from restricted progenitors. These leukaemias resemble human
leukaemias in many respects, even though the targeted genetic
changes cause the leukaemias to arise from restricted progenitors
rather than stem cells. For example, we have generated transgenic
mouse models for myeloid leukaemias using an hMRP-8 promoter,
which targets the expression of transgenes specifically to myeloid
progenitors35. The enforced expression of the anti-apoptotic gene
bcl-2 in the myeloid lineage leads to a disease that is similar to human
chronic myelomonocytic leukaemia, including monocytosis,
splenomegaly and neutropenia, as the mice age. However, these mice
rarely develop acute malignancies.
To test whether additional mutations are required to synergize
with bcl-2 to promote AML, hMRP8–bcl-2 transgenic mice were bred
with lpr/lpr Fas-deficient mice. Remarkably, the loss of these two 
distinct apoptosis pathways led to the development of AML in 15% of
the mice36. These mice have an expansion of myeloblasts in all
haematopoietic tissues, with a substantially lowered number of 
granulocytes in the marrow and blood. These studies show that 
prevention of cell death is a crucial event in myeloid leukaemogenesis
and that restricted progenitors can be transformed. As described
above, in the case of spontaneously arising human leukaemias it is
likely that stem cells accumulate the mutations that are necessary for
neoplastic proliferation; however, these mutations may accumulate
in stem cells even while the effects of the mutations are expressed in
restricted progenitors. That is, mutations that accumulate in stem
cells may lead to neoplastic proliferation of primitive progenitors
downstream of stem cells.
Perhaps the reason why only 15% of mice progress to AML in mice
expressing Bcl-2 and lacking Fas is that the progenitors in these mice
also must acquire an additional mutation that causes dysregulated
self-renewal (Fig. 3). If a single additional mutation causes transfor-
mation then this transforming event is probably a gain-of-function
mutation, such as one that promotes constitutive self-renewal.
Because stabilized !-catenin can promote the self-renewal of HSCs
and other types of progenitors (ref. 25, and T.R. et al., submitted; 
Fig. 2), we propose that gain-of-function mutations in !-catenin
may, in many cases, transform deathless pre-malignant cells to 
cancer cells by promoting proliferation. In support of this is evidence
to show that activation of !-catenin and dysregulation of the Wnt
signalling pathway in general is common in cancer37, and that the 
targeted overactivation of this pathway can lead to tumours in 
transgenic mice38. It is also possible that mutations in other signalling
pathways promote progenitor self-renewal. It is important to study
this further, because understanding the molecular basis of the 
unregulated self-renewal of cancer cells will allow the design of more
effective therapies.
In essence, newly arising cancer cells may appropriate the
machinery for self-renewing cell divisions that is normally expressed
in stem cells. In the haematopoietic system, the only long-term self-
renewing cells in the myeloerythroid pathway (Fig. 1, bottom) are
HSCs; however, at least two differentiated cell types (Fig. 1, top) can
also self-renew. Both T and B lymphocytes undergo clonal expansion
on stimulation to produce resting memory lymphocytes. These 
lymphocytes proliferate again when the antigens are re-encountered.
Lymphoid leukaemias can activate these receptor-mediated 
mitogenic pathways in the course of leukaemogenesis39–43.
Cancer stem cells and aberrant organogenesis
Basic cancer research has focused on identifying the genetic changes
that lead to cancer. This has led to major advances in our understand-
ing of the molecular and biochemical pathways that are involved in
tumorigenesis and malignant transformation. But while we have
focused on the molecular biology of cancer, our understanding of the
cellular biology has lagged. That is, although we understand (to a first
approximation) the effects of particular mutations on the prolifera-
tion and survival of model cells, such as fibroblasts or cell lines, we
insight review articles
















Stem cell Progenitor cell Mature cell
Figure 3 Comparison of self-renewal during haematopoietic stem cell development
and leukaemic transformation. Because of their high level of self-renewal, stem cells
are particularly good targets of leukaemic transformation. Unlike normal
haematopoiesis, where signalling pathways that have been proposed to regulate self-
renewal are tightly regulated (top), during transformation of stem cells, the same
mechanisms may be dysregulated to allow uncontrolled self-renewal (middle).
Furthermore, if the transformation event occurs in progenitor cells, it must endow the
progenitor cell with the self-renewal properties of a stem cell, because these
progenitors would otherwise differentiate (bottom).
© 2001 Macmillan Magazines Ltd
Figure 2.4: Cellular origin of ca cer stem cells. Cancer stem cells may form as a result of
either mutated stem cells or mutated progenitors that acquire the ability to self-renew.
Figure from [110].
lessly self-renew even though they have high proliferative potential. Eventually they
terminally di!eren iate and thus do no have the longevity of s em c lls. However,
if progenitors acquire the ability to self-renew, this permits the accumulation of ad-
ditional mutations, thereby creating a cancer stem cell population [4, 60, 102, 110].
Another possibility is that some mutations could occur in stem cells that are inher-
ited by progenitor daughter cells and thus predispose these progenitors to transfor-
mation [103, 105, 110]. Figure 2.4 schematically shows how tumor growth can be
initiated in stem and progenitor cell populations. Cellular origin and order of mu-
tation acquisition likely influence the tempo of disease progression, therefore further
investigation of the pathways causing tumorigenesis may provide insight useful in
preventing malignant transformation.
Aberrant self-renewal is a key component in the behavior of cancer stem cells.
Deregulated pathways governing stem-cell self-renewal, such as Bmi-1, Wnt, and
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Shh, contribute to tumorigenesis in various tissues [3, 12, 23, 57, 102]. Mechanisms
mediating the balance between symmetric and asymmetric divisions may be po-
tential targets for mutation as well. For example, when the machinery governing
asymmetric division is deregulated, symmetrically dividing neuroblasts form tumors
while the oncogene NUP98-HOXA9 that favors symmetric self-renewal in hematopoi-
etic cells causes Acute Myelogenous Leukemia [89, 125]. It has been hypothesized
that asymmetric divisions may suppress tumors, whereas increased symmetric self-
renewal leads to malignancy [89]. Due to the recent findings regarding deregulated
self-renewal, more attention has been focused towards understanding how balanced
division is controlled.
In considering the important role that the stem-cell niche has in maintaining the
homeostasis of stem cells, it is not surprising that alteration in the microenvironment
may also contribute to cancer formation. First, it is thought that cancer stem cells
become more independent of the niche. They may not rely on environmental cues
to self-renew or proliferate and may ignore inhibitory signals [74]. Mutations may
also a!ect receptors and molecules that bind stem cells in the niche, and loss of this
control could potentially lead to metastasis [74, 105]. In addition, mutations could
a!ect the supporting cells found in the niche rather than the stem cells themselves,
thereby altering stem cell behavior. It has been demonstrated that stromal cells may
be manipulated in ways that cause cancer, proving that the niche itself can become
tumorigenic [16].
It is important to characterize tumor-initiating cells so that treatment successfully
targets them. Unfortunately, cancer stem cells may be more resistant to therapy
than other cancer cells. As shown in Figure 2.5, the cancer di!erentiated cells that
compose the bulk of the tumor are eradicated, but cancer stem cells persist, causing
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have unlimited proliferative potential and can acquire the ability to
metastasize. For many years, however, it has been recognized that
small numbers of disseminated cancer cells can be detected at sites
distant from primary tumours in patients that never manifest
metastatic disease58,60. One possibility is that immune surveillance is
highly effective at killing disseminated cancer cells before they can
form a detectable tumour. Another possibility is that most cancer
cells lack the ability to form a new tumour such that only the 
dissemination of rare cancer stem cells can lead to metastatic disease
(reviewed in ref. 45). If so, the goal of therapy must be to identify and
kill this cancer stem cell population. If solid cancer stem cells can be
identified prospectively and isolated, then we should be able to iden-
tify more efficiently new diagnostic markers and therapeutic targets
expressed by the stem cells.
If tumour growth and metastasis are driven by a small population
of cancer stem cells, this might explain the failure to develop thera-
pies that are consistently able to eradicate solid tumours61. Although
currently available drugs can shrink metastatic tumours, these effects
are usually transient and often do not appreciably extend the life of
patients62,63. One reason for the failure of these treatments is the
acquisition of drug resistance by the cancer cells as they evolve;
another possibility is that existing therapies fail to kill cancer stem
cells effectively.
Existing therapies have been developed largely against the bulk
population of tumour cells because they are often identified by their
ability to shrink tumours. Because most cells with a cancer have 
limited proliferative potential, an ability to shrink a tumour mainly
reflects an ability to kill these cells. It seems that normal stem cells
from various tissues tend to be more resistant to chemotherapeutics
than mature cell types from the same tissues64. The reasons for this are
not clear, but may relate to high levels of expression of anti-apoptotic
proteins65–68 or ABC transporters such as the multidrug resistance
gene69,70. If the same were true of cancer stem cells, then one would
predict that these cells would be more resistant to chemotherapeutics
than tumour cells with limited proliferative potential. Even therapies
that cause complete regression of tumours might spare enough 
cancer stem cells to allow regrowth of the tumours. Therapies that 
are more specifically directed against cancer stem cells might 
result in much more durable responses and even cures of metastatic
tumours (Fig. 5).
Genomics may provide a powerful means for identifying drug 
targets in cancer cells. Although targeting genetic mutations does not
require isolation of the stem cells, there are likely to be differences in
gene expression between cancer stem cells and tumour cells with 
limited proliferative potential. The application of microarray 
analysis to malignant tumours has shown that patterns of gene
expression can be used to group tumours into different categories,
often reflecting different mutations71–74. As a result, tumour types
that cannot be distinguished pathologically, but that can be 
distinguished on the basis of differences in gene-expression profile,
can be examined for differences in treatment sensitivity. 
However, gene-expression profiling is often conducted on tumour
samples that contain a mixture of normal cells, highly proliferative
cancer cells, and cancer cells with limited proliferation potential.
This results in a composite profile that may obscure differences
between tumours, because the highly proliferative cells that drive
tumorigenesis often represent a minority of cancer cells. 
Gene-expression profiling of cancer stem cells would allow the 
profile to reflect the biology of the cells that are actually driving
tumorigenesis. Microdissection of morphologically homogeneous
collections of cancer cells is one way of generating profiles that reflect
more homogeneous collections of cells75,76. The next frontier will be
to purify the cancer stem cells from the whole tumour that retain
unlimited proliferative potential and to perform gene-expression
profiling on those cells. In addition to being a more efficient way of
identifying new therapeutic and diagnostic targets, the profiling of
cancer stem cells might sharpen the differences in patterns observed
between different tumours.
Perspectives
The ideas discussed in this review can be summarized as a set of
propositions. First, self-renewal is the hallmark property of stem cells
in normal and neoplastic tissues. Second, in the haematopoietic 
system, long-term self-renewal is limited to rare long-term HSCs and
some lymphocytes; other cell types lack this potential. Third, 
cells that continue to divide over long periods of time are much more
likely to accumulate mutations that cause neoplasia. Thus 
genetic changes that lead to myeloid leukaemias must occur either in
long-term HSCs or in progeny that first acquire the ability to 
self-renew. The fact that normal long-term HSCs in leukaemia
patients often have leukaemia-associated translocations strongly
supports the idea that leukaemic mutations often accumulate in
HSCs. Mutations that lead to certain types of lymphoma may 
accumulate in lymphocytes, given their ability to self-renew over the
long term. Fourth, in other normal tissues that contain self-renewing
stem cells, such as the epithelia, the genetic changes that are steps in
the progression to solid tumours probably also occur in the stem
cells, or in progeny that acquire the potential for self-renewal. 
Fifth, distinct signalling pathways control stem cell self-renewal in
different tissues. But perhaps within individual tissues, the same
pathways are used consistently by both normal stem cells and cancer
cells to regulate proliferation. For example, Wnt signalling regulates
the self-renewal of normal stem cells in the blood and epithelia. 
Constitutive activation of the Wnt pathway has been implicated 
in a number of epithelial cancers. The regulation and consequences
of Wnt signalling in normal and neoplastic cells need to be 
further elucidated. Sixth, understanding the signalling pathways that
are used by for normal stem cells and neoplastic cells should 
facilitate the use of normal stem cells for regenerative medicine and
the identification of cancer stem cell targets for anticancer therapies.
Seventh, within most tumours there may exist cancer stem cells that
can self-renew indefinitely, in contrast to most stem cells that 
may have limited proliferative potential. Finally, in order to cure 
cancer, it is necessary and sufficient to kill cancer stem cells. To
accomplish this it will be necessary to identify and characterize the
properties of these cells.
There are many connections between stem cells and cancer that
are important to understand. Just as the signals that are known to
control oncogenesis are providing clues about the control of 
insight review articles

















Figure 5 Conventional therapies may shrink tumours by killing mainly cells with
limited proliferative potential. If the putative cancer stem cells are less sensitive to
these therapies, then they will remain viable after therapy and re-establish the
tumour. By contrast, if therapies can be targeted against cancer stem cells, then they
might more effectively kill the cancer stem cells, rendering the tumours unable to
maintain themselves or grow. Thus, even if cancer stem cell-directed therapies do
not shrink tumours initially, they may eventually lead to cures.
© 2001 Macmillan Magazines Ltd
Figure 2.5: Cancer stem cells must be targeted for disease elimination. Tumors return
when cancer stem cells persist, but are eradicated when cancer stem cells are targeted.
Figure from [110].
recurrence of the disease [62, 102, 110, 123]. There are various explanations as to
why cancer stem cells may be insensitive to current drug regimens. First, normal
stem cells resist drug-induced apoptosis due to multidrug resistant and ATP-binding
cassette transporters that pump drugs out of the cell. These could also be present in
canc r stem c lls [29, 55, 62, 102, 110, 123]. Second, many d ugs specifically target
cycling cells, but cancer stem cells may have long periods of quiescence, thereby
avoiding drug sensitivity [29, 62]. Third, additional mutations may ccumulate,
causing drug resistance [29, 83]. Unfortunately, treatment strategies that successfully
eradicate cancer stem cells may also eliminate healthy stem cells, therefore it is
imperative that additional research is conducted to identify potential drug targets
unique to cancer stem cells to minimize toxicity to healthy cells.
The cancer stem cell hypothesis provides a new paradigm of tumorigenesis that
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accounts for heterogeneity, drug resistance, and relapse. It has reshaped the under-
standing of cancer and continues to influence how research is conducted. Since the
cancer stem cell hypothesis was first introduced, cancer stem cells have been identi-
fied in malignancies of the blood, brain, breast, colon, and skin [40, 123]. The next
section reviews a specific example of cancer that is driven by leukemic stem cells.
2.3 Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia (CML) is a form of leukemia caused by hyper-
cellarity of cells of the granulocyte lineage. In 2008, approximately 5,000 new cases
of CML will be diagnosed and 450 people will die from the disease in the United
States [45, 93]. CML generally manifests in later stages of life with the median diag-
nosis age ranging from 45-66 years, but it can a!ect people of all ages [45, 93, 112].
Although it takes a relatively long time to present itself, disease progression is fairly
rapid. Patients progress through three stages of disease, starting with a slow-growing
chronic phase that turns into an accelerated phase and finally ends in the aggressive
blast phase [41, 45, 59, 112, 120]. The whole process is fairly rapid as approximately
50% of patients die within five years of diagnosis, though survival times depend on
how early disease is detected and the success of treatment [93].
Symptoms alone are not su"cient to diagnose CML since they resemble those of
other diseases including weight loss, fatigue, night sweats, and enlarged spleen [45,
73]. Detection is often the result of a routine blood test due to elevated levels of
white blood cells [45]. A cytogenetic analysis concludes if the patient has CML by
determining the presence of the BCR-ABL fusion gene, the hallmark identifier of the
disease. BCR-ABL alone cannot initiate disease, however, as it has been traced in
healthy patients that do not develop CML [22, 47, 57, 60]. The mutations occurring
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in CML are discussed in greater detail in Section 2.3.1.
2.3.1 Mutations Causing Chronic Myelogenous Leukemia
The Philadelphia (Ph) chromosome formed by the translocation t(9; 22)(q34;
q11) is believed to be the primary source of CML [47, 103]. This mutation creates
the fusion gene BCR-ABL that alters cellular kinetics that give the mutated clone
growth advantage [47, 60, 119]. Many types of cancers have great variety in the
mutations that cause them, but approximately 90-95% of CML patients have the
Ph chromosome [41, 59, 103, 112]. Although the World Health Organization uses
the Ph chromosome and BCR-ABL to diagnose CML, there are cases that are not
Ph-positive, but they express a mutation whose e!ects are similar to those of BCR-
ABL [112, 120].
The BCR-ABL mutation alters several aspects of normal cellular behavior. It
inhibits apoptosis through increased survival and independence from signals that
negatively regulate growth [27, 47, 48, 112]. BCR-ABL also deregulates prolifera-
tion, though there is conflicting evidence as to how this is achieved. In vitro data
from hematopoietic precursor cells demonstrated that cycling time decreased, thereby
increasing the proliferation rate, while other reports argue that leukemic stem cells
retain long periods of quiescence and proliferation rates may be unaltered or even
slower [48, 62, 122, 125]. Cells expressing BCR-ABL still retain the ability to di!er-
entiate, but it is hypothesized that they are able to complete extra rounds of division,
increasing the number of progeny they produce and causing hypercellularity [27, 55].
Furthermore, Ph-positive cells are more susceptible to additional mutations, increas-
ing genetic instability [47].
It is believed that CML originates in stem cells but driven by aberrant progenitor
expansion [22, 47, 112]. In patients that are Ph-positive, the mutated chromosome
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can be detected in stem cells as well as di!erentiated cells of the granulocytic, mono-
cytic, megakaryocytic, erythroid, and occasionally lymphoid lineages, suggesting that
the initial mutation occurs at the stem cell level [47, 59, 103]. It is suggested that the
e!ects of BCR-ABL are not fully manifested in stem cells, but rather progenitors [22].
Consequently, it is likely that the progenitor population that is Ph-positive suppresses
normal hematopoiesis because of its competitive growth advantage [41, 48].
The Ph chromosome alone is not su"cient to initiate CML, and additional mu-
tations occur as the disease progresses [22, 57]. The additional expression of the
anti-apoptotic protein Bcl-2 has been linked to progression into a more advanced
stage [59]. In addition, mutations to tumor suppressor genes, such as p53, may also
contribute to malignancy [45, 112, 122]. Deregulation of self-renewal pathways are
of particular interest in monitoring the progression from chronic to blast phase. For
instance, !-catenin is believed to give granulocytic progenitors self-renewal capabil-
ities, and levels are normal in cells during the chronic phase, but increased in the
later accelerated and blast phases [60]. Further investigation may determine which
mutations are most significant in promoting malignant transformation.
2.3.2 Three Phases of Disease Progression
Disease progression in CML is classified into three phases: chronic, accelerated,
and blast. In the chronic phase, di!erentiation still occurs, even in mutated cells [60].
As the disease progresses, immature leukemic cells self-renew instead of di!erentiat-
ing, and immature blast cells accumulate [60]. Staging is based on the percentage
of immature blasts that are in the blood or bone marrow, as determined by blood
tests and bone marrow aspirates. The World Health Organization classification la-
bels the chronic phase when blasts comprise less than 10% of bone marrow or blood.
Approximately 85% of diagnoses are during this stage. Accelerated phase is reached
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when blasts compose 10-19% of cells. When blasts are 20% of cells, the fatal blast
phase is diagnosed [120].
The chronic phase of CML is believed to be initiated by the BCR-ABL mutation.
BCR-ABL deregulates cell proliferation and increases survival to cause hypercellu-
larity, particularly in cells of the granulocytic lineage [47, 55, 59, 60]. During the
chronic phase, it is thought that the hematopoietic stem cell population remains at
levels comparable to those in healthy individuals [60]. In contrast, mutated progeni-
tor and di!erentiated cell populations expand and suppress hematopoiesis of healthy
cells due to competitive advantage [41, 60, 119].
The duration of the chronic phase ranges from 3-7 years [41, 59, 112]. During
this time, mutated cells slowly take over the bone marrow, depleting Ph-negative
cells [41]. Additional mutations accumulate that contribute to the progression from
the chronic to accelerated and blast phases [48, 57, 59, 103]. In particular, much
evidence suggests that progenitors acquire an increased capacity for self-renewal di-
visions that produce undi!erentiated blast cells [22, 48, 60]. The immature blast
population expands and di!erentiation ceases so that blasts compose a greater per-
centage of all cells, and the accelerated phase is reached when blasts comprise 10%
of cells [48, 59, 60, 112, 120].
The accelerated phase is characterized by the increasing accumulation of blast cells
in the blood and bone marrow. In healthy hematopoiesis, the number of precursors
circulating in the peripheral blood is negligible. In contrast, blood tests from CML
patients show significant amounts of immature blasts due to extensive progenitor
expansion, inability to di!erentiate, and poor adhesion to bone marrow stroma [112].
Normal hematopoiesis is suppressed due to the dominance of the leukemic blasts, and
as a result, patients may experience anemia [73]. Although not as fatal as the more
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aggressive blast phase that follows, an estimated 10-20% of CML patients die in the
accelerated phase [45].
Once blast phase is reached, prognosis is extremely poor, with a median survival
time of five months if patients have already failed therapy with imatinib [45]. In blast
phase, patients experience night sweats, fever, and bone pain as well as increased
infections and bleeding as a result of lacking di!erentiated granulocytes and ery-
throcytes [45]. By this time, the leukemic clone has displaced normal hematopoiesis
and granulocytic precursors are increased [59]. As portrayed in Figure 2.6, it is be-
lieved the progression to blast phase is caused by mutated progenitors that have
acquired self-renewal capabilities [22, 60, 82]. Sadly, current treatment options do
not eradicate leukemic stem cells, and blast accumulation persists, ultimately causing
death [47, 55].
2.3.3 Treatment Options
Although prognosis is poor for patients in advanced phases of CML, the introduc-
tion of imatinib mesylate, commonly referred to as Gleevec, has demonstrated great
potential and revolutionized treatment. Imatinib was first used to treat patients in
1998, and since then has become the first choice of treatment options [47]. The use
of imatinib has displaced interferon-", though the latter may be used in patients
that are resistant to imatinib [45].
Imatinib is one of the more successful drugs used in fighting cancer because it
successully attacks cancer cells without toxicity to healthy cells [46]. This drug
inhibits ABL tyrosine kinases, which allows it to selectively target cells expressing
BCR-ABL and inhibits their proliferation [55, 62]. Consequently, it is not uncommon
for patients to have molecular and cytogenetic responses after treatment; that is, they
have undetectable levels of BCR-ABL and the Ph chromosome, respectively [26, 47].
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P E R S P E C T I V E
this procedure is limited by the toxicity of the treat-
ment, the risk of graft-versus-host disease, and the
lack of suitable donors for many patients. Up to 60
percent of patients with chronic-phase CML enter a
period of remission when treated with imatinib, an
inhibitor of the BCR-ABL kinase. Despite its re-
markable efficacy, imatinib may not be curative,
because early progenitor cells carrying the Phila-
delphia chromosome persist in most patients, de-
spite treatment. Just as the Hydra regenerated two
Figure. Cellular Hierarchy in Normal Hematopoiesis and in CML.
Proposed cell compartments in normal hematopoiesis (Panel A), chronic-phase CML (Panel B), and CML blast crisis 
(Panel C) are shown. The circular arrows represent self-renewing compartments that contain cells with nuclear b-cate-
nin. Secondary events involving ongoing mutations leading to progression to blast crisis could occur in CML stem cells, 






































































Chronic Myelogenous Leukemia — Identifying the Hydra’s Heads
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Figure 2.6: Progression of CML. Cells of the myeloid lineage expand during chronic phase, but
di!erenti tion still occurs. As disease progresses, progenitors acquire the ability to self-
renew, causing the accumulation of immature blasts in the bone marrow and blood.
Figure from [22].
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If treatment is discontinued, however, relapse shortly follows, demonstrating that
imatinib does not completely eliminate all leukemic cells [26, 62].
The success of imatinib demonstrates that chemotherapeutic agents may be syn-
thesized to attack cancerous cells without also causing toxicity to healthy cells. Un-
fortunately, imatinib does have shortcomings in that it is not curative. One obstacle
is that imatinib cannot kill quiescent cells, which allows cancer stem cells to persist
and regenerate the cancer population once treatment is stopped [55]. In addition,
imatinib is more successful in killing cells that are more committed, whereas primi-
tive cells might be forced into quiescence instead of apoptosis [55]. Another challenge
is one that is common in treating many forms of cancer in that cells acquire addi-
tional mutations that increase resistance to the drug [47]. For these various reasons,
imatinib is unsuccessful in treating CML as it advances.
Allogeneic stem cell transplantation is the only curative treatment option known
to date, but it is not considered appropriate for all cases. The percentage of pa-
tients surviving ten years ranges between 30-60%, but there is a 5-50% chance of
mortality related to the procedure, which is why it is not always used as the first
option of treatment [45]. Disease phase and patient age are both critical factors that
determine whether or not to proceed with this treatment option. Allogeneic stem
cell transplantation is generally conducted for patients in the chronic phase because
survival chances decrease in more advanced stages [45]. Likewise, survival decreases
as age increases, so this aggressive treatment is likely reserved for young patients in
early chronic phase [45].
The progression of CML provides a perfect example of how cancer stem cells
initiate and drive malignancy. The dynamics of this type of leukemia are partic-
ularly interesting because it is slow to develop but advances quickly as a result of
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accumulating immature cells. Mathematical modeling can assist in gaining further
understanding of this disease by examining the mutation pathways that generate
disease while monitoring changes in stem, progenitor, and di!erentiated cell popu-
lations. The next chapter reviews previously developed mathematical models that
address such issues in order to highlight areas that require additional investigation.
CHAPTER III
Mathematical Modeling of Cancer in Hierarchical Tissue
Mathematical modeling has long been utilized to supplement biological research.
It can be used to interpret scientific data, make short- or long-term predictions based
on recorded observations, and quantify parameters that are di"cult to determine
experimentally. In the area of cancer research, mathematical modeling addresses
issues such as malignant growth, mutation acquisition, chemotherapy regimens, and
tumor heterogeneity. The goal of this dissertation is to develop a mathematical model
that investigates mutation acquisition in hierarchical tissue. In this chapter, existing
relevant mathematical models are reviewed. Specifically, this chapter summarizes
previous investigations of hierarchical tissue, multi-step tumorigenesis, and cancer
stem cells.
3.1 Modeling Hierarchical Tissue
Most mammalian tissues are organized into a hierarchical structure consisting of
stem, progenitor, and di!erentiated cells, and the cellular kinetics of each of these
populations di!ers. Therefore, one cannot accurately model hierarchical tissue by
assuming tissue cells are homogeneous. It is true that meaningful biological conclu-
sions can be derived from models that simulate only one population of cells, but all
of the cells must exhibit similar characteristics. For instance, it is not unreasonable
28
29
to model one cell population when all the cells are stem cells, but if di!erentiated
cells are added to the system, then these two cell types should be separately modeled
in order to capture the distinct dynamics of each population.
Stem cells generate all cells within the tissue, and under normal conditions, it
is believed that the equilibrium of the stem-cell population dictates tissue home-
ostasis. Consequently, several mathematical models specifically focus on stem-cell
regulation. In particular, the balance of self-renewal, di!erentiation, and apoptosis is
commonly investigated. A simple time-discrete model by Hardy and Stark examined
the relationship between stem and di!erentiated cells at steady state [51]. It was
determined that stem-cell equilibrium ensured homeostasis in di!erentiated cells as
well. Although this model simplified the mechanisms governing stem-cell division
and di!erentiation by using constant probabilities for each, the general conclusion
that stem-cell kinetics dictate tissue homeostasis is insightful.
More complicated models attempt to depict the intricate feedback regulations that
govern stem-cell self-renewal, di!erentiation, and quiescence. For instance, Mackey
introduced a model in which proliferating and quiescent stem cells were separated
and the rate of self-renewal was dependent on the number of stem cells in the sys-
tem [77]. By making stem-cell proliferation dependent on the number of stem cells,
proliferation increases when stem cells are depleted and decreases when stem cells
are numerous to prevent over-expansion, thereby incorporating negative feedback as
a means of achieving and maintaining homeostasis. Further complexity was included
in this model by the incorporation of a time delay that corresponded with the cycling
time of proliferating cells. This feature helped to capture the dynamics of cyclical
neutropenia.
Collaborators later extended Mackey’s modeling framework in various ways. In
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2001, Andersen and Mackey used the model to investigate chemotherapeutic e!ects
on cancerous cells in Acute Myelogenous Leukemia [5]. Cell dynamics were modeled
for both normal and malignant bone marrow cells, in order to determine the success
or failure of several types of chemotherapy that target proliferating cells. To make
predictions, normal and cancer cell dynamics were simulated separately, that is they
did not coexist in the same tissue, with appropriate corresponding parameters. In
addition, heterogeneity of bone marrow cells was not considered and mutation ac-
quisition initiating malignancy was not discussed. However, from this model, the
authors predicted that chemotherapy would not be e!ective, especially if tumor cells
were capable of proliferating faster than normal cells.
Bernard et al. and Colijn and Mackey added mature cell populations to create
a more comprehensive model of the hematopoietic system [13, 24]. The former
considered only mature neutrophils in a model that simulated cyclical neutropenia.
The latter included neutrophils, platelets, and erythrocytes to capture the cyclical
dynamics of Periodic Chronic Myelogenous Leukemia. Both models incorporated
negative feedback mechanisms controlling the rate of di!erentiation into committed
lineages. As a result, regulatory mechanisms governed both stem-cell symmetric
self-renewal and symmetric commitment di!erentiation.
The inclusion of regulatory feedback is a significant improvement in modeling
tissue homeostasis. One shortcoming of the models by Mackey et al. is the absence
of asymmetric stem-cell divisions. As a result, di!erentiated progeny only increase
when stem-cell di!erentiation occurs, which depletes the stem-cell population by one.
Although stem-cell loss is balanced by symmetric self-renewal divisions, the omission
of asymmetric division does not permit di!erentiated-cell expansion without some
expense to the stem-cell pool. Another limitation is the exclusion of intermediate
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progenitor populations. Progenitors are not explicitly modeled but are represented
in an amplification factor that incorporates precursor proliferation and apoptosis
rates as well as the number of divisions that transpire between näıve stem cells and
terminally di!erentiated cells.
Tissue hierarchy naturally lends itself to a maturity-structured mathematical
framework. Several approaches have been taken in developing models that include
progenitor populations. A simple structure classifies cells into stem, progenitor,
and di!erentiated populations and model parameters are values that are averaged
throughout the entire subpopulation [83, 118]. The addition of an intermediate
progenitor pool more accurately simulates hierarchical tissue and may be accept-
able when the characteristics of early progenitors resemble those of late progenitors.
However, early progenitors often behave markedly di!erent from progenitors later
downstream, so that averaging the kinetics of all progenitors may not provide favor-
able results.
There are two general model structures that can capture the detailed growth
dynamics in all of the intermediate progenitor populations. One discretizes ma-
turity based on the number of divisions a cell has completed, while the other is
maturity-continuous [36]. The former was conducted by Stochat et al. and re-
cently in collaboration with Ashkenazi et al., while the latter has been used to model
hematopoiesis [7, 100, 117]. These maturity-structured models are not to be confused
with age-structured models in which cell age represents progression through the cell
cycle [14, 111]. Such models provide useful insight about the cycling distribution of
cells within a tissue but are not within the scope of this dissertation.
When maturity is discretized, equations are created for each subpopulation. In
so doing, all rates of entry or exit are specific for that cell population and need not
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be uniform throughout all populations. Generally, cells of maturity i exit through
apoptosis or by dividing and maturing to form cells of maturity i+1. If self-renewal
is permitted, then the cell does not advance in maturity and remains in the ith popu-
lation after division. This type of structure explicitly simulates all of the dynamics of
intermediate populations, but one potential drawback is the system of equations may
be rather large since the number of equations in the system is often determined by
the maximum number of divisions that can occur. In contrast, maturity-continuous
models can capture the same dynamics as discretized models with only a few equa-
tions. A maturity variable is introduced, enabling rates to depend on cell maturity.
Because maturity is continuous, smooth distribution curves can be generated that
quantify the number of cells in any maturity bracket. One hindrance of this model
is that it involves partial di!erential equations, which can be di"cult to analyze
theoretically.
In essence, both discretized and continuous model structures e!ectively capture
the dynamics of hierarchical tissue, but each has its own disadvantages and advan-
tages. A discretized approach was used in collaboration with Ashkenazi et al., but
in the present work, a maturity-continuous model will be developed. In particular,
it will di!er from previous models by including all three modes of stem-cell divi-
sion and incorporating regulatory mechanisms that govern stem-cell self-renewal and
di!erentiation.
3.2 Modeling Multi-Step Tumorigenesis
It is well known that cancer is a multi-step process in which somatic mutations
accumulate to initiate malignancy [10, 50]. While it is generally accepted that muta-
tions causing angiogenesis and metastasis occur later in development, there is much
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uncertainty regarding the order of mutation acquisition in the early stages of tumori-
genesis. Mathematical modeling has provided insightful information regarding these
mutagenic pathways. In particular, modeling can help highlight which transforma-
tions most increase cell fitness, determine which mutations speed cancer onset and
progression, and predict the order of mutation acquisition in specific malignancies.
Because cancer is a result of genetic mutations, there is some degree of probability for
cell transformation. Stochastic models can explore random events, while determin-
istic models predict the average outcome based on mutation rates and probability
distribution functions. In this section, the latter are summarized.
In order to address issues of healthy cell loss that contribute both to aging and
tumorigenesis, Wodarz developed a model of hierarchical tissue that modeled the
degeneration of stem cells and subsequent progenitors [124]. Two scenarios of mu-
tation accumulation were considered. When mutations did not occur during cell
division, it was hypothesized that a faster rate of cell turnover protected against the
mutation of normal cells. However, if mutations occurred during division, then the
model predicted that faster proliferation rates promoted cancer, since cells had more
opportunities to acquire mutations. This mathematical model did not explicitly in-
clude mutated cell populations, but rather investigated the loss of non-mutated cells
in a hierarchical tissue.
The order of mutation acquisition likely a!ects the tempo of malignant growth.
Spencer et al. developed a model of ordinary di!erential equations of a homogeneous
tissue to address which pathway instigated the fastest tumor growth [116]. Loosely
based on breast cancer data, their model predicted that evasion of apoptosis, followed
by increased replication, then angiogenesis, then genetic instability constituted the
fastest path to cancer. Their model, however, did not actually discriminate the se-
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quential order in which mutations were acquired. For instance, cells with the ability
to evade apoptosis as well as increased proliferation were collectively combined into
the same subpopulation and the historical order of mutation was not distinguished.
Since cells with the mutation for evasion of apoptosis surpassed all other popula-
tions expressing only one mutation, it was assumed that this was the first event in
the fastest sequence. Similar calculations concluded subsequent transformations to
establish the fastest path, ignoring the specific order of mutagenic events.
To specifically model mutli-step tumorigenesis in the breast, Enderling et al. de-
veloped a model that incorporated the multi-step approach of Spencer et al. for a
specific mutation sequence [38]. Breast stem cells sequentially acquired two muta-
tions to knock out one tumor suppressor gene, followed by an additional two muta-
tions that removed a second tumor suppressor gene. Cells that had completely lost
both tumor suppressor gene alleles were considered cancerous stem cells. In addition,
the authors included radially symmetric spatial aspects to simulate tumor growth.
As a result, non-cancerous cell populations were modeled with ordinary di!erential
equations, while cancerous cells were modeled with a partial di!erential equation
that was dependent both on time and a one-dimensional space variable. This model
predicted that in order to generate a tumor within the clinically observed time, either
mutations are acquired before puberty that make cells predisposed to accumulating
additional mutations or genetic instability occurs early.
Several models have been developed that emphasize the significance of genetic
instability in cancer-initiation. These models demonstrate that genetic instability
promotes faster tumor growth. Beckman and Loeb used a deterministic model to
figure out the probability that a cell would become cancerous based on the order
in which the mutator phenotype was acquired [11]. They concluded that genetic
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instability confers the greatest advantage when it occurs as the initial mutagenic
event and becomes increasingly significant in highly proliferative tissues. Their re-
sults confirm those of Michor et al., who established that chromosomal instability is
likely an early event in the initiation of colon cancer [84, 85].
To demonstrate the competitive advantage of mutator cells over those that are not
unstable, Komarova and Wodarz developed a di!erential equations model that con-
trasted the fitness of these two cell types [69]. This study hypothesized that mutator
cells do not necessarily expand faster than stable cells during mutation acquisition.
For instance, the magnitude of mutation rate and the extent to which apoptotic
checkpoints remain in tact both influence whether the mutator or stable phenotype
is favored. Therefore, they conclude genetic instability is most tumorigenic when
programmed cell death is previously deregulated.
Clearly the order of mutation acquisition a!ects tumor dynamics. The multi-
step models mentioned here were did not consider how hierarchical organization may
a!ect the pathways to tumorigenesis. Due to the longevity and increased proliferative
potential of stem cells in comparison to terminally di!erentiated cells, it is reasonable
to propose that transformed stem cells are more capable of propagating malignancy.
As a result, segregating stem, progenitor, and di!erentiated cells in multi-step models
can generate more accurate results of mutation acquisition in hierarchical tissue.
3.3 Modeling Cancer Stem Cells
Not all mutated cells are equal in their ability to promote malignancy. It is be-
lieved that only a small percentage of tumor cells are responsible for cancer initiation
and growth. These tumor-initiating cells share many qualities with stem cells, partic-
ularly the ability to self-renew and di!erentiate into various types of progeny, which
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has led them to be called cancer stem cells [110]. Cancer stem cells are generated ei-
ther as a result of mutations in stem cells that deregulate the mechanisms controlling
proliferation and apoptosis, or they can arise from mutated progenitor populations
that have regained self-renewal capacity [4, 22, 60, 102, 110]. The mechanisms that
factor into the emergence of cancer stem cells are not fully understood. Consequently,
mathematical models have been developed in order to gain insight into the dynamics
of these tumorigenic cells.
Using a simple discrete mathematical model, Tomlinson and Bodmer established
that mutations at the stem-cell level were most significant in promoting malig-
nancy [118]. They argued that expansion could result from the failure of apoptosis
or the block of di!erentiation rather than unbridled proliferation. Furthermore, they
were able to demonstrate the importance of incorporating tissue hierarchy in cancer
models, because mutated progenitors and di!erentiated cells were unable to cause
exponential growth, unlike mutated stem cells. The model was first developed to sim-
ulate a normal system in homeostasis. Predictions of cancer cells were made based
on the variation of model parameters, so the actual process of mutation acquisition
was not studied.
One possible approach to distinguishing stem cells from di!erentiated cells is to
classify them based on their location in the tissue. For instance, stem cells reside
in the base of the colon crypt whereas di!erentiated progeny work their way up the
crypt until they die and are removed [8, 84]. Nowak et al. used a linear process to
simulate mutation acquisition in cells of the colon crypt [96]. Because of the way
di!erentiated cells move up the crypt, mutations in non-stem cells are eventually
removed, providing protection from cancer. A subsequent study employed the same
linear structure and demonstrated that the first mutation of the tumor suppressor
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APC gene must happen at the stem-cell level and predicted that a mutation causing
chromosomal instability also occurred in the initial stages of colon cancer [84].
To model the cancer stem cell hypothesis in neural tumors, Ganguly and Puri
created a deterministic model of tumorigenesis that compartmentalized stem, pro-
genitor, and di!erentiated cells as well as their mutated counterparts [44]. In this
model, stem and progenitor cells could become cancer cells through the acquisition
of one mutation, so the multi-step pathways initiating cancer were not explicitly
explored. The model predicted that mutations occurring in stem cells had more of
an e!ect on tumorigenesis than mutations to progenitors. In addition, by incorpo-
rating feedback regulatory mechanisms between the various cell populations, it was
suggested that repeated injury to mature cells, such as repeated radiation, could
promote stem-cell proliferation, which in turn could increase mutation acquisition.
This model is a good example of tumorigenesis in regulated hierarchical tissue and
emphasizes the impact of mutations in stem cells, but it does not investigate the
sequential order of mutation acquisition that promotes cancer.
In order to investigate what type of cell initiates blast crisis during the progression
of Chronic Myelogenous Leukemia, Michor developed a model of two ordinary di!er-
ential equations, one for leukemic stem cells, the other for leukemic progenitors [82].
It was argued that if leukemic stem cells promote blast crisis, then there should be
no di!erence in the time of disease progression between patients treated with ima-
tinib versus those that were not treated because imatinib does not kill leukemic stem
cells. In contrast, if leukemic progenitors drive blast crisis, then there should be a
noticeable di!erence between treated and untreated patients, which is indeed the
case.
Mathematical models that incorporate cancer stem cells can also predict how
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tissue dynamics will change as a result of treatment. In particular, cancer stem
cells are not eradicated by current chemotherapeutic regimens, and therefore cause
relapse by regenerating the tumor. With a simple system of ordinary di!erential
equations, Michor et al. modeled the e!ects of imatinib administration to patients
with Chronic Myelogenous Leukemia [83]. Treatment successfully killed progenitor
and di!erentiated cells, but not all cancer stem cells. Consequently, when treatment
was stopped, cancer regenerated from leukemic stem cells. In addition, the model
was used to investigate the role of drug resistance in disease progression.
To further emphasize the need for therapies that target cancer stem cells, Dingli
and Michor presented a simple model to investigate the e!ects of various treatment
regimens on both normal and cancer cells [31]. The model consisted of four ordinary
di!erential equations to simulate four distinct subpopulations in the tissue: normal
stem cells, cancer stem cells, normal di!erentiated cells, and cancer di!erentiated
cells. Numerical simulations started with the normal steady state values of healthy
stem and di!erentiated cells and one cancer stem cell, and tumor generation was
modeled. After cancer had reached detectable levels, various methods of treatment
were simulated and it was confirmed that targeting cancer di!erentiated cells is
insu"cient to eradicate malignancy. In contrast, the model predicted that therapies
either inhibiting proliferation or increasing death in cancer stem cells could eliminate
cancer altogether.
Due to new discoveries of cancer stem cells, it is now more common to find math-
ematical models of cancer that incorporate some level of maturity-structure. To our
knowledge, however, no existing mathematical model examines the sequential ac-
quisition of mutations within hierarchically structured tissue governed by regulatory
mechanisms. This dissertation aims to fulfill this lacking need in cancer modeling.
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In the following chapter, mutation acquisition in hierarchical tissue is studied with a
maturity-structured model. In Chapters V, VI, and VII, stem-cell governing mech-
anisms are discussed and their deregulation is investigated as a potential cause of
cancer. Finally, in Chapter VIII, both maturity structure and regulatory mechanisms
are combined into one comprehensive model, and the relevance of this model is il-
lustrated with a simulation of mutation acquisition instigating Chronic Myelogenous
Leukemia.
CHAPTER IV
A Maturity-Structured Mathematical Model of Mutation
Acquisition in the Absence of Homeostatic Regulation
It is well known that mammalian tissue is not a homogeneous collection of cells,
but is instead a composition of di!erent types of cells that each have specific roles.
Healthy tissue is carefully organized in a hierarchical structure consisting of stem,
progenitor, and di!erentiated cells. Rare näıve stem are long-lived and unique in that
they both self-renew and di!erentiate [4, 98]. Progenitor cells are more committed
in lineage, but too immature to carry out specific functions. As they complete
additional divisions, progenitors expand in number and become more specific, until
they are fully di!erentiated [4]. Although di!erentiated cells are responsible for
completing tasks that ensure the tissue functions properly, stem cells are crucial
because their division kinetics ultimately maintain tissue homeostasis.
It has been suggested that the cells capable of initiating tumorigenesis share many
characteristics of stem cells. Both malignant cells and normal stem cells are long-
lived, evade apoptosis, have high proliferative potential, and are able to produce
daughter cells of di!erent phenotypes [4, 50, 57, 110]. Realizing these similar prop-
erties, tumor-initiating cells have been called cancer stem cells. The cancer stem cell
hypothesis suggests that malignant growth is driven by a subpopulation of tumor
cells that are capable of self-renewal. It is predicted that these cancer stem cells are
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mutated stem cells or progenitors that have acquired stem-cell characteristics [110].
Since this cancer stem cell hypothesis originated, cancer stem cells have been identi-
fied in tumors of the breast, brain, colon, and blood, among others [4, 12, 40, 43, 57].
Due to the di"culty of isolating and studying stem cells experimentally, mathe-
matical modeling provides further insight into the growth dynamics involved during
tumorigenesis in hierarchical tissue. In order to simulate the cancer stem cell hy-
pothesis mathematically, it is necessary to model cancer stem cells as a distinct
subpopulation from other tumor cells. Furthermore, tissue hiearchy must be con-
sidered because stem, progenitor, and di!erentiated cells have very di!erent prop-
erties. In this chapter, a maturity-structured mathematical model is presented that
investigates mutation acquisition in stem, progenitor, and di!erentiated cells. The
development of cancer stem cells is the focus, and mutation pathways causing the
fastest emergence of disease are determined. In addition, tumor heterogeneity and
composition are discussed.
4.1 A Maturity-Structured Mathematical Model of Hierarchical Tissue
Due to the varying properties of cells in hierarchical tissue, it is desirable to
create a mathematical model that allows cellular kinetics to depend on cell maturity.
Stem cells are the most immature cells in the tissue and they are capable of self-
renewal. Though still immature, progenitors are more committed in lineage, and as
they divide, they di!erentiate to increase cell maturity. Progenitors must complete
a number of divisions to expand and generate an adequate amount of terminally
di!erentiated cells. Therefore, the rate of proliferation must be significantly greater
than the rate of apoptosis to allow expansion in this cell population. Fully mature
cells are terminally di!erentiated, do not have any proliferative potential, and exit
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Figure 4.1: Maturity scheme for mathematical model. Stem cells are the most immature
and can self-renew. Progenitors are more committed and di!erentiate as they divide.
Terminally di!erentiated cells cannot divide and eventually die.
the tissue through cell death. Consequently, the rate of apoptosis is substantial
in terminally di!erentiated cells. Figure 4.1 provides a schematic of the maturity
progression from stem to di!erentiated cell.
There are various ways of explicitly modeling each of the cell subpopulations in a
tissue. Some mathematical models compartmentalize stem cells, progenitor cells, and
di!erentiated cells [5, 13, 24, 83], while others distinguish cells based on maturity,
be it through discrete cell divisions [7] or continuous cell maturity level [100]. In this
chapter, a di!erential equations model is presented in which both time and maturity
are continuous. First, a model of healthy tissue will be established, and then this
model will be used to investigate the process of mutation acquisition in hierarchical
tissue. An ordinary di!erential equation is used to model the stem-cell population
since it is assumed stem cells do not mature. In contrast, a partial di!erential
equation is used for non-stem cells that is dependent on both time and maturity. To
our knowledge, this is the first mathematical model that addresses the emergence of
cancer stem cells within a maturity-continuous structure.
4.1.1 Model Structure
It is known that the properties of stem, progenitor, and di!erentiated cells are
markedly di!erent from each other. Stem cells are unique in that they are näıve
and have the potential to remain in an undi!erentiated state. Under homeostatic
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conditions, it is thought that the majority of stem cells are in a quiescent state and
divide infrequently. In contrast, progenitors eventually reach full maturity through
extensive proliferation that produces di!erentiated progeny. As progenitors mature,
their proliferative and apoptotic behavior may also change. For instance, immature
myeloid precursor cells, such as myeloblasts, divide faster than more di!erentiated
myelocytes [109]. Consequently, it is desirable to mathematically model hierarchical
tissue in such a way as to allow cell kinetics to depend on cell maturity.
In 2003, Ostby et al. presented a continuous maturity-structured model of granu-
lopoiesis, which simulated cells from the myeloblast stage through terminally di!er-
entiated granulocytes in a normal, healthy system [100]. Stem cells were not modeled,
but rather were assumed to be at a constant level in homeostasis that fed into the
progenitor population. A one-dimensional wave equation dependent on time and cell
maturity was employed for progenitor cells in the bone marrow. Rates of prolifera-
tion, mobilization from the bone marrow to blood, and apoptosis were all dependent
on cell maturity. Cell maturity was scaled such that the most immature cell had
maturity level zero, the most mature cell had maturity level one, and the matura-
tion rate determined how quickly cells progressed through each stage. This model
assumed that cells in the blood were terminally di!erentiated, and thus were fully
mature and did not proliferate, so that blood cells were modeled with an ordinary
di!erential equation dependent on time only. From numerical simulations, it was
suggested that progenitor apoptosis may be significant under certain assumptions.
In particular, the authors determined that the significance of cell death depended on
the times precursors spent in each phase and concluded that model accuracy would
be improved with more reliable predictions of these transit times.
In the present work, a mathematical model is introduced that imparts a similar
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maturity-continuous structure, while making various significant alterations from the
Ostby model. It is important to note that the Ostby model simulated granulopoesis
in homeostasis, which permitted the omission of explicitly modeling stem cells. In
modeling tumorigenesis, and specifically the generation of cancer stem cells, it is
essential to include an equation monitoring the dynamics of the stem-cell population.
Therefore, the most significant di!erence between the present work and the Ostby
model is the inclusion of a stem-cell equation that fosters investigation of the e!ects
that stem cells have on tissue dynamics.
Other di!erences between the two models are not as striking, but still noteworthy.
For instance, because the Ostby model was specifically tailored for granulopoiesis,
the maturity-structured progenitor population was contained in the bone marrow,
while all cells in the blood were assumed to be fully mature and thus did necessitate
maturity structure in the blood compartment. Although the hematopoietic system
will be simulated in this chapter as well, the mathematical model developed here is
general and can be applied to any hierarchical system. The models also slightly di!er
in how the measurement of maturity is handled. In the Ostby model, maturity was
on a scale of zero to one, and a constant maturation rate was derived from the time
needed for a cell to progress from myeloblast to granulocyte. In contrast, maturity
is not scaled in the current presentation, but rather progresses according to the time
scale. A cell with a maturity level measured in weeks has completed an approximate
number of divisions depending on the proliferation rate, which determines its progress
to terminal di!erentiation. Therefore, the models slightly di!er in how maturity is
defined, but in essence are comparable since both models rely on average proliferation
rates to determine maturity.
A continuous maturity-structured model is now introduced. Consider a time- and
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maturity- continuous model in which time is denoted by t and the maturity of cells
is denoted a. Stem cells are the most näıve cells in the system. They do not mature,
and, therefore, the size of the stem cell population, denoted S(t), is not dependent
on a. Stem cells proliferate at rate k. Assume that each stem cell encounters one
of four fates during each division: symmetric self-renewal, asymmetric self-renewal,
symmetric commitment di!erentiation, and apoptosis. Stem cells symmetrically self-
renew with probability "S, which increases the stem cell pool by one. Stem cells
asymetrically self-renew with probability "A, which does not change the stem cell
pool but increases the progenitor pool of maturity level zero by one. Stem cells
symmetrically di!erentiate with probability "D, which decreases the stem cell pool
by one and increases the progenitor pool of maturity level zero by two. Finally, stem
cells die with probability #S, and it follows that "S +"A +"D +#S = 1. It is assumed
in this model that stem cells only die and di!erentiate when dividing, though the
model equations could easily be slightly modified to allow for division-independent
di!erentiation and apoptosis.
The maturity density of di!erentiated cells at time t is denoted n(t, a), where the
number of cells between maturity level a and a + #a is approximately n(t, a)#a.
The proliferation rate of di!erentiated cells, denoted by the function !(a), allows
immature to proliferate but tends to zero as maturity is reached. The death rate of
di!erentiated cells, given by the function µ(a), increases after full maturity. If the
initial stem cell population is S0, the initial maturity distribution of di!erentiating
cells is given by f(a), and the total number of non-stem cells in the tissue is N(t),




















For ease of reference, this model is labeled the Maturity-Structured Model in the
Absence of Homeostatic Regulation (MSMAHR). In the MSMAHR model, probabil-
ities of stem-cell division are constant, but in the next chapter, dynamic regulatory
feedback mechanisms that influence the pattern of self-renewal and di!erentiation
will be discussed.
There are many potential functions that would be suitable choices for !(a) and
µ(a). Generally, !(a), should be greater than µ(a) for immature cells that have not
yet completed terminal di!erentiation in order to allow for progenitor expansion.
Furthermore, as a # $, !(a) # 0 and µ(a) increases well beyond !(a). By not
explicitly defining functions for the proliferation and death rates of di!erentiating
cells, the MSMAHR model remains a general enough framework to be used modeling
various types of hierarchical tissue. In Section 4.1.3, specific examples are given in
order to generate numerical simulations of the hematopoietic system.
4.1.2 Model Analysis
The solution of the stem-cell equation is S(t) = S0e(!S!!D!"S)kt. The method of
characteristics may be used to solve the di!erentiated cell equation [92]. Assuming
cell maturity is determined by time passed since a di!erentiated cell was formed gives
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da
dt = 1, and the di!erentiated cell population equation is simplified to
dn
dt = !n"µn.
Note that dadt = 1 implies that a = t+C, for some constant C. For a > t, C = a0 and
for a < t, C = "t0.






































At time t = 0, a = a0, and so K = n(a0, 0). If the initial age distribution is given by
n(a, 0) = f(a), then since a0 = a" t,
















Note that if f(a) = 0, then n(a, t) = 0 for a > t. That is, it their are no di!erentiating
cells in the tissue at time t = 0, then it is impossible for the maturity level of a cell
to be greater than the time that has elapsed. For instance, if n(a, 0) = 0, then at
two weeks all di!erentiating cells must have maturity that is less than or equal two
weeks.
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When a = 0, t = t0, so that K = n(0, t0) = n(0, t), which in this model gives
K = (2"D + "A)kS. Therefore, for a < t,






The di!erentiated-cell population will go to steady state as long as the stem-cell
population is in steady state, as seen in Equation 4.5. The stem-cell population
is in steady state if "S " "D " #S = 0. Otherwise, it either grows or decays ex-
ponentially, which causes the di!erentiated-cell population to behave accordingly.
Thus stem-cell population dynamics dictate di!erentiated-cell population dynamics,
which correlates with previous modeling results from Hardy and Stark that predicted
stem-cell equilibrium determines tissue homeostasis [51].
4.1.3 Parameter Estimation
Due to the di"culty of isolating and studying stem cells in vivo, there are limited
data for stem-cell kinetics. The hematopoietic system is perhaps the best quantified
system, and as a result, parameter values for model simulations are derived from
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Parameters Used
Parameter Biological Meaning Value Range Value Used
S0 Initial number of stem cells 11,000 - 22,000 cells [1] 18,000 (cells)
!S Probability SSR (derived from [125]) 0.20
!A Probability of ASR (derived from [125]) 0.60
!D Probability of SD (derived from [125]) 0.15
"S Probability of stem-cell death 0.05 [83] 0.05
k Proliferation rate of stem cells 0.4043 weeks!1 [21] 0.4043 weeks!1
b Max. prol. rate of progenitors 9.0 - 10.6 weeks!1 [109] 9.7 weeks!1
#! Steepness of proliferation switch No information 2
$! Maturity at proliferation switch No information 2.05 weeks
d Max. death rate of di!. cells 15 - 18 weeks!1 [9, 13] 16.8 weeks!1
#µ Steepness of death switch No information 10
$µ Maturity at death switch No information 4.10 weeks
Table 4.1: Baseline parameters used to simulate the Maturity-Structured Model in the Absence of
Homeostatic Regulation, found in Equations 4.1.
hematopoietic stem cells and progenitor and di!erentiated cells of the granulocytic
lineage. The parameters used are presented in Table 4.1.3.
Although hematopoietic stem cells are better understood than stem cells in other
tissues, there is still much uncertainty concerning in vivo measurements. Part of
the discrepancy comes from the process of isolating stem cells. There are several
markers that isolate immature cells from those that are more di!erentiated, but it
can be di"cult to separate stem cells from early progenitor cells. Therefore, it is
not uncommon for a population of “stem” cells to also include early progenitor cells,
which can taint the true measurements of stem versus early progenitor cells. As a
result, the current literature includes a wide range of values regarding hematopoietic
stem-cell kinetics. Because this mathematical model separates stem cells from all
other cells, the parameters used here attempt to reflect the most purified stem-cell
population
As cells di!erentiate, they lose their ability to proliferate. Stem and early progen-
itor cells have high proliferative potential, whereas terminally di!erentiated cells are
unable to complete further divisions. Although some terminally di!erentiated cells
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are long-lived, such as lymphoid cells, this model assumes that fully mature cells have
a short half-life and, consequently, a significant rate of apoptosis [9, 13, 61]. In order
to capture the dependence of proliferation and apoptosis on cell maturity, functions
that smoothly transition between two di!erent baseline rates are used. There are
many possibilities for such functions, but for simplificity, this model assumes that
the proliferation rate is approximately constant until terminal di!erentiation, after
which it approaches zero. In contrast, the death rate is assumed to be approximately
zero until terminal di!erentiation, after which it is approximately constant with a
short half-life. Instead of incorporating step functions that introduce discontinuity,
















The maximum rate of proliferation is given by b and the maximum rate of death is
given by d. The maturity at which non-stem cells proliferate at half the maximum
rate is '#, and &# is the steepness of the decreasing switch. Similarly, the maturity
at which non-stem cells die at half the maximum rate is 'µ and the steepness of the
increase in the switch is &µ. It is also assumed that progenitors die at a rate at least
as great as stem cells. The proliferation and death rate functions in Equations 4.6
are plotted in Figure 4.2.
4.1.4 Numerical Simulations and Results
In the Section 4.2, mutation pathways generating cancer in hierarchical tissue
will be explored, but before this can be investigated, the steady state of healthy
tissue must be first determined. In order to conduct numerical simulations, model
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Figure 4.2: Proliferation and death rates of di!erentiating cells depend on cell maturity.
The functional forms presented in Equations 4.6 are plotted versus cell maturity.
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equations were discretized with the upwind method and simulations were conducted
in MATLAB. Step sizes for #t and #a satisfy the CFL condition. For the boundary
condition of di!erentiating cells, at the jth time step, nj0 = (2"D + "A) kS
j!1#t.
To determine the steady state maturity-distribution of cells, it is necessary to
generate the progeny resulting from a steady state of stem cells. Since hematopoi-
etic stem cells are arguably the most observed, the hematopoietic system is used to
illustrate the dynamics of hierarchical tissue. It is estimated that there are between
11,000 - 22,000 hematopoietic stem cells in an adult human [1]. In future chapters,
the mechanisms regulating stem cell hematopoiesis will be discussed, so in order to
correlate with following work, suppose a system is infused with 18,000 stem cells and
zero progenitor and di!erentiated cells. Assume stem cells divide with probabilities
that maintain equilibrium within the stem-cell compartment so it possible to de-
termine the steady state maturity distribution of progenitor and di!erentiated cells
resulting from this many stem cells. Progenitors are formed through asymmetric
and symmetric commitment divisions of the existing stem cells. Progenitors prolif-
erate and expand in number to generate fully-di!erentiated cells, and eventually a
steady-state distribution of progenitor and di!erentiated cells is reached.
Figure 4.3 plots tissue dynamics as stem cells generate progenitor and di!eren-
tiated cells. The maintained homeostasis of stem cells and the generation of the
resulting progeny of non-stem cells is displayed in a log plot in Figure 4.3A. Initially,
there is a low number of non-stem cells that are all progenitors formed from the stem-
cell population. As time progresses, progenitors proliferate and expand in number as
the stem-cell source continues to form early progenitors. As equilibrium is reached,
the total number of non-stem cells includes all progenitors and fully-di!erentiated
















































Figure 4.3: The generation of hierarchical tissue from stem cells. (A) A log plot of stem
(blue) and non-stem (red) cells in the tissue versus time. Starting at stem-cell home-
ostasis, the stem-cell population remains constant over time, while the non-stem cell
population expands until it reaches homeostasis. (B) The maturity distribution of non-
stem cells at steady state demonstrates the majority of cells are fully mature.
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reaches 6.54% 1011 cells, which is within the range of 5" 15% 11 cells of the granu-
locytic lineage estimated in a human adult [52, 100, 109]. It takes approximately 4.6
weeks for N to reach 90% of its equilibrium value, though the time to constitution
can be altered by the rate of proliferation in both stem and progenitor cells. In Fig-
ure 4.3B, the maturity distribution of non-stem cells at steady state demonstrates
that the majority of stem cells are fully mature. At homeostasis, it is estimated that
1.3%1011 cells are fully di!erentiated, which correlates with the estimated 1.2%1011
granulocytes that are released from the bone marrow to the blood daily.
The proliferation and death rate functions, ! and µ, respectively, are those dis-
played in Figure 4.2. Cells are considered to be fully mature when µ > !, which
occurs at approximately 3.8 weeks in this simulation. The cycle times of immature
myeloblasts, myelocytes, and promyelocytes are estimated to be 11, 27, and 39 hours,
respectively [109]. Therefore, the proliferation rate is greater for lower maturity lev-
els, with a maximum rate of 9.7 divisions per week to correlate with the doubling
time of myeloblasts. Neutrophils reside in the bone marrow for approximately 4 days
after their final division before being released into the blood [39]. Once in the blood,
the half-life of neutrophils is estimated at seven hours, thus the maximum of the
death rate is achieved soon after cells have reached full maturity.
This section presented a maturity-structred model of hierarchical tissue that is
continuous both in time and cell maturity. Mathematical analysis determined the
solution for both stem and non-stem cell populations, and it was concluded that the
number of progenitor and di!erentiated cells is directly dependent on the number of
stem cells present in the system. Through numerical simulations in which cells of
the granulocytic lineage were produced from an initial population of hematopoietic
stem cells, it was possible to determine the steady state of non-stem cells as well as
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the maturity distribution of progenitor and di!erentiated cells at homeostasis. These
findings will be used as the baseline values of healthy hierarchical tissue in exploring
the process of mutation acquisition and tumorigenesis in the next section.
4.2 Mutation Acquisition in Stem, Progenitor, and Di!erentiated Cells
It is believed that tumorigenesis does not result from a single mutation, but
rather is a multistep process [20, 50]. Although it is known several events are needed
to cause the malignant transformation of a normal cell, the order in which these
mutations are acquired can a!ect tumor dynamics. Deregulated proliferation, evasion
of apoptosis, and genetic instability are likely involved in the early stages of cancer,
whereas mutations causing angiogenesis and metastasis are probably acquired in
later stages, after a tumor has grown beyond a certain threshold size [50]. In this
section, mutation acquisition in hematopoietic cells is investigated; consequently,
angiogenesis and metastasis may be disregarded.
The hierarchical organization of most mammalian tissues may o!er protection
against cancer. The vast majority of tissues consist of di!erentiated cells that have
a high rate of turnover and generally don’t live long enough to accumulate enough
mutations to become malignant [102, 110]. In addition, most di!erentiated cells do
not self-renew, and when they reach full maturity, mutations are not passed on to
any progeny. Generally, stem cells, or progenitors that have gained self-renewal capa-
bility, are the only tissue cells that live long enough to acquire a su"cient number of
mutations and possess a su"cient proliferative potential that allows the propagation
of mutations to their progeny [28, 110].
In this section, the pathways leading to tumorigenesis in hierarchical tissue are
explored. This mathematical model is one of the first that permits the investigation
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of sequential mutation acquisition within hierarchically structured tissue [7]. Be-
cause mutation order is monitored, it is possible to quantify the increased advantage
gained through each transformation. Furthermore, tissue composition can be deter-
mined that is based on the percentages of cells with a certain number of mutations.
An additional feature of this model is the explicit inclusion of all three models of
stem-cell division: symmetric self-renewal, asymmetric self-renewal, and symmetric
commitment di!erentiation. This di!ers from other mathematical models of can-
cer in which asymmetric divisions are often ignored. To our knowledge, this is the
first model to incorporate all of these novel features within a maturity-continuous
framework.
4.2.1 Model Structure for Mutation Acquisition
To study the process of oncogenesis in hierarchical tissue, the MSMAHR model
presented in Equations 4.1 is expanded to incorporate mutation acquisition in both
stem and di!erentiated cells. Normal stem cells, S0, acquire their first mutation at
rate m0, at which time they are labeled as S1. Likewise, S1 cells acquire the second
mutation at rate m1 to become S2 cells, and S2 cells acquire the third mutation at
rate m2 to become S3 cells. Stem cells with i mutations, Si, form progenitor cells
with i mutations, ni, when they di!erentiate. Committed cells may also mutate as
they continue to divide, and Mi is used to denote the mutation rates from ni to
ni+1. It is assumed that cells may only acquire one mutation at a time. Cells with i
mutations may alter any of the model parameters, depending on which mutation is
acquired, thus each parameter is denoted with an i-subscript to allow these values
to di!er from the baseline value. A schematic diagram is displayed in Figure 4.4 and
the model equations for mutation acquisition are presented below.
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Figure 4.4: Schematic diagram of mutation acquisition in hierarchical tissues. Stem cells
with zero, one, two, or three mutations may self-renew or di!erentiate to form pro-
genitors, which in turn continue dividing and maturing. Each time cells divide, there
is a small probability they will acquire a mutation. Cells can accumulate up to three





= [(1" 2m0)"S0 "m0"A0 " "D0 " #S0] k0S0(4.7)
dS1
dt
= [(1" 2m1)"S1 "m1"A1 " "D1 " #S1] k1S1
+ [2m0"S0 + m0"A0] k0S0
dS2
dt
= [(1" 2m2)"S2 "m2"A2 " "D2 " #S2] k2S2
+ [2m1"S1 + m1"A1] k1S1
dS3
dt
= ["S3 " "D3 " #S3] k3S3

























= [!3(a)" µ3(a)] n3 + 2M2!2(a)n2














for i = 0, 1, 2, 3.
Initial Conditions:
n0(a, 0) = f(a)(4.10)







(0, t) = [2(1"m0)"D0 + (1"m0)"A0] k0S0(4.11)
$n1
$t
(0, t) = [2(1"m1)"D1 + (1"m1)"A1] k1S1
+ [2m0"D0 + m0"A0] k0S0
$n2
$t
(0, t) = [2(1"m2)"D2 + (1"m2)"A2] k2S2
+ [2m1"D1 + m1"A1] k1S1
$n3
$t
(0, t) = [2"D3 + "A3] k3S3
+ [2m2"D2 + m2"A2] k2S2
To easily refer to this model in subsequent discussion, it is named the Maturity-
Structured Model of Mutation Acquisition (MSMMA).
4.2.2 Exploring the Pathways to Tumorigenesis
Several types of genetic transformations have been implicated in oncogenesis, but
in this investigation, focus is directed towards somatic mutations that occur during
DNA replication. In their review and classification of cancer cells, Hanahan and
Weinberg identified commonalities in malignant cells: independence of growth sig-
nals, increased proliferation, evasion of apoptosis, insensitivity to anti-growth signals,
and the abilities to promote angiogenesis and metastasize [50]. In addition, genetic
instability is believed to be widespread in various cancers [15].
To examine the initiation of cancer, three mutations are considered in this work.
The D mutation decreases the percentage of stem cells that go through apoptosis
and decreases the maximum death rate of non-stem cells. The G mutation increases
the rate at which subsequent mutations are acquired. The R mutation alters cell
proliferation, by either increasing the rate of proliferation or shifting the balance of
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stem-cell division to favor symmetric self-renewal. A cell is considered to be healthy
and normal if it does not have any mutations and assumed to be cancerous once it
has acquired all three mutations. For model simulations, all mutations are one-hit,
though mutations requiring two genetic events could easily be incorporated simply
by increasing the number of mutations that must occur to malignantly transform
a cell. Mutations enabling angiogenesis and metastasis are not considered because
model simulations are of the hematopoietic system.
The order in which mutations are acquired is noted by the order in which D, G,
and R are listed. There are six possible sequences in which the mutations accumulate:
• D & G & R
• D & R & G
• G & D & R
• G & R & D
• R & D & G
• R & G & D
Tumor dynamics are compared and contrasted for all six pathways. Note that each
pathway produces cancer cells that have acquired the same three mutations, but
each pathway is di!erent in the order in which mutations occur. Because a specific
cancer is not being modeled, it is assumed that for each D, G, and R mutation in
the model, there are approximately 100 genes that may cause transformation [116].
As a result, the mutation rate is one hundred times the suggested mutation rate of
10!8 per division [83, 116].
Numerical simulations were conducted using MATLAB. The upwind method was
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Parameters Used
Parameter Biological Meaning Normal Value Mutated Value
S0 Normal stem-cell homeostasis 18,000 (cells) [83] 18,000 (cells)
!S Probability of SSR 0.20 [125] 0.40
!A Probability of ASR 0.60 [125] 0.425
!D Probability of SD 0.15 [125] 0.15
"S Probability of stem-cell death 0.05 [83] 0.025
k Stem-cell proliferation rate 0.4043 (weeks!1) [21] 0.8086 (weeks!1)
m Mutation rate of stem cells 10!6 [6, 58, 116] 10!4 [58, 116]
M Mutation rate of non-stem cells 10!6 [6, 58, 116] 10!4 [58, 116]
b Max. progenitor proliferation rate 9.7 (weeks!1) 19.4 (weeks!1)
#! Steepness of prog. prol. switch 2 2
$! Maturity at prol. switch 2.05 (weeks) 1.025 (weeks)
d Max. di!erentiated cell death rate 16.8 (weeks!1) [9, 13] 8.4 (weeks!1)
#µ Steepness of di!. cell death switch 10 10
$µ Maturity at death switch 4.10 (weeks) [39] 3.075 (weeks)
Table 4.2: Parameters used for the Maturity-Structured Model of Mutation Acquisition.
used to discretize model equations, as described in Section 4.1.4. It is assumed
that the hierarchical tissue begins in the healthy steady state determined by the
MSMAHR model in equation set 4.1. As a result, the number of stem cells and the
maturity distribution of di!erentiating cells for healthy tissue in homeostasis is the
initial condition for simulations of tumorigenesis. Parameter values used to simulate
healthy and mutated cells are presented in Table 4.2.2.
Because cancer stem cells are believed to drive tumor growth, the emergence of
the first cancer stem cell establishes the onset of malignancy. As a result, the time
required to generate the first cancer stem cell is recorded for each mutation pathway
in order to determine which is the fastest in cancer development.
Four scenarios of mutation acquisition are investigated. In the first case, all
mutations are advantageous and increase the cell’s competitive advantage in some
way. In the second case, mutations occurring in cells that have not yet acquired the
ability to evade apoptosis are disadvantageous and increase cell death. The third
case investigates the e!ects of a shift in the stem-cell division pattern that increases
symmetric self-renewal. Finally, increased expansion in the progenitor pool due to
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extra divisions is explored in the fourth case.
All Mutations are Advantageous
Consider a case in which all mutations are advantageous, which for convenience
shall be referred to as Case A. In particular, suppose all mutations give the cell
a specified advantage over its normal counterpart and do not cause an increase in
cell death upon mutation. Specifically, the D mutation decreases the probability
of stem-cell death by half and the decreases the death rate of di!erentiating cells
by half. The G mutation augments genetic instability, increasing the rate at which
mutations are acquired from 10!6 to 10!4. The R mutation doubles the proliferation
rate of both stem and progenitor cells. It is worth noting that progenitor cells with
the R mutation reach full maturity in half the time of normal cells since the cells are
dividing twice as fast but this mutation does not increase the number of divisions
they are able to complete.
Under these conditions, genetic instability is the most significant contributor to
cancer onset. The GDR and GRD pathways produce the first cancer stem cell in the
shortest time, followed by the DGR and RGD pathways, and finally the DRG and
RDG pathways. Figure 4.5 plots the cancer stem cells and cancer non-stem cells for
each pathway over time, and illustrates that there is negligible di!erence between
the GDR and GRD pathways, between the DGR and RGD pathways, and between
the DRG and RDG pathways. Thus, it is evident that the order in which the G
mutation is acquired determines the speed of cancer stem cell generation.
The fastest pathways are those in which G is acquired first, while the slowest
acquire G last. The significance of the G mutation may at first seem surprising
because it does not increase the cell’s fitness as the D and R mutations do. In fact,
the G mutation might be thought of as a silent mutation that does not appear to
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Figure 4.5: Genetic instability determines the fastest path when all mutations are ad-
vantageous. (A) Cancer stem cells for each pathway versus time. The order in which
genetic instability is acquired has the greatest influence on determining tumor growth.
Pathways in which G is acquired first are the fastest, while those that acquire G last
are slowest. (B) Cancer non-stem cells reflect the behavior of cancer stem cells.
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give the mutated cell any advantage. However, the acquisition of G accelerates the
rate at which additional mutations are acquired, and therefore decreases the time
required to generate the first cancer stem cell.
The sequential order of the G mutation is the most important in determining the
fastest pathway, but no such conclusion can be made about the order of D and R
mutations. Whether D or R occurs earlier in the fastest pathway depends on the
amount of change between normal and mutated proliferation and death rates. For
instance, using certain parameter values, GDR could be the fastest, while for others
it would predict that GRD is fastest. Over a wide range of parameters, however,
the impact of the G mutation is still most significant in determining the time to
cancer onset. As a result, the conclusion that genetic instability dictates the time to
malignancy is robust.
As shown in Figure 4.5, cancer di!erentiating cells are present in the tissue at
early times. In fact, all pathways generate a small number of cancer di!erentiating
cells years before the first cancer stem cell emerges. In this case it is assumed that no
mutation occurs in progenitor populations that arrests di!erentiation. As a result,
mutated di!erentiating cells may cause hypercellularity in the tissue, but they do
not instigate malignancy because they die after completing a prescribed number of
divisions. Instead, it is the emergence of the first cancer stem cell that marks the
onset of disease because these cells can both self-renew to expand their number and
di!erentiate to form mutated di!erentiating cells.
From Figure 4.5, one may also notice the correlation between the growth dynamics
of the stem-cell population with those of the di!erentiating population. The model
predicts that tumor growth is dependent upon the behavior of a small subpopulation
of cancer cells. Therefore, under the assumptions of Case A, the model supports the
65
cancer stem cell hypothesis in that a select subgroup of cells promotes tumorigenesis.
That is, if di!erentiating cells do not acquire self-renewal capability, then a small
population of mutated stem cells is the driving force in tumor growth.
Death Increases Without an Anti-apoptotic Mutation
Because cell division is a tightly regulated process, the presence of mutations can
force apoptosis. This defense mechanism prevents the propagation of mutations to
progeny, thereby maintaining the genetic integrity of cells in the tissue. As a result,
cells that have become transformed are more prone to programmed death unless they
have also acquired a mutation that allows them to evade apoptosis. The next case,
labeled Case B, investigates the consequences of increased death in cells that have
acquired either R or G without obtaining D previously.
Suppose the mutations are defined as in Case A, with the additional condition that
cells with either a G or R mutation have a higher death rate if D has not previously
been acquired. The DGR and DRG pathways do not change in comparison with
Case A since the D mutation is acquired first, but all other pathways are a!ected.
Figure 4.6 demonstrates that cancer onset is delayed in pathways in which D is
not acquired first. Specifically, in sequences where D is acquired second, the first
cancer stem cell appears approximately ten years later than it did in case A for
parameter values found in Table 4.2.2. When D is acquired last, the first cancer
stem cell appears approximately twenty years later than it did for the same sequence
in Case A. These results suggest that the acquisition of a mutation decreasing cell
death is most advantageous in producing cancer cells if mutations are lethal. This
follows from the fact that in this simulation, cells with only R and G mutations
are suppressed through apoptosis, whereas cells with the D mutation can expand.
For that reason, it is not surprising that the DGR pathway is the fastest, with the
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Figure 4.6: The emergence of cancer is slowed when all mutations are not advantageous.
The emergence of cancer is delayed in pathways in which the D mutation is not acquired
first. Case A is plotted with dashed lines while case B is plotted with solid lines.
first cancer stem cell appearing in 25.8 years, while the RGD pathway is slowest and
produces the first cancer stem cell in 46.4 years.
The contrasting results from Case A and Case B demonstrate that the fastest
pathway is dependent upon the assumptions that are made to characterize mutations.
When all mutations are advantageous as in Case A, acquiring the G mutation first
leads to the fastest appearance of a cancer stem cell. On the other hand, when
mutated cells have increased death without the ability to evade apoptosis as in Case
B, acquiring the D mutation gives rise to the first cancer stem cell. In addition,
the tissue composition of the fastest pathway from Case A, denoted GDRA, and the
fastest pathway from Case B, denoted DGRB, are notably di!erent, as illustrated in
67
Figure 4.7. Following the GDRA pathway, the majority of cells are normal for the
first 28 years, after which cancer cells dominate, while cells with one or two mutations
remain a small portion of the system, as shown in Figure 4.7A. Compare this with
the tissue composition of the DGRB pathway plotted in Figure 4.7B. Normal cells
are the majority until 31 years, after which cells with one mutation, namely the D
mutation, are most numerous. Cells with the D mutation dominate until cancer cells
surpass them at 36 years. Thus the decline of normal cells in the system is comparable
between the two pathways, but the system following the GDRA pathway is usurped
by cells having all three mutations, whereas the tissue following the DGRB pathway
first fills up with cells having only one mutation before being filled with cancer cells.
The dominance of cancer is nearly thirteen years faster in GDRA than in DGRB,
indicating that the disease created through the former is more aggressive than the
latter.
Due to cellular machinery that arrests proliferation of mutated cells, it is likely
that mutations would be detected that would force the cell into apoptosis unless the
machinery itself was also erroneously transformed. Consequently, the assumptions
of Case B are likely a more realistic depiction of mutation acquisition in human cells.
In this case, acquiring the D mutation first bears greatest importance since it ensures
the cell’s survival, allowing it to accumulate further abnormalities. As in Case A,
the population of cancer stem cells drives tumorigenesis and is a very small minority
of all tumor cells.
Unbalanced Stem-Cell Division Pattern
Deregulation of cell proliferation can refer either to the alteration of proliferation
rate or the transformation of cell division pattern. Both Cases A and B defined the
R mutation as an increase in proliferation rate. Now consider Case C in which the
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Figure 4.7: Comparison of tissue composition for fastest paths when all mutations are
advantageous versus when some are lethal. (A) The changing tissue composition
in the GDR pathway, fastest for Case A in which all mutations are advantageous. Within
28 years, cancer cells dominate the tissue. (B) The changing tissue composition for the
DGR pathway, fastest for Case B in which R and G are not advantageous without D
first. At approximately 31 years, cells with the D mutation are the majority, but cancer
cells increase and take over the tissue in 36 years.
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R mutation doubles the probability of symmetric self-renewal in stem cells, while
the proliferation rate of stem cells and the division properties of progenitors are
unaltered. In essence, progenitor cells with the R mutation do not behave di!erently
than those without the R mutation, but stem cells with the R mutation are more
likely to symmetrically self-renew than normal stem cells. The G and D mutations
are defined as in Case A, and it is assumed that all mutations are advantageous.
Increasing symmetric self-renewal significantly quickens the pace of cancer devel-
opment. In fact, all pathways have a first cancer stem cell within eight years. The
fastest pathway is the GRD pathway, with the first cancer stem cell formed in 5.5
years, but the slowest pathway, DRG, is less than three years slower. Therefore, the
di!erence between the fastest and slowest pathways is relatively insignificant, imply-
ing that increased symmetric self-renewal minimizes the impact of other mutations.
In other words, when a mutation increases symmetric self-renewal, cancer stem cells
rapidly emerge in all pathways so that the order of mutation acquisition does not
meaningfully influence the time to first cancer stem cell.
Figure 4.8 compares the time to first cancer stem cell for each pathway in Cases
A, B, and C. Cancer stem cells in Case C emerge 15 to 20 years faster than in Case
A and 20 to 40 years earlier than in Case B. The speed of disease onset suggests
that aberrant symmetric self-renewal may be a key contributor in aggressive forms
of cancer, whereas deregulated cell proliferation may be characteristic of diseases
that progress more slowly. Furthermore, increased symmetric self-renewal appears
to diminish the impact of genetic instability because the di!erence between slowest








































Figure 4.8: Unbalanced symmetric self-renewal significantly decreases the time to can-
cer. When stem-cell division pattern is unbalanced with an increase in symmetric
self-renewal, cancer stem cells rapidly develop.
71
Progenitors Complete Additional Divisions
It is unknown if cancer stem cells are mutated stem cells or mutated progenitor
cells that have gained stem-cell characteristics, particularly the ability to self-renew.
To address this issue, Case D assumes the R mutation a!ects the proliferation of
progenitor cells by increasing the number divisions before terminally di!erentiating.
Stem cells may acquire the R mutation, though it does not alter the stem-cell kinetics
and therefore acts as a pre-cancerous mutation that later manifests in progeny that
are more di!erentiated. The proliferation rate of both stem and non-stem cells does
not increase with the R mutation so that this mutation only increases the number of
progenitor divisions. As in Cases A, B and C, the D mutation decreases apoptosis,
the G mutation increases the mutation rate. In addition, it is assumed that all
mutations are advantageous.
The time to first cancer stem cell is slower for all six pathways than in the previous
cases because mutated stem cells do not proliferate faster or symmetrically self-renew
more than normal stem cells. However, progenitor and di!erentiated populations
expand due to the extra divisions completed by progenitors, as shown in Figure 4.9A.
The percentage of tissue cells having one mutation is plotted in Figure 4.9B. The
DGR pathway, in which R is acquired last, is the only pathway in which a majority
of tissue cells have one mutation over time. As demonstrated in Figure 4.9C, the
majority of tissue cells following the DRG and RDG pathways have two mutations, D
and R. All other pathways are taken over by cells with all three mutations, as shown
in Figure 4.9D. The hypercellularity resulting from the D and R mutations alone
could lead to death as the tissue reaches a fatal burden of cells as in the DRG and
RDG pathways. However, tissues following these pathways are primarily composed
of cells with the D and R mutations that might be more reactive to treatment since
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genetic instability has not been acquired. If treatment successfully targets cells that
have not acquired all three mutations, then pathways generating tumors mainly
composed of cells with all three mutations are more problematic.
Unlike Cases A, B, and C, the composition of non-stem cells in the tissue does
not mirror the composition of stem cells because the R mutation only manifests itself
in progenitor cells. Consider the GDR pathway, which is the first pathway to have
a cancer stem cell in this case. Figure 4.10A plots the composition of the stem-
cell pool over time. Normal stem cells dominate for the first forty-nine years, after
which the majority of stem cells have the G and D mutations. There are a small
number of cancer stem cells, and although they exceed normal stem cells in 57 years,
they do not surpass those with only two mutations. In contrast, the composition of
di!erentiated cells is markedly di!erent, as plotted in Figure 4.10B. Cells with all
three mutations take over the non-stem cell pool within 34 years, while cells with one
or two mutations remain a small percentage of progenitor and di!erentiated cells.
The contrast between stem-cell and non-stem cell compositions proves that cancer
growth is due to expansion in the progenitor pool, not the stem-cell pool.
Because mutated di!erentiating cells continue to mature and have not acquired
the ability to limitlessly self-renew, it is still the small percentage of cancer stem cells
that drives tumorigenesis. Without the self-renewing cancer stem cell population,
mutated di!erentiating cells would cause hypercellularity but ultimately reach a state
of homeostasis, even though elevated. It should be noted that the R mutation is what
causes significant expansion in progenitors, and the growth of cell populations with
the R mutation may cause proliferative disorders, even if all three mutations have
not been acquired.
This case in which R extends proliferation of progenitors without a!ecting stem
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Figure 4.9: Progenitor and di!erentiated cells accumulate due to extra progenitor divi-
sions. (A) The total non-stem cell population for each pathway. The DRG pathway
generates hypercellularity the fastest. However, most of these cells only have 2 muta-
tions. (B) The percentage of progenitor and di!erentiated cells that have one mutation.
DGR is the only pathway dominated by cells with one mutation. (C) The percentage of
progenitor and di!erentiated cells that have two mutations over time. Tissues following
the DRG and RDG pathways are mainly composed of cells with both the D and R mu-
tations. (D) The percentage of progenitor and di!erentiated cells with three mutations
over time. Tissues following GDR, GRD, and RGD are eventually taken over by cancer
cells.
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Figure 4.10: Comparison of stem cell composition and non-stem cell composition for
the GDR pathway in case D. (A) The percentage of stem cells with 0, 1, 2, or
3 mutations over time. After 30 years, the majority of stem cells have only the D
mutation. (B) The percentage of non-stem cells with 0, 1, 2, or 3 mutations. After
20 years, the majority of non-stem cells have all 3 mutations due to the extra division
and amplification of progenitor cells that have acquired the R mutation.
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cells is unique in that the system may reach a fatal level of cancer cells before any
cancer stem cells are formed. By increasing the number of divisions progenitors
complete before terminal di!erentiation, there is a massive expansion in mutated
progenitor and di!erentiated cell populations and may be indicative of a myelopro-
liferative disease. However, this type of R mutation is not su"cient in causing cancer
without pre-cancerous mutations occurring in the stem-cell pool, which is illustrated
in Figure 4.11. If stem cells are capable of acquiring one, two, or three mutations,
then the cancer cell population grows due to the exponential growth of mutated stem
cell populations. In contrast, if stem cells do not acquire any mutations, then cancer
progenitor and di!erentiated cells remain at low, undetectable levels because can-
cer progenitors eventually reach terminal di!erentiation and die, thereby preventing
expansion. Therefore, at least one mutation must occur in stem cells that initiates
exponential growth in order to generate malignancy.
These results indicate that unless progenitor cells acquire a mutation that per-
mits them to self-renew and prevent maturation as stem cells normally do, stem-cell
mutations are critical in promoting tumorigenesis. However, the model predictions
from Case D demonstrate the substantial impact that extra progenitor divisions have
on tissue hypercellularity. As a result, it is hypothesized that progenitor self-renewal
would generate an even greater increase in tissue mass and would be a more ag-
gressive disease. Such a mutation is believed to facilitate the transition between
chronic to blast phase in Chronic Myelogenous Leukemia. As a result, the possi-
bility of progenitors gaining limitless self-renewal potential will be investigated later
in Chapter VIII, where a mathematical model is presented that simulates disease
progression in Chronic Myelogenous Leukemia.
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Figure 4.11: At least one mutation is needed in stem cells for malignant tumor growth.
Cancer growth is fastest when stem cells acquire all three mutations, but cancer growth
still occurs when one or two mutations may be acquired at the stem cell level. When




Although many types of mutations have been identified in cancer cells, it is dif-
ficult to determine the order in which they were acquired that led to malignancy.
In this chapter, mutation acquisition in hierarchical tissue has been examined with
a maturity-structured mathematical model in order to investigate the impact that
mutation order has on tumor dynamics. In particular, the sequential accumulation
of somatic mutations was modeled to examine the multi-step process that initiates
cancer. Importantly, it was concluded that the order in which mutations are acquired
does a!ect the tempo of tumorigenesis. In addition, tumor composition varies for
di!erent mutation pathways, so that some sequences generate tumors that are dom-
inated by cancerous cells, while others are primarily comprised of cells with only one
or two mutations.
For each mutation pathway considered, the time to first cancer stem cell deter-
mined the onset of malignancy, so that the fastest pathway could be established.
If all mutations are advantageous, genetic instability is the key determining factor
for the emergence of cancer stem cells, and this result is robust for a wide range
of parameters. The fastest pathways acquired genetic instability first, which agrees
with the results of Michor et al., who predicted that chromosomal instability was
an early event in colon cancer [84]. This result di!ers from the work by Spencer et
al., who predicted that the fastest pathway to cancer ends with genetic instability.
Rather than following the particular order in which mutations accumulate, however,
Spencer et al. did not distinguish the chronological order of mutations that gener-
ated cells with a particular phenotype. In contrast, the predictions presented in this
chapter suggest that the specific sequential order of mutation acquisition decisively
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influences tumor dynamics.
In addition to the importance of mutation sequence, model predictions indicate
that certain types of mutations are more significant than others in dictating cancer
onset. For instance, when all mutations are advantageous, acquiring genetic insta-
bility first leads to the fastest path. In contrast, if mutations are lethal when evasion
of apoptosis has not yet been acquired, then the fastest pathways are initiated with
mutations decreasing cell death. Particularly significant are mutations that cause the
stem-cell division pattern to be unbalanced in the favor of symmetric self-renewal.
Increased symmetric self-renewal significantly quickens cancer onset and progression
because it rapidly expands the cancer stem cell population. Furthermore, it dimin-
ishes the importance of all other mutations in that cancer stem cells emerge in all
pathways within a relatively short time of each other.
When mutations a!ect stem and progenitor cells similarly, the model predicts
that the dynamics of the di!erentiating-cell population are dictated by the dynamics
of the stem-cell population. As a result, the cancer stem cell population is the
driving force of tumor growth. However, if a mutation is acquired in stem cells, but
is not manifested until inherited in a progenitor, then the dynamics of stem cells
and non-stem cells do not closely correlate. For example, a mutation that increases
the number of progenitor divisions contributes to hypercellularity and tumorigenesis,
even before the formation of cancer stem cells. Yet, if progenitor and di!erentiated
cells do not acquire limitless self-renewal potential, malignancy does not form unless
some initial mutations occur in the stem-cell population. This result demonstrates
the driving force of cancer stem cells in tumor formation and disease progression.
Furthermore, the model predicts that the cancer stem cell population is a small
minority of tumor cells for all cases discussed in this chapter. Because di!erentiation
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pathways are not disabled, mutated progeny continue to expand and mature, forming
cancerous di!erentiated cells that significantly outnumber stem cells. According to
model results, it is predicted that the percentage of tumor cells that are cancer stem
cells significantly increases only if di!erentiation is somehow inhibited.
The mathematical model presented in this chapter provides a general framework
that could be used to investigate tumorigenesis in any hierarchical tissue. To demon-
strate the usefulness of this model, simulations of mutation acquisition in hematopoi-
etic cells were conducted, but the model structure is general enough to be adapted
to other tissues and include any number of mutations. The maturity structure o!ers
unique insight into the maturity distribution of tumor cells, which may be bene-
ficial for studying malignancies in which the distribution of stem, progenitor, and
di!erentiated cells is significantly altered. Another novel feature of this model is
the incorporation of all three modes of stem-cell division, which makes it possible
to determine the e!ects on tumor dynamics when the balance is deregulated. In
this model, it is assumed the probabilities of symmetric self-renewal, asymmetric
self-renewal, and symmetric commitment di!erentiation are constant and regulatory
mechanisms governing stem-cell division pattern are not incorporated. There are
many factors that influence self-renewal and di!erentiation, however, which moti-
vates the investigation of stem-cell regulation in the next chapter.
CHAPTER V
Regulatory Mechanisms in Hierarchical Tissue
The previous chapter introduced a mathematical framework for hierarchical tissue
in which stem cells were modeled with an ordinary di!erential equation while dif-
ferentiating cells were modeled with a maturity-structured partial di!erential equa-
tion. The Maturity-Structured Model in the Absense of Homeostatic Regulation
(MSMAHR) presented in Equations 4.1 used constant probabilities to determine the
outcomes of stem-cell division. Although useful information about tumorigenesis can
be obtained by starting with such a model, cellular growth dynamics in hierarchical
tissue are more accurately modeled when regulatory factors governing stem-cell divi-
sion are incorporated. In particular, the stem-cell niche and chemical signaling can
influence both self-renewal and di!erentiation to promote tissue homeostasis. When
constant probabilities of stem-cell division are employed, there are three possible sce-
narios of tissue dynamics: cell populations may exponentially grow without bound,
cell populations may decline to elimination, or cell populations may remain in steady
state for all time. While homeostasis is likely most common in healthy individuals,
clearly there are times when tissue expansion is needed, such as in tissue generation
or reconstitution after injury, and others when suppression is required, such as when
correcting hypercellularity. Because cellular kinetics can adjust in accordance with
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tissue demands, the MSMAHR model is insu"cient in capturing the intricacies of
feedback regulations acting within hierarchical tissue. Rather, probabilities of stem-
cell self-renewal and di!erentiation are likely dependent upon the number of stem
and di!erentiated cells within the tissue, thereby necessitating a non-linear model.
It is not surprising that abnormalities in tissue regulation can potentially insti-
gate tumor formation. Therefore, mathematical investigation of feedback interac-
tions may highlight the types of genetic mutations that cause greatest malignancy
within hierarchical tissue. However, in order to understand how irregularities con-
tribute to tumorigenesis, it is necessary to first validate a model that accurately
simulates healthy tissue. This chapter incorporates mechanisms that regulate stem-
cell division and quiescence in order to mathematically simulate homeostasis of the
hematopoietic system. First, biological background of regulatory mechanisms is re-
viewed. Then, an introductory mathematical model is developed to fit experimental
data of the stem-cell division pattern. Subsequently, cycling and quiescent stem
cells and di!erentiated cells are incorporated into a non-linear model of ordinary
di!erential equations, which is then used to simulate tissue generation. In contrast
with the MSMAHR model, intermediate classes of di!erentiating cells are not explic-
itly modeled, thereby removing the maturity-structured partial di!erential equation
modeling non-stem cells. Instead, terminally di!erentiated cells are assumed to have
reached full maturity and are modeled with an ordinary di!erential equation. This
was done to focus more on regulatory mechanisms governing the stem-cell population
without added complexities from the maturity structure. In Chapter VIII, a model
will be introduced that incorporates both regulatory mechanisms in stem cells and
a maturity-structured population of di!erentiating cells. Finally, this chapter con-
cludes by discussing the significance of feedback regulations contributing to tissue
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homeostasis.
5.1 Regulation of Tissue Homeostasis
The proliferation of stem cells is a tightly regulated, yet responsive, process, con-
trolled by various mechanisms that are not fully understood. For instance, certain
chemical signals may promote stem-cell self-renewal, while others initiate di!eren-
tiation in response to a need for additional mature cells [89, 125]. Furthermore,
environmental cues also influence stem-cell division [125]. Changes in the microenvi-
ronment have the ability to alter stem-cell function and in some cases, could lead to
malignancy, so it is important to understand how interactions within the surrounding
microenvironment a!ect stem cells [2].
5.1.1 The Stem-Cell Niche
Because the percentage of stem cells in healthy tissues is very small, these cells
must be protected and maintained through tight regulation. It is believed that the
stem cell niche is crucial in both aspects [42, 95, 126]. The niche is the microenvi-
ronment composed of neighboring cells and cytokines that surround the stem cells
in a tissue [126]. One of the obstacles in stem-cell research is the inability to scien-
tifically reconstruct niches, which makes it di"cult to maintain stem cells in vitro
because signals from the niche a!ect stem-cell survival, proliferation and di!erenti-
ation [42, 95, 126].
In recent years, researchers have investigated the importance of the stem-cell
niche in various tissues such as bone marrow, testis, hair follicle, colon, ovary,
and brain [42]. The mathematical model presented in this chapter investigates tis-
sue homeostasis in the hematopoietic system, therefore the bone marrow niche of
hematopoietic stem cells (HSCs) is now discussed. The bone marrow is composed
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of red and yellow marrow. Fatty cells constitute yellow marrow, while red marrow
is responsible for blood cell production [39]. Soft bone marrow and blood vessels
comprise the inner bone cavity, while the rigidity of the outer bone capsule provides
external protection and maintains the balance of pressure needed to release appro-
priate amount of new blood cells into circulation [39, 126]. Many details regarding
the hematopoietic stem cell niche remain uncertain, but it is believed that endosteal,
vascular, and perivascular cells may all play a role [66].
The stem-cell niche also includes cytokines that are found in the microenviron-
ment. Several proteins are associated with stem-cell maintenance and di!erentiation,
and scientists have recently begun identifying these molecules and their functions.
For instance, the expression of Notch, a transmembrane protein used in cell-to-cell
communication, may promote stem-cell quiescence, and integrins may a!ect the inter-
actions between stem cells and the extracellular matrix [42]. The growth-promoting
Wnt family of proteins are prevalent during embryogenesis and may play a role in
cell proliferation and di!erentiation [42]. Independence from the control of niche
signaling leads to cancer, which is further evidence that the niche is crucial in main-
taining tissue balance. Loss of tumor suppressor Pten causes HSC mobilization and
leukemia [76]. Alteration in the balance between the anti-growth bone morphongenic
protein, BMP, and Wnt signaling promotes tumorigensis [74, 76]. Therefore, it is
clear that signaling pathways in the niche mediate tissue homeostasis.
It is known that a small number of hematopoietic stem cells circulate in the blood,
but their function remains a mystery [70]. Stem cells may temporarily leave the niche
and maintain stemness through mobilization, and return to the niche in a process
known as homing [70, 126]. Stem-cell mobilization and homing are crucial for suc-
cessful stem-cell transplantation, and will only occur if the niche is intact [39]. While
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all of the mechanisms involved in mobilization and homing are not fully understood,
it is known that the niche significantly impacts the maintenance and growth of stem
cells.
5.1.2 Signals Promoting Di!erentiation
Within hierarchically structured tissues, immature progenitors are responsible for
expanding and eventually di!erentiating into fully mature cells that carry out specific
functions for the tissue. Hematopoietic stem cells are precursors for all types of blood
cells including lymphocytes, macrophages, erythrocytes, platelets, and granulocytes.
Chemical signaling may influence the proliferation and di!erentiation of stem cells
into di!erent progeny types as demanded. Several colony-stimulating factors have
been identified in the hematopoietic system that impact stem and progenitor cell be-
havior. Interleukin-3, IL-3, has been used as part of stem-cell mobilization regimens
and promotes the survival and proliferation of progenitors to increase production
of various di!erentiated progeny including macrophages, granulocytes, mast cells,
megakaryocytes, and erythrocytes [9, 86]. Macrophage colony-stimulating factor,
M-CSF, and granulocyte colony-stimulating factor, G-CSF, promote survival, prolif-
eration, and di!erentiation of mature and precursor macrophages and granulocytes,
respectively [9, 30].
Additional knowledge of the role of G-CSF is of particular interest in develop-
ing a mathematical model of stem cells and neutrophils. G-CSF is the primary
signal involved in promoting the survival, proliferation, and di!erentiation cells
within the neutrophil lineage, and it is essential for terminal di!erentiation of ma-
ture neutrophils [9]. In an immune response, G-CSF is produced by monocytes and
macrophages. It then binds to cells expressing the G-CSF receptor, which are pri-
marily neutrophils and their precursors [9]. It is interesting to note that G-CSF
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receptors are not expressed by cells of the erythroid or megakaryocytic lineage [30].
Thus G-CSF binding is a mechanism specifically used to maintain homeostasis of
granulocytic cells in that its presence promotes di!erentiation and ensures a suf-
ficient neutrophil response, but its absence prevents hypercellularity by inhibiting
surplus production [9].
5.2 Stem-Cell Division Pattern
It is believed that stem cells are capable of three types of division: symmet-
ric self-renewal (SSR), asymmetric self-renewal (ASR), and symmetric commitment
di!erentiation (SCD). It is di"cult to determine the mode of stem-cell division ex-
perimentally, but current investigation continues to identify potential signals that
promote self-renewal and di!erentiation. In a recent experiment, Wu et al. used
time-lapse imaging techniques to record the divisions of murine hematopoietic pre-
cursor cells in vitro. Immature cells were isolated by expression of the GFP marker,
which is downregulated as cells di!erentiate. Over the course of three days, GFP+
cell division was recorded to investigate the e!ects of both extrinsic and intrinsic cues
on cell proliferation and self-renewal [125]. Although in vitro observations cannot
possibly mirror in vivo human hematopoietic stem cell kinetics perfectly, the experi-
mental data quantifies all three types of stem-cell division in mammals and provides
an opportunity to determine appropriate parameter values, which will be useful in
subsequent modeling investigations.
5.2.1 Mathematical Modeling of Feedback Mechanisms Governing Stem-Cell Division
The in vitro experiment by Wu et al. is certainly a simplification of the behavior of
stem and progenitor cells in vivo, but it provides rare data on the division pattern of
stem cells. Unfortunately, scientists are currently unable to monitor stem-cell kinetics
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and division patterns in vivo, which makes it di"cult to create a mathematical model
that accurately simulates in vivo behavior. Modeling these in vitro results may assist
in quantifying parameters that would otherwise be unattainable. Consequently, a
simplified model of stem and early progenitor cells is now used to investigate stem-
cell division patterns.
The experimental data may be modeled with a system of di!erential equations for
two types of cells, GFP+ and GFP-. The GFP+ cell population, denoted S, contains
the most immature cells, including stem cells, while the GFP- cell population, de-
noted N , consists of cells more di!erentiated. Every successful GFP+ division results
in one of three fates: symmetric self-renewal (SSR) with probability "S, asymmetric
self-renewal (ASR) with probability "A, and symmetric commitment di!erentiation
(SCD) with probability "D. Therefore, "S +"A +"D = 1. Furthermore, GFP+ cells
divide at rate k and die with rate #S, and GFP- cells die with rate #N . GFP- cells are
formed through asymmetric and di!erentiation divisions of the GFP+ population.
The amplification factor, A, incorporates the average number of progeny resulting
from the di!erentiation of a precursor cell as well as the rate of division for GFP-
cells, which was not directly measured in the experiment. Using an amplification
factor to eliminate the need for explicitly modeling all intermediate cellular popula-
tions has been done in various mathematical models of hematopoiesis [13, 24, 83].
The resulting model is a system of two ordinary di!erential equations:
dS
dt
= [k ("S " "D)" #S] S(5.1)
dN
dt
= (2"D + "A) kAS " #NN
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"A(S) = 1" "S(S)" "D.
Symmetric self-renewal of stem cells may be controlled by both extrinsic and
intrinsic chemical signaling. Certain environmental cues may promote self-renewal,
while others promote di!erentiation. Similarly, proteins produced within the cell






in "S has been used
in previous mathematical models of hematopoiesis and is derived from receptor-
ligand binding kinetics [5, 13]. As the number of stem cells, S, approaches zero, the
probability of symmetric self-renewal based on chemical signaling approaches the
maximum value of one. The parameter (S may be interpreted as the number of stem
cells at which the probability of symmetric self-renewal based on chemical signaling
is equal to one-half. Higher values of the exponent n > 0 increase the sensitivity
of GFP+ cells to the chemical signaling for symmetric self-renewal. Because the
cells are monitored for three days, it is assumed that progeny cells do not reach full
maturity, and thus there is no feedback of di!erentiated cells to a!ect the probability
of symmetric commitment di!erentiation. Therefore, "D is approximately constant
over the course of three days. The model terms are summarized in Table 5.1.
5.2.2 Environmental E!ects on Stem-Cell Division Pattern
To test the role of the extrinsic signaling on proliferation and division pattern,
GFP+ cells were plated in two di!erent environments. Both groups of cells exhibited
similar rates of proliferation and cell death, but the pattern of GFP+ cell division
was markedly di!erent. The OP9 medium, composed of stroma cells capable of
maintaining hematopoietic stem cells in vitro, promoted symmetric self-renewal. In
88
Term Definition
S Number of GFP+ cells
N Number of GFP- cells
!S(S)







!D Proportion of GFP+ cells that symmetrically di!erentiate
!A(S)
Proportion of GFP+ cells that asymmetrically self-renew
= 1" !S(S)" !D
%S Switch parameter of symmetric self-renewal
n Exponent that determines sensitivity for symmetric self-renewal
k Proliferation rate of GFP+ cells
"S Death rate of GFP+ cells
A Amplification factor
"N Death rate of GFP- cells
Table 5.1: Definitions of terms used in modeling experimental data from Wu et al [125].
contrast, the 7F2 medium, composed of osteoblastic cells from mice, promoted dif-
ferentiation and asymmetric self-renewal. It was thus concluded that environmental
cues can a!ect the outcome of stem cell division[125].
Experimental Procedure and Results
In the experiment performed by Wu et al., 5000 GFP+ cells were plated on either
a 7F2 or OP9 feeder layer. Over the course of three days, division modes were
observed. At the end of three days, the number of GFP+ and GFP- cells were
recorded along with the average percentage of all three types of GFP+ cell division
that occurred over the three days. The 7F2 feeder layer promoted asymmetric self-
renewal. Of all GFP+ cell divisions, only 33% resulted in symmetric self-renewal,
whereas 50% were asymmetric divisions and 17% were di!erentiation divisions. In
contrast, the OP9 feeder layer promoted symmetric self-renewal over di!erentiation.
Of all GFP+ cell divisions observed for three days, 60% resulted in symmetric self-
renewal divisions, whereas 26% were asymmetric, and 14% were di!erentiation. The
death rate and division rate of GFP+ cells did not vary significantly between the
two di!erent feeder layers. The di!erent environments, however, altered the death
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rate of GFP- cells. In the 7F2 medium, it was estimated that the death rate of GFP-
cells was approximately twice that of GFP+ cells, while in the OP9 medium, it was
estimated that the death rate of GFP- cells was approximately three to four times
that of GFP+ cells [125].
Model Simulations of Experimental Data
Due to the lack of published data on the three potential outcomes of stem-cell
division, these experimental results provide a rare opportunity to quantify math-
ematical parameters used to model regulatory mechanisms. Many of the model
parameters may be determined directly from the experimental data. Specifically,
the division rate of GFP+ cells, k, death rate of GFP+ cells, #S, probability of
symmetric commitment di!erentiation, "D, and death rate of GFP- cells, #N , were
recorded experimentally. The Hill function parameters, (S and n, and amplification
factor, A, are determined to fit the experimental results. In Table 5.2, we present
the parameters used in the mathematical simulations.
For numerical simulations, the ordinary di!erential equation solver ode15s in
MATLAB was used. Using the experimental initial condition of 5000 GFP+ cells and
zero GFP- cells, the number of GFP+ and GFP- cells was modeled for a time span
of three days. The average occurrence of each division type was found by calculating
the average of the functions for "S, "A, and "D over the three-day span. As demon-
strated in Table 5.2, the model predictions are in coherence with the experimental
data. Over the course of three days on the 7F2 feeder layer, the experimentalists
found that the fraction of GFP+ cells undergoing symmetric self-renewal, asym-
metric self-renewal, and di!erentiation was 33%, 50%, and 17%, respectively. With
parameter values (S = 4, 300, n = 2, and A = 1.3, the model derives the same
division fractions and predicts the three-day cell count total of 5,666 GFP+ cells
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Model Comparisons with Experimental Data
7F2 7F2 OP9 OP9
Param. Range Model Param. Range Model
k (per day) * 0.6238-0.9935 0.8087 0.6469-0.9242 0.7856
%S (cells) + 4,100-4,600 4,300 11,000-14,800 13,000
n + 2-4 2 2-5 2
"S (per day) * 0.0662-0.0959 0.0828 0.0622-0.0786 0.0744
"N (per day) * 2"S 0.1756 4"S 0.2976
A + 1.0-1.6 1.3 0.7-1.0 1.0
GFP+ cells + N/A 5,666 N/A 12,617
GFP+ cells (%) * 34% ± 5% 33% 65% ± 5% 61%
GFP- cells + N/A 11,400 N/A 8,129
GFP- cells (%) * 66% ± 5% 67% 35% ± 5% 39%
GFP-:GFP+ cells * 1.56-2.45 2.01 0.43-0.67 0.64
!S (%) * 32-34% 33% 61-67% 65%
!A (%) * 47-53% 50% 19-25% 23%
!D (%) * 16-18% 17% 11-14% 12%
Parameters with * are experimentally determined
Parameters with + are mathematically determined
Table 5.2: A comparison of the experimental data with the predicted model values. Cell numbers
are determined at the end of the three-day experiment. Division percentages are average
values figured over the course of the experiment.
and 11,400 GFP- cells. For the OP9 feeder layer, the experimental data concluded
that the fraction of GFP+ cells undergoing symmetric self-renewal, asymmetric self-
renewal, and di!erentiation was 65%, 25%, and 10% respectively. With (S = 13, 000,
n = 2, and A = 1, the model achieves these results for division pattern and predicts
a three-day cell count of 12,617 GFP+ cells and 8,129 GFP- cells. A comparison of
the experimental data with model predictions is presented in Table 5.2.
Figure 5.1 plots the growth dynamics of the cells in the 7F2 medium in A and
B, and the dynamics of the OP9 medium in C and D. There are striking di!erences
in both cellular composition and mode of GFP+ cell division when the 7F2 medium
is contrasted with the OP9 medium. GFP+ cells plated in the 7F2 medium fa-
vor asymmetric self-renewal over other division outcomes. Consequently, the GFP+
population grows minimally whereas the GFP- cell population experiences signif-
icant expansion, as seen in Figure 5.1A. In particular, GFP- cells surpass GFP+
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cells in approximately 1.3 days and by the end of the three-day experiment, GFP-
cells compose 67% of all cells. In contrast, GFP+ cells plated in the OP9 medium
favor symmetric self-renewal over both asymmetric and commitment di!erentiation
divisions. As a result, it is not surprising that the GFP+ population expand consid-
erably and remain the majority of cells over the three-day experimental course, as
shown in Figure 5.1C.
The properties of cells in the 7F2 and OP9 environments are alike for proliferation
and death of GFP+ cells, but the division pattern is significantly di!erent. There-
fore, it is not surprising that the majority of parameters are comparable between
both cases while the switch parameter a!ecting symmetric self-renewal, (S, di!ers
significantly. The value used for (S in the OP9 environment is more than three times
that of the 7F2 environment. In the 7F2 environment, the probability of symmetric
self-renewal due to chemical signaling is 50% when there are 4,300 GFP+ cells, but
since 5,000 GFP+ cells are initially plated, throughout the three-day experiment
the probability of symmetric self-renewal divisions is less than 50%, and asymmetric
division is dominant. In contrast, in the OP9 environment, 13,000 GFP+ cells are
needed before the GFP+ cell division mode switches from symmetric to asymmetric
self-renewal, so symmetric division is dominant during the experiment. Therefore,
knowing the value of (S is crucial in determining the balance between symmetric and
asymmetric self-renewal divisions. Although this particular experimental procedure
focused on the division pattern of GFP+ cells, thereby highlighting the significance
of (S in the mathematical model, the e!ects of other model parameters are better
understood through a sensitivity analysis.
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Figure 5.1: Growth dynamics of GFP+ cells in 7F2 and OP9. (A) GFP+ and GFP- cells
in 7F2 versus time. (B) Asymmetric division is favored in 7F2. (C) GFP+ and GFP-
cells in OP9 versus time. (D) Symmetric self-renewal is favored in OP9.
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Figure 5.2: Sensitivity Analysis. The ratio of the number GFP+ cells to GFP- cells (green) and
the ratio of symmetric self-renewal to asymmetric division (blue) are plotted as each
parameter varies. Baseline parameters are taken from the 7F2 model set in Table 5.2.
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Parameter Sensitivity Analysis
A sensitivity analysis can be used to determine the e!ects of parameter changes
on the model. The sensitivity analysis was conducted for parameters used for 7F2
as opposed to OP9 because the 7F2 medium is believed to be more representative of
the hematopoietic stem-cell environment for an adult human. Using the parameter
values determined for the 7F2 medium, Figure 5.2 plots the ratio of GFP+ cells to
GFP- cells as well as the ratio of symmetric self-renewal to asymmetric self-renewal
divisions as the specified parameter varies. Cell counts and division averages are
determined at the end of a three-day period of observation and then compared to
the data from modeling the original experimental results.
As shown in Figure 5.2A, increased GFP+ cell proliferation decreases the ratio of
GFP+ to GFP- cells. Recalling that asymmetric divisions are dominant in the 7F2
environment, increasing the proliferation rate increases the number of asymmetric
divisions more than the number of symmetric self-renewal divisions, thereby increas-
ing the GFP- cell population in comparison with GFP+ cells. Doubling the rate of
GFP+ cell proliferation decreases the ratio of GFP+:GFP- cells from approximately
1:2 to 1:4, because an increase in k does not a!ect GFP+ steady state, but greatly
increases GFP- cells. In addition, the frequency of symmetric self-renewal decreases
in relation to asymmetric division. Increasing the rate of proliferation switches o!
symmetric self-renewal faster, thereby decreasing the three-day average. However,
the ratio of divisions does not decrease as quickly as the ratio of cells. In contrast,
increasing GFP+ cell death increases both ratios, as demonstrated in Figure 5.2B.
An increase in #S decreases the number of GFP+ cells, which increases symmetric
self-renewal. If #S > 0.35, symmetric division is favored over asymmetric division,
as stem cells divide symmetrically to avoid elimination. The increase in symmetric
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self-renewal subsequently decreases asymmetric and di!erentiation divisions, which
decreases the number of GFP- cells as compared to GFP+ cells.
Figures 5.2C and D plot the model sensitivity to the Hill function parameters, (S
and n. The switch parameter (S has more e!ect on GFP+ division pattern than any
other parameter. Doubling (S from 5,000 to 10,000 cells more than doubles the ratio
of symmetric self-renewal to asymmetric self-renewal. The increase in symmetric
self-renewal increases the number of GFP+ cells, which in turn increases the ratio
of GFP+ cells to GFP- cells. Increasing the Hill function exponent, n, does not
significantly decrease the ratio of GFP+ to GFP- cells, but rather has more impact
on decreasing the frequency of symmetric self-renewal. Increasing n sharpens the
switch for symmetric self-renewal so that when S > (S, the probability of SSR
approaches zero faster. Since the initial condition of 5,000 plated GFP+ cells is
greater than the baseline parameter value of (S = 4, 300, the probability of SSR
decreases for higher values of n. Although n a!ects the division pattern, it has
minimal impact on the steady state of the system, suggesting that there are several
values that could fit this parameter.
Figure 5.2E demonstrates that the amplification factor, A, does not a!ect the
ratio of cell division, but decreases the ratio of GFP+ to GFP- cells. It does not
alter the steady state of GFP+ cells, but increasing A does increase the steady state
of GFP- cells, thereby increasing the number of GFP- cells for every GFP+ cell.
Figure 5.2F plots the model sensitivity to the frequency of symmetric di!erentiation.
As expected, increasing the probability of symmetric di!erentiation increases the
frequency of SSR as GFP+ cells must symmetrically self-renew to compensate for
GFP+ cells lost through di!erentiation. In addition, the number of GFP- cells
increases as di!erentiation increases, decreasing the ratio of GFP+ to GFP- cells.
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Although the experiment is only run over the course of three days, long-run predic-
tions may be made through a steady state analysis. The steady states of the system
are the elimination state (0, 0) and a positive steady state (S#, N#) corresponding to
healthy tissue containing both stem and mature cells, where
S# = (S
$










(k " #S) A
#N
S#.
Specifically, when n = 2,
S# = (S
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k (1" 2"D)" #S
k"D + #S
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For biological parameter values, (S, k, "D, #S, A, and #N are non-negative. When
k < "S(1!2!D) , the healthy tissue steady state does not exist and the elimination state
is stable. The positive steady state exists when k > "S(1!2!D) and it is stable. Careful
consideration of the parameters shows that the latter case holds true for biologically
relevant values.
The steady state analysis proves that the relationship between GFP+ cell prolifer-
ation, k, symmetric di!erentiation, "D, and the death rate of GFP+, #S determines
the existence of a healthy tissue steady state as well as the instability of the elimi-
nation state. Bifurcation diagrams of GFP+ cell steady state as dependent on the
rates of GFP+ proliferation, di!erentiation, and death are presented in Figure 5.3.
As expected, increasing symmetric di!erentiation or GFP+ cell death decreases the
steady state until the positive solution is eliminated completely and the elimina-
tion state becomes stable. Increasing the GFP+ cell proliferation rate increases the
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steady state of GFP+ cells, but the change in steady state is small in comparison
with changes in k. This corresponds with the sensitivity analysis, which concluded
that increasing GFP+ cell proliferation had greater impact on the steady state of
GFP- cells than GFP+ cells.
Although stability does not depend on (S, A, and #N , each of these parameters is
important in determining the actual value of the steady state of the system. First,
observe that N# is linearly dependent on S#, so the parameters that most greatly
a!ect the steady state of stem cells will similarly a!ect di!erentiated cells. Note S#
depends linearly on (S. Thus, increasing (S and thereby increasing the probability
of symmetric self-renewal has a greater impact on increasing GFP+ cells than does
increasing the GFP+ cell proliferation rate, k. Although a large increase in k may
result in minor GFP+ cell increase, it is important to note that N# is linearly de-
pendent on (k " #S), so that large increases in k significantly increase GFP- cells.
In addition, N# is linearly dependent on the amplification factor, A, which means
that extra divisions during maturation contribute to an elevated level of GFP- cells.
From this analysis, we conclude that the number of GFP+ cells is most a!ected by
(S, and the number of GFP- cells is most a!ected by (S, k, and A.
By studying each parameter’s e!ects on model outcomes, it is possible to predict
how mutations might alter the growth dynamics of both the GFP+ and GFP- cell
populations. Clearly, mechanisms controlling the balance between asymmetric and
symmetric self-renewal could be potential targets for oncogenesis, as demonstrated
by the impact of the parameter (S. Mutations increasing the GFP+ proliferation
rate or increasing the amplification factor may not significantly contribute to the
accumulation of GFP+ cells, but may lead to hypercellularity of di!erentiated cells.
Although this in itself may be problematic, it is likely less pathologically aggressive
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Figure 5.3: Stability and existence of the positive steady state. The existence and stability of
the positive steady as well as the stability of the elimination steady state depends on the
GFP+ cell proliferation rate (A), the probability of GFP+ cell symmetric di!erentiation
(B), and the GFP+ cell death rate (C).
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than the accumulation of GFP+ cells because current treatment regimens are often
able to eliminate di!erentiated cells but are unsuccessful in targeting näıve stem
cells. These issues were addressed in an additional experiment in which Wu et al.
investigated the mechanisms of two specific mutations that are known to cause very
di!erent forms of leukemia.
5.2.3 Intrinsic Properties A!ect Cellular Proliferation
Both extrinsic and intrinsic signals contribute to the regulation of the many pro-
teins and signaling pathways involved in cellular proliferation and maintenance. The
di!erent GFP+ cell division patterns of cells on 7F2 versus OP9 media prove that en-
vironmental cues are capable of altering cellular signaling. To demonstrate how mu-
tated proteins contribute to oncogenesis by way of intrinsic signals, Wu et al. tested
the e!ects of BCR-ABL and NUP98-HOXA9 in murine hematopoietic cells [125].
Both mutations are found in hematopoietic precursor cells and are causes of leukemia,
but each leads to the development of very di!erent forms of disease. Therefore, by
investigating the cellular properties that are deregulated by each protein, it is possi-
ble to gain further understanding regarding the causing mechanisms and progression
of disease.
Although other mutations are involved in the development of Chronic Myeloge-
nous Leukemia (CML), expression of the BCR-ABL fusion protein is the primary
marker used for diagnosis of the disease [17, 22, 120]. Caused by the translocation
t(9; 22)(q34; q11) in hematopoietic precursor cells, BCR-ABL inhibits apoptosis and
enables additional cellular divisions [27, 46]. It is believed that BCR-ABL-positive
cells suppress normal hematopoiesis by creating a dominant clone that hinders the
di!erentiation of non-mutated progenitors [48]. BCR-ABL does not, however, block
di!erentiation altogether, and the initial chronic phase of CML is characterized by
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an increase of both progenitor and mature cells [55].
In contrast, the fusion protein NUP98-HOXA9 caused by the translocation t(7;
11)(p15; p15) is expressed in cells of patients with Acute Myelogenous Leukemia
(AML) and blast crisis CML [37, 88]. It is believed NUP98-HOXA9 expression in-
creases self-renewal in myeloid progenitor cells, contributing to an increased number
of immature blast cells of the myeloid lineage [88]. Furthermore, in patients express-
ing NUP98-HOXA9, both erythroid and myeloid di!erentiation is inhibited [88].
Therefore, this mutation shifts the balance of stem-cell division mode in favor of
symmetric self-renewal.
Experimental Procedure and Results
In order to investigate how these mutations a!ect cell proliferation and death,
three thousand GFP+ cells were infected with BCR-ABL, three thousand GFP+
cells were infected with NUP98-HOXA9, and then compared to three thousand non-
infected GFP+ cells in a control group. Cell divisions, pattern of division, and death
were monitored in each group over three days in vitro. The data suggests that BCR-
ABL has greater impact on the cell proliferation rate and survival, while NUP98-
HOXA9 alters the pattern of cell division. In three days, GFP+ cells completed an
average of 2.7 divisions in the control group, 6.5 divisions in BCR-ABL cells, and 3.5
divisions in NUP98-HOXA9 cells, corresponding to the derived proliferation rates
of 0.6238 per day, 1.5018 per day, and 0.8087 per day, respectively. The percent of
GFP+ cells lost to apoptosis was 14% in the control cells, 7% in the BCR-ABL cells,
and 12% in NUP98-HOXA9 cells. Consequently, the death rate was 0.0503 per day
in the control cells, 0.0242 in BCR-ABL cells, and 0.0426 in NUP98-HOXA9 cells. In
the control group, the frequency of symmetric self-renewal (SSR), asymmetric self-
renewal (ASR), and symmetric commitment di!erentiation (SCD) was 42%, 48%,
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Parameter Control BCR-ABL NUP98-HOXA9
Exper. Model Exper. Model Exper. Model
k(day!1) 0.6238 0.6238 1.5018 1.5018 0.8087 0.8087
"S(day!1) 0.0503 0.0503 0.0242 0.0242 0.0426 0.0426
%S(cells) n/a 3,200 n/a 4,900 n/a 7,300
"N (day!1) 0.1006 0.1006 0.0484 0.0484 0.0852 0.0852
A n/a 1.3 n/a 1.4 n/a 1.4
GFP+ cells n/a 4,385 n/a 8,210 n/a 7,698
GFP- cells n/a 5,758 n/a 28,086 n/a 9,653
GFP-:GFP+ n/a 1.31 3.45 3.42 1.22 1.25
Avg. SSR (%) 42 41 45 45 62 62
Avg. ASR (%) 48 49 42 42 25 25
Avg. SCD (%) 10 10 13 13 13 13
Table 5.3: Parameter values, experimental observations, and model predictions for mutated
cells [125].
and 10%, respectively. In BCR-ABL cells, SSR was slightly greater with 45%, ASR
slightly less with 42% and SCD slightly greater with 13%. In NUP98-HOXA9 cells,
SSR increased to 62%, ASR decreased to 25%, and SCD was 13% [125].
Model Simulations of Experimental Data
The mathematical model presented in Equations 5.1 can also be used to simu-
late the growth dynamics of BCR-ABL and NUP-HOXA9 infected cells. Table 5.3
presents the model parameters and a comparison of experimental data with model
predictions. With an initial condition of 3,000 uninfected GFP+ and zero GFP-
cells, mathematical modeling predicts the control GFP+ population grows to 4,461
cells and the control GFP- population grows to 5,752 cells. The average frequency
of SSR is 41%, ASR is 49%, and SCD is 10%, in accordance with 42%, 48%, and
10% experimentally recorded.
Model predictions for the BCR-ABL group are compared with the control group.
Both are plotted in Figure 5.4A-B, where BCR-ABL curves are solid, and control
curves are dashed. With the initial condition of 3,000 BCR-ABL-infected GFP+
cells and zero GFP- cells, the model predicts GFP+ growth to 8,210 cells and GFP-
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growth to 28,086 cells. The ratio of GFP- cells to GFP+ cells is 3.42, which is more
than 2.6 times that of the non-infected cells, demonstrating that cell di!erentiation
is successful, and cell accumulation occurs from increased proliferation and survival.
In the BCR-ABL group, the GFP- population surpasses the GFP+ population by
day one, which is less than half the time needed in the control group. However,
the average frequency of SSR is 45%, ASR is 42%, and SCD is 13%, which is not
significantly di!erent from measurements of the control group. Therefore, BCR-ABL
causes disease by accumulating cells through increased proliferation and decreased
apoptosis.
Similarly, in Figure 5.4C-D, model predictions for the NUP98-HOXA9 group are
plotted with solid lines and compared to the control group plotted with dashed lines.
With the initial condition of 3,000 NUP98-HOXA9-infected GFP+ cells and zero
GFP- cells, the model predicts that over three days, the GFP+ population grows
to 7,698 cells and the GFP- population grows to 9,653 cells. In comparison to the
non-mutated control group, the ratio of GFP- cells to GFP+ cells decreased slightly
to 1.25, demonstrating the preference for symmetric divisions of immature cells over
di!erentiation. In contrast, the percentage of cells symmetrically self-renewing is
markedly di!erent from those in the control group. In NUP98-HOXA9 cells, the
average frequencies of SSR, ASR, and SCD are 62%, 25%, and 13%, as compared with
42%, 48%, and 10%, respectively. In the control group, the switch from symmetric to
asymmetric self-renewal occurs within a half day, but in the NUP98-HOXA9 group,
the switch does not occur until two-and-a-half days, indicating the dominance of
symmetric self-renewal in mutated cells. It may be concluded that NUP98-HOXA9
causes disease through abnormal symmetric self-renewal, which increases immature
blast cells and prevents the formation of di!erentiated cells, thereby inhibiting the
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Figure 5.4: BCR-ABL and NUP98-HOXA9 promote cancer growth through di!erent
mechanisms. (A) BCR-ABL (solid) expression increases proliferation and decreases
apoptosis, causing greater expansion of both cell types, but particularly GFP- cells,
compared to control cells (dashed). (B) The mode of GFP+ cell division in cells infected
with BCR-ABL is comparable to uninfected cells. (C) GFP+ cell proliferation and
death rates of cells infected with NUP98-HOXA9 (solid) are not significantly di!erent
from those in control cells (dashed), but the ratio of GFP- cells to GFP+ cells is slightly
decreased in comparison with control cells due to increased SSR. (D) NUP98-HOXA9
shifts the mode of GFP+ cell division to favor symmetric self-renewal.
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daily functions performed by mature blood cells.
5.2.4 Conclusions
The experiments conducted by Wu et al. employ time-lapse imaging to demon-
strate that mammalian hematopoietic precursor cells can complete three types of di-
vision: symmetric self-renewal, asymmetric self-renewal, and symmetric commitment
di!erentiation. In addition, their results confirm that both external environmental
cues and internal cellular signals may a!ect cell division pattern and proliferation
rate. A mathematical model was created that accurately captures the experimen-
tal data. Further investigation determined that mutations a!ecting the GFP+ cell
proliferation rate, k, and the symmetric self-renewal switch parameter, (S, have the
most potential in causing abnormal growth, though each instigates di!erent forms
of disease. Increased GFP+ cell proliferation contributes to the hypercellularity of
GFP- cells, whereas increased symmetric self-renewal increases the fraction of prim-
itive cells. The former is observed in Chronic Myelogenous Leukemia, but the latter
found in the more aggressive Acute Myelogenous Leukemia, which suggests that
deregulation of symmetric self-renewal may be involved in speeding disease progres-
sion.
Although this in vitro experiment cannot fully characterize hematopoietic stem
cells, the conclusions derived from this model may be usefully employed in creating
a mathematical model of the hematopoietic system in vivo. It is accepted that stem
cells are capable of three types of division, but there is minimal data quantifying the
proportions of division type because mammalian stem cells are di"cult to isolate,
maintain, and observe experimentally. Of the cells and environments used in these
experiments, the non-mutated GFP+ cells in the 7F2 environment most resemble
hematopoietic stem cells in vivo. This environment favors asymmetric division, and
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if the plated cells reached steady state, the probabilities of symmetric self-renewal,
asymmetric self-renewal, and symmetric di!erentiation would be approximately 20%,
65%, and 15%. While it is certainly possible for other division patterns to occur in
human hematopoietic stem cells, it is currently impossible to conclusively determine
these probabilities in vivo. Because this division pattern is determined from experi-
mental data that can be referenced, this estimation of division pattern will be used
is subsequent modeling of hematopoiesis.
5.3 Cycling and Quiescent Stem Cells
The use of regulatory mechanisms to influence stem-cell division pattern is one
way that homeostasis is maintained. Another is through mechanisms that govern the
transition between quiescence and cycling in the stem-cell population. The ability
to remain quiescent for long periods of time is one of the major di!erences of stem-
cell behavior in vivo versus in vitro [63]. In adults, it has been estimated that
5-25% of hematopoietic stem cells are actively cycling [21, 90, 104]. Consequently,
under homeostatic conditions, the majority of hematopoietic stem cells are quiescent,
resting in the G0 phase of the cell cycle. However, the percentage of cycling stem
cells is not static throughout the life of the host. For instance, in tissue generation,
a larger proportion of stem cells actively divide in order to expand cell number [89].
If the majority of cells remained quiescent, the tissue would never expand or could
even be eliminated. Yet stem cells could not perpetually sustain an elevated amount
of cycling or the tissue would exponentially grow without bound. Clearly, there are
mechanisms in place that control the balance between cycling and quiescent stem
cells, and these regulations likely depend on the number of cells in the system.
Due to the di"culty of reproducing stem cell niches in vitro, it is challenging to
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experimentally quantify the kinetics of the interchange between the quiescent and
cycling stem-cell compartments. Mathematical modeling enables theoretical inves-
tigation of the interactions between cycling and quiescent stem cells. In addition,
predictions may be made pertaining to how the balance between quiescent and cy-
cling cells subsequently e!ects the growth dynamics of the tissue. In this section,
a mathematical model is presented that incorporates regulatory mechanisms gov-
erning stem-cell division pattern similar to those discussed in Section 5.2 while also
including mechanisms that mediate the balance between cycling and quiescent stem
cells.
5.3.1 Incorporating Cycling and Quiescent Stem-Cell Compartments
To accurately model tissue generation followed by maintenance in vivo, it is nec-
essary to separate stem cells into cycling and quiescent compartments. In doing so,
it is possible to capture the initial stages of expansion, followed by tapering growth
leading to homeostasis. In contrast with the model presented in Section 5.2.1, the
stem-cell population is divided into quiescent stem cells, Q, and cycling stem cells,
C. Mature di!erentiated cells are denoted N . At this time, intermediate progen-
itor cells are not explicitly modeled, however, an amplification factor is included,
denoted A. Quiescent stem cells enter the cycling compartment at maximum rate p
and cycling cells enter the quiescent compartment at maximum rate q. The proba-
bility that a quiescent cell will enter cycling is $ and the probability that a cycling
cell will go into quiescence is %. Cycling cells proliferate with rate r. Once in the
cycling compartment, stem cells complete one of four processes during the division
process: symmetric self-renewal, asymmetric self-renewal, symmetric di!erentiation,
or apoptosis. The proportions of stem cells that symmetrically self-renew, asym-











Figure 5.5: Schematic diagram of quiescent and cycling stem cells and di!erentiated
cells. Stem cells enter cycling and quiescent compartments with probabilities that are
dependent on stem-cell numbers. Cycling stem cells are capable of three types of divi-
sions. Di!erentiated cells are formed through asymmetric and symmetric commitment
di!erentiation divisions.
and #S, respectively. Cycling stem cells are the source for the mature di!erentiated-
cell population. Di!erentiated cells are formed through symmetric di!erentiation or
asymmetric divisions of a cycling stem cell, and di!erentiated cells die with rate #N .
A schematic diagram of the flow of cells between quiescent, cycling, and di!erentiated
compartments is presented in Figure 5.5.
In contrast with Equations 5.1, the number of terminally di!erentiated cells in
the tissue influences the probability of symmetric commitment di!erentiation in stem
cells, which was previously irrelevant in modeling experimental data due to the short
time frame. It should also be noted that this model di!ers from others in which
di!erentiation occurs after division. In such models, cycling cells always self-renew
and progeny enter the quiescent compartment. Stem cells exit the quiescent pool
by di!erentiating, dying, or entering the cycling pool to self-renew [13, 24]. Instead,
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this model employs the recent observations of Wu et al. that suggest symmetric
di!erentiation can occur at the time of division [125].
Regulatory mechanisms that control the transition between cycling and quiescent
stem cells are poorly understood. However, it is known that in times of stress or
tissue generation, quiescent stem cells may enter the cycling compartment to promote
expansion. The interchange of quiescent and cycling cells is likely dependent on




2 , where )C is the number of cells in the cycling compartment at
which the probability that a quiescent cell enters cycling is 50%. A higher number
of cycling cells yields a lower probability that a quiescent cell will enter the cycling
compartment. Cycling cells are forced into quiescence when a su"cient number




2 , where )Q is the number of cycling cells at which the probability of a
cycling cell entering quiescence is 50%. As cycling cells approach zero, % approaches
zero so that the few cycling cells do not become quiescent. As cycling cells increase,
% approaches one.
Because stem cells are long-lived and tightly regulated, it is assumed stem-cell
death only occurs due to errors in the division process. Therefore, death of quiescent
stem cells is negligible and the small constant probability that a cycling stem cell
goes through apoptosis during division is denoted #S. The probabilities of division
outcomes of cycling stem cells adhere to the condition "S + "A + "D + #S = 1.
The proportion of cycling stem cells that symmetrically self-renew, denoted "S, is
dependent on stem-cell chemical signaling as well as the physical size of the stem-cell
niche, KS. Specifically,











where the Hill function is described in Section 5.2.1 and was used in previous model-
ing by Mackey et al. [13, 24, 77]. Stem-cell interaction with the niche is necessary for





restraint of the niche size on symmetric self-renewal due to limited available space for
stem-cell sustenance [124]. Note that symmetric self-renewal cannot exceed (1" #S),
since it is assumed that stem cells die with constant probability.
To further illustrate why both chemical signaling and niche control are found in the










, where a and c are arbitrary positive
constants. Note that "S resembles f(x), the chemical signaling function shares the
form of g(x), and the niche control function is similar to h(x). Let c = 1 for the
purpose of this example. Figure 5.6 displays two examples for f(x) with di!erent
a values. In Figure 5.6A, symmetric self-renewal is more restricted by chemical
signaling than the niche, whereas the converse is true in Figure 5.6B. In both cases,
f(x) captures key components of both the Hill function and the logistic function.
Note that f(x) is zero when the niche is full, which is x = 1 in this example, but it
also follows the qualitative behavior of the Hill function due to chemical signaling.
As a result, both functional forms are incorporated into "S in order to capture both
traits.
The proportion of cycling stem cells that divide into di!erentiated cells is given
by














reflects the e!ects of chemical signaling that promote or
suppress di!erentiation depending on the existing population of mature cells and
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Figure 5.6: Functional forms used to determine the probability of symmetric self-
renewal. The probability of symmetric self-renewal follows that of function f(x), which
takes into account both chemical interactions and niche control. Probability based solely
on chemical signaling is given by function g(x), and probability based solely on niche
control is given by function h(x).
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preference is given to self-renewal division over di!erentiation in cases where both
stem and di!erentiated cells are depleted so the system is not compromised and
extinguished [117].
The proportion of cycling stem cells that asymmetrically self-renew is determined
by
"A(C, Q, N) = 1" "S(C, Q)" "D(C, Q, N)" #S.(5.6)
It is important to note that the model does not discriminate based on the mechanism
by which asymmetric division is achieved. The asymmetric division term can encom-
pass divisions that occur by the immortal-strand hypothesis or divisions in which two
identical cells determine their fates from cues after division. The stem-cell division
types are merely classified by the state of the two daughter cells at the time of their
subsequent division. The system of di!erential equations for the model under the
presented assumptions is as follows:
dQ
dt
= "p$Q + q%C(5.7)
dC
dt
= p$Q" q%C + r ["S " "D " #S] C
dN
dt
= (2"D + "A) ArC " #NN.
For ease, this model is labeled the ODE Model of Tissue Generation (ODEMTG)
when referenced in subsequent text. The model terms and definitions are summarized
in Table 5.4.
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Definition of Model Terms
C Cycling stem cells
Q Quiescent stem cells
N Di!erentiated cells






&C Number of cells at which quiescent cells enter cycling at 50%





&Q Number of cells at which cycling cells enter quiescence at 50%
r The division rate of cycling stem cells
p The rate at which quiescent cells enter cycling
q The rate at which cycling stem cells enter quiescence
!S(C,Q)









%S Number of cells at which SSR due to signaling occurs at 50%
!D(C,Q,N)









%N Number of cells at which SCD due to signaling occurs at 50%
!A(C,Q,N)
Proportion of stem cells that renew asymmetrically
= [1" !S(C,Q)" !D(C,Q,N)" "S ]
"S The proportion of cycling stem cells that go through apoptosis
KS Carrying capacity of all stem cells, determined by the niche
A Amplification factor
"N Death rate of di!erentiated cells
Table 5.4: The biological meaning of the model terms used in the ODE Model of Tissue Generation.
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5.3.2 Steady States and Stability Analysis
The steady states of the model include an elimination state whose eigenvalues
correspond to the solutions for * in the polynomial
"*3 + (r(1" 2#S)" q)*2 + (p + #N)(r(1" 2#S)" q)* + p#Nr(1" 2#S) = 0.
All parameters are measurements of biological qualities and therefore cannot be
negative. When #S <
1
2 , according to Descartes’ Rule of Signs, there exists at least
one positive eigenvalue, and therefore the solution is unstable. Furthermore, when
#S >
1
2 , all roots for * are negative, so the elimination is stable. In other words,
when stem cells die with at least 50% probability, the tissue is eliminated, which is
sensible considering that stem cells are the source of all other cells in the tissue.









which leads to the condition
"S " "D " #S = 0.








2 + P1C + P0 = 0
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with the following coe"cients:
P7 = "(1" #S)#N(Nq
P6 = "(1" #S)(2S(1" 2#S)rAq
P5 = "(1" #S)(2S#N(Nq " (1" #S)#N(N
)





P4 = "(1" #S)(2S(1" 2#S)rA)2C(p + q)"KSp)2C#S#N(N
P3 = (1" #S)(2S)2C ((1" 2#S)rApKS " #N(N(p + q))
"(1" #S)#N(N)2C
)




"KSp)2C#S((2S + )2Q)(1" 2#S)rA
P2 = (1" #S)(2Sp)2C(#N(NKS " (1" 2#S)rA)2Q)
"KSp)2C#S((2S + )2C)#N(N
P1 = (1" #S)(2Sp)2C)2Q ((1" 2#S)rAKS " #N(N)








By Descartes’ Rule of Signs, there exists at least one positive steady state (Q#, C#, N#)
since P7 < 0 and P0 > 0 for all positive parameter values with #S <
1
2 . In particu-
lar, when using the parameters given in Table 5.5, there is only one positive steady
state at (Q#, C#, N#) = (1.52e4, 2.75e3, 2.62e10) and it is stable, with eigenvalues
*1,2,3 = "0.0151,"0.6296,"2.7420.
5.3.3 Numerical Simulations of Tissue Generation
There is little conclusive data regarding the in vivo cellular kinetics of stem cells.
The hematopoietic system is the most studied, but there are still many unknown be-
haviors, particularly regarding the interchange between quiescent and cycling stem
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Parameters
Term Value Range Used Value
r 0.002 - 0.6931 (1/day) [1, 21] 0.2310 (1/day)
p No Information 0.4620 (1/day)
q No Information 0.2310 (1/day)
&C No Information 750 (cells)
&Q No Information 1,500 (cells)
%S No Information 3,000 (cells)
%N No Information 1% 1010(cells)
"S 0.05 (calculated from [83]) 0.05
KS 15,000 - 1,000,000 (cells) [1, 83] 3% 104(cells)
A No Information 1.1% 108
"N 2.4 (1/day) [9, 13] 2.4 (1/day)
Model Steady State Predictions
C 5-25% of stem cells [21, 90, 104] 2,750 (cells)
Q 75-95% of stem cells [21, 90, 104] 15,200 (cells)
N 2" 6% 1010 (cells) [9, 100] 2.62% 1010
$ No Information 0.7701
# No Information 0.0694
!S 0.1850 - 0.2760 (derived from [125]) 0.2073
!A 0.5540 - 0.7150 (derived from [125]) 0.5853
!D 0.1000 - 0.1700 (derived from [125]) 0.1573
Table 5.5: Parameter values for the ODE Model of Tissue Generation are from in vivo hematopoi-
etic cells when possible.
cells. Furthermore, there is some discrepancy in the classification of long-term ver-
sus short-term stem cells and early progenitor cells, making it di"cult to isolate
parameter values for a pure stem-cell population. The following simulations use the
parameter values presented in Table 5.5, measured in hematopoietic cells when pos-
sible. The di!erential equation solver ode15s in MATLAB was used to run numerical
simulations.
By separating cycling and quiescent stem cells into two compartments, it is possi-
ble to investigate stem-cell dynamics during tissue generation. For instance, consider
the case in which one stem cell must generate additional stem cells and neutrophils
until homoestasis is reached. As seen in Figure 5.7A-B, one stem cell is capable of
generating enough progeny to achieve a healthy steady state. Initially, the majority
of stem cells are cycling, but as the system is reconstituted, most become quiescent
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and at steady state, 85% of stem cells are quiescent, while 15% are cycling. With
an initial condition of one cycling stem cell and zero quiescent stem cells and dif-
ferentiated cells, it takes 7.25 weeks to reach 1010 di!erentiated cells, bringing the
system out of neutropenia, and 22.55 weeks weeks to reach 90% of the steady state of
di!erentiated cells. The corresponding probabilities for stem-cell transition between
quiescence and cycling and division outcomes are plotted in Figure 5.7C-D. When
the system begins to regenerate, no cycling cells enter quiescence, but at steady state,
77% of cycling cells enter quiescence. In contrast, the probability that quiescent cells
enter cycling is initially the maximum 100%, but this decreases to approximately
7% at steady state. Stem-cell division patterns also change throughout the time of
generation. Symmetric self-renewal first expands the cycling pool of stem cells, then
asymmetric and di!erentiation divisions create di!erentiated cells. Initially, 95% of
all stem-cell divisions result in symmetric self-renewal, but as steady state is achieved,
this decreases to about 21%, and the probabilities of symmetric di!erentiation and
asymmetric division increase from 0% to 16% and 59%, respectively.
Such dynamics of tissue generation could not be studied with a model using
constant probabilities of cycling and stem-cell division. Note that in this model,
100% of stem cells are initially cycling, and they self-renew with 95% probability
and die with 5% probability. With a stem-cell proliferation rate of 0.231 per day, the
net growth rate of stem cells is 0.207 per day. If constant division probabilities were
used, the stem-cell population would exponentially grow. One stem cell proliferating
at a rate of 0.207 per day would expand into a population that would surpass the
niche size of 30,000 cells within 50 days, and in the meantime, zero di!erentiated
cells would be formed due to the lack of di!erentiation. On the other hand, at
homeostasis, the net growth rate of the stem-cell population is zero, and it would be
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Figure 5.7: Tissue generation from one cycling stem cell. (A) Quiescent stem cells, Q, cycling
stem cells, C, and total stem cells, T, are plotted versus time for 60 weeks as a system
is generated by one cycling stem cell. (B) Di!erentiated cells reach 90% of the steady
state in 22.6 weeks. (C) The probability that cycling cells enter quiescence, increases
from 0 to 77% while the probability that quiescent cells enter cycling, decreases from
100 to 7%. (D) Symmetric self-renewal decreases from 95 to 21%, while asymmetric
and symmetric di!erentiation increase from zero to 59% and 16%, respectively.
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impossible for one stem cell to expand and generate an entire tissue. It is therefore
evident that a mathematical model incorporating feedback regulatory mechanisms
is preferable when investigating hierarchical tissue.
5.4 Conclusions
In order to accurately capture characteristics found in hierarchical tissue, a math-
ematical model has been presented that incorporates feedback mechanisms between
stem- and di!erentiated-cell populations. A three-compartment mathematical model
of quiescent stem cells, cycling stem cells, and di!erentiated cells may be used to
study generation or reconstitution of normal tissue. Furthermore, it permits inves-
tigation of the balance between cycling and quiescent stem cells as well as the three
modes of stem-cell division involved in hematopoiesis. The parameters used in nu-
merical simulations were derived from the hematopoietic system, but the model could
easily be adapted to gain insight into other types of tissue by changing appropriate
parameter values.
Accurately modeling healthy tissue enables the study of mutation acquisition in
cells within a hierarchical structure. In particular, it fosters investigation of aber-
rant feedback mechanisms that contribute to abnormal tissue growth. The bal-
ance between symmetric self-renewal, symmetric di!erentiation, and asymmetric self-
renewal divisions is especially important in achieving and maintaining homeostasis,
which implies that disturbing this balance is a potential cause of malignancy. Sub-
sequent work will further examine these e!ects to indicate the types of mutations
that are most problematic, but before mutation acquisition is addressed, a sensi-
tivity analysis of the ODEMTG model is presented in the next chapter in order to
investigate the significance of parameters on homeostasis.
CHAPTER VI
Modeling the Regulation of Tissue Homeostasis
The preceding chapter introduced a mathematical model of hierarchical tissue
that enabled investigation of the mechanisms governing stem-cell division pattern
and the transition of stem cells between quiescence and cycling. This model was
used to simulate tissue generation and to establish homeostasis. In this chapter, the
sensitivity of model parameters is discussed in further detail in order to highlight the
regulatory aspects that have the greatest e!ect on tissue generation and equilibrium.
First, a di!erential sensitivity analysis is conducted that quantifies the change in
cell populations during tissue generation due to parameter perturbations. Next, a
system of two ordinary di!erential equations is derived from the reduction of the
ODE Model of Tissue Generation (ODEMTG) system in Equations 5.7 to model
tissue homeostasis. Finally, a principle component analysis is conducted in order to
determine parameter combinations that significantly impact equilibrium solutions.
6.1 Di!erential Sensitivity Analysis
Tissue generation is a dynamical process likely influenced by several aspects of
cellular kinetics. For instance, the stem-cell proliferation rate determines the speed
at which daughter cells can be produced, a!ecting the time required to reach full
constitution. In addition, the mechanisms regulating the pattern of stem-cell division
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can factor into tissue composition by controlling the ratio between stem cells and
di!erentiated cells. In this section, a sensitivity analysis of the ODEMTG model in
equation 5.7 is conducted in order to quantify the e!ects of parameter perturbations
on tissue generation.
6.1.1 Sensitivity Equations
Following the techniques outlined by Bortz and Nelson, sensitivity equations are
generated by di!erentiating model equations with respect to the parameter in ques-
tion [18]. Thus the sensitivity equations are partial derivatives of the solution curves,
and interpret how parameter changes alter solutions over time. For any arbitrary













For example, to investigate the e!ects of the stem-cell proliferation rate, r, the three
equations in the ODEMTG model are di!erentiated with respect to r, resulting in
the following system:
Q̇r = "p$Qr " pQ$r + q%Cr + qC%r(6.2)
Ċr = p$Qr + pQ$r " q%Cr " qC%r + r ("S " "D " #S) Cr
+ C [r ("Sr " "Dr) + ("S " "D " #S)]
Ṅr = (2"D + "A) ArCr + AC [r (2"Dr + "Ar) + (2"D + "A)]" #NNr.
The sensitivity solutions can be analyzed in two ways. Semi-relative sensitivity
solutions can be computed by multiplying the parameter of interest by the sensitivity
equations, for example, rCr, rQr, and rNr. Solving the resulting system quantifies
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how solutions change when a parameter is varied by a factor of choice. For instance,
it is often of interest to know how solutions behave when the sensitivity parameter is
doubled. Semi-relative solutions have the same units as the original model solutions;
that is, the units of rCr are those of C, which in this case is cycling stem cells.
Logarithmic sensitivity solutions are computed by multiplying the parameter of
interest by the sensitivity equations and dividing by the baseline solutions. For








C Cr. In contrast
to semi-relative solutions, logarithmic sensitivity solutions are dimensionless and
determine the percentage change of solutions according variation in the parameter
of choice. Although useful information is obtained from both types of sensitivity
solutions, only logarithmic solutions are presented in this chapter.
6.1.2 Logarithmic Sensitivity Solutions
The system of di!erential equations needed to produce sensitivity solutions were
analytically derived for each of the eleven parameters in the ODEMTG model. Sen-
sitivity solution curves were produced using the ode15s solver in MATLAB. In order
to visually manage all of the corresponding sensitivity solution curves, parameters
are classified into three groups. The first group consists of parameters found in the
functional forms governing stem-cell transition between quiescent and cycling pools:
p, q, )C , and )Q. The second group of parameters are involved in regulating stem-
cell division probabilities: (S, KS, (N , and #S. The third group is composed of the
parameters most significantly a!ecting the number of di!erentiated progeny in the
system: r, A, and #N .
First, the parameters involved in stem-cell transition between quiescence and cy-
cling are studied. Specifically, the logarithmic sensitivity solutions with respect to
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Figure 6.1: Sensitivity of parameters a!ecting stem-cell transition. Parameters controlling
the transition between quiescence and cycling have little e!ect on homeostasis.
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the parameters p, q, )C , and )Q are plotted in Figure 6.1. Recall that p is the max-
imum rate at which quiescent stem cells enter cycling and q is the maximum rate at
which cycling stem cells enter quiescence. Parameters )C and )Q are found in the
functional forms for $(C) and %(C), the probabilities at which stem cells enter the
cycling and quiescent compartments, respectively. The solution curves in Figure 6.1
may be interpreted as the percentage change to the solutions for quiescent stem cells,
cycling stem cells, and di!erentiated cells due to the doubling of the parameter in
question. This type of analysis gives insight into the temporal changes in solution
curves due to the variation of a parameter. For instance, according to Figure 6.1A,
at time t = 0, the solutions generated by doubling q increase baseline solutions
by approximately 100%, but as time progresses, the logarithmic sensitivity solution
approaches zero, suggesting that q has minimal e!ect on homeostasis of quiescent
cells.
Interestingly, doubling any of the parameters involved in stem-cell transitioning
does not significantly change homeostatic population levels. While at first this may
seem surprising, one must remember that regulatory mechanisms such as symmetric
self-renewal and symmetric di!erentiation remain intact that control any increase or
decrease in cycling stem cells, thereby minimizing extreme expansion or depletion of
all populations. Although each cell population is fairly robust to changes in these
parameters over the long term, there are short-term e!ects that are worth noting.
In particular, perturbations to the rate at which cycling cells enter quiescence, q,
and the parameter )Q have significant e!ect on the quiescent stem-cell compartment
during the initial stages of tissue generation. Increasing )Q increases the number of
cells needed in the cycling compartment before cycling cells enter quiescence with
50% probability. Therefore, doubling )Q decreases the number of quiescent stem
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cells at the start of tissue generation by 200% because less cells exit the cycling
compartment. On the other hand, doubling the maximum rate at which cells enter
quiescence, q, causes an initial 100% increase of quiescent cells at the start of tissue
generation. As homeostasis is reached, however, perturbations in both )Q and q are
negligible.
Next, the parameters found in the functional forms governing stem-cell division
are investigated. The ODEMTG model in Equations 5.7 incorporates feedback mech-
anisms that regulate four possible outcomes of stem-cell division. Parameters (S and
(N respectively determine how many stem or di!erentiated cells are needed for sym-
metric self-renewal or commitment di!erentiation to occur with 50% probability due
to chemical signaling. The size of the stem cell niche, KS, also contributes to the
probability of symmetric self-renewal and symmetric commitment di!erentiation. Fi-
nally, the probability of stem-cell death, #S, also influences the outcome of stem-cell
division. The logarithmic sensitivity solutions with respect to (S, (N , #S, and KS
are plotted in Figure 6.2.
Perturbations to the size of the stem-cell niche, KS, have the greatest long-term
e!ects on tissue homeostasis. Doubling the niche increases the cycling stem-cell and
di!erentiated-cell populations at homeostasis by approximately 30%, but increases
the number of quiescent stem cells by approximately 100%. This implies that if other
regulatory mechanisms remain unaltered, a larger niche supports a greater number of
stem cells, but favors these additional cells in quiescence. Doubling the parameters
(S, (N , and #S has less e!ect on homeostatic population levels, but variation in #S
significantly alters all of the cell populations in the initial stages of tissue generation.
Since tissue generation is initiated with one cycling stem cell, a significant increase
in the probability of stem-cell death will negatively impact the cycling population of
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Figure 6.2: Sensitivity of parameters involved in determining stem-cell division mode.
The size of the stem-cell niche is most significant in a long-term increase of quiescent
stem cells. The probability of stem-cell death significantly impacts all cell populations
early in tissue generation, but the e!ect is neutralized within ten weeks.
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stem cells, which in turn diminishes the number of cells able to enter quiescence as
well as the potential for producing di!erentiated progeny. These e!ects are contained
within the first 10 weeks of tissue generation, however, and do not radically alter
homeostasis.
The final group of parameters features those most directly a!ecting the number
of di!erentiated cells in the system. The stem-cell proliferation rate, r, is the rate
at which cycling stem cells divide. The amplification factor, A, accounts for the
expansive cell divisions of intermediate progenitors that produce the necessary num-
ber of di!erentiated cells. Lastly, #N is the death rate of terminally di!erentiated
cells. Since this last group of parameters each appear linearly in the model equa-
tion for di!erentiated cells, it is expected that doubling the stem-cell proliferation
rate or amplification factor leads to a 100% increase in di!erentiated cells, whereas
increasing di!erentiated cell death rate leads to a 100% decrease in di!erentiated
cells. Furthermore, neither of these parameters a!ects the long-term equilibrium of
the cycling or quiescent stem-cell populations. Because perturbations of the ampli-
fication factor and di!erentiated cell death rate do not cause significant temporal
changes during the early stages of tissue generation, these are not explicitly plotted.
However, perturbation of the stem-cell proliferation rate has a major impact on gen-
eration time, and as a result, the final plot focuses on this parameter, and only plots
the logarithmic sensitivity solutions with respect to r in Figure 6.3.
It is particularly important to highlight the short-term impact of increasing the
stem-cell proliferation rate. If cycling stem cells proliferate faster in the initial stages
of tissue generation, then it takes less time to reach homeostasis as all cell populations
expand more quickly. Perturbation of stem-cell proliferation realizes its maximal
e!ect approximately four weeks after the start of tissue generation. At this time,
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Figure 6.3: Sensitivity of the stem-cell proliferation rate. The stem-cell proliferation rate
dramatically increases all cell populations early in tissue generation. In addition, it
significantly a!ects the homeostatic level of di!erentiated cells, but does not alter the
equilibrium of both stem-cell populations.
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the doubling of r increases the quiescent stem-cell population by 17-fold, the cycling
compartment by approximately 5.5-fold, and the di!erentiated-cell population by
nearly 15-fold. Clearly the rate at which cycling stem cells divide is an important
factor in determining how long it takes for tissue to be generated. Since increasing
the stem-cell proliferation does not alter the steady state of stem cells in homeostasis,
the dramatic temporal variation due to increased stem cell proliferation would not
have been detected without conducting this type of sensitivity analysis.
6.1.3 Discussion
In comparing and contrasting the sensitivity solutions for each of the model pa-
rameters, it is evident that some parameters have significant e!ects on the long-term
outcome of homeostatic solutions, while others have an immediate, but short-lived
e!ect during the initial stages of tissue generation. The stem-cell proliferation rate,
r, is unique in that it impacts both long-term and short-term dynamics consider-
ably. Variations in this parameter cause the greatest e!ect during the initial stages
of generation in comparison with all other parameters. Increasing the stem-cell pro-
liferation rate increases the number of stem cell divisions that occur in a given time
frame, promoting faster expansion in all cell populations. These e!ects do not per-
sist over time in the stem cell populations, however, as the number of quiescent and
cycling stem cells at homeostasis remains unaltered due to a balanced pattern of
stem-cell division. In contrast, long-term e!ects are realized in the di!erentiated-cell
population due to the increased number of stem-cell divisions producing di!erenti-
ated progeny through asymmetric and commitment di!erentiation divisions. Home-
ostatic solutions of the di!erentiated-cell population are also significantly altered by
the amplification factor, A, and di!erentiated-cell death rate, #N . Specifically, the
di!erentiated cell population increases by 100% when A is doubled, and decreases
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by 100% when #N is doubled, but this is expected.
There are other parameters that cause significant variation in the the initial stages
of tissue generation. The maximum rate at which cells enter quiescence, q, and the
switch parameter at which cycling cells enter quiescence with 50% probability, )Q,
notably alter the solution of quiescent stem cells at the beginning of tissue formation,
but these e!ects diminish after five weeks. This result implies that alterations in the
rate and probability at which cycling cells enter quiescence have greater significance
in earlier stages of tissue growth rather than the later period of homeostasis. Simi-
larly, the probability of stem-cell death, #S, initially impacts both quiescent stem cells
and di!erentiated cells negatively, decreasing these solutions by approximately 180%
and 150%, respectively, but as tissue continues generating, the percentage change at
homeostasis diminishes.
Although various parameters have significant short-term e!ects during tissue gen-
eration, the change in solutions is normalized over the long run due to regulatory
mechanisms that control tissue homeostasis. Parameters q, )Q, #S and particularly
r all significantly a!ect tissue dynamics early, but do not maintain their influence
as time progresses and tissue equilibrium is reached. Consequently, single parameter
perturbations may influence the pace of tissue generation, but are held in check by
regulatory mechanisms that govern tissue dynamics.
The sensitivity solutions for the size of the stem-cell niche, KS reveal several
details regarding the importance of this parameter. First, it is the most important
parameter in determining the number of stem cells at homeostasis. Although the
long-term solution of cycling cells does increase, a greater percentage change occurs
in the quiescent population. Specifically, doubling the size of the stem-cell niche
increases the number of cycling stem cells by 30% and quiescent cells by 100%. In
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addition, doubling the niche initially decreases the solution of di!erentiated cells
by 100%, though this variation goes to zero in approximately five weeks. When
the niche is increased and there are few stem cells in the system, as at the start
of tissue generation, symmetric self-renewal is favored over the other types of stem-
cell division, which inhibits the production of di!erentiated cells. As the stem-cell
population expands and the niche is filled, however, symmetric self-renewal decreases
and di!erentiation proceeds. The logarithmic sensitivity solution of the di!erentiated
cell population with respect to KS is unique in that it is the only one in which the
initial percentage change is negative while the change at homeostasis is positive. This
is explained by the fact that the larger niche supports a greater number of stem cells
in the long-run, which in turn produces more di!erentiated cells at homeostasis.
One may notice that with the exception of the initial spike caused by increasing
the stem-cell proliferation rate, all other sensitivity solutions for cycling stem cells
have percentage changes of magnitude less than 100%. Even more telling is the
observation that no parameter alters the long-run solution of cycling stem cells by
more than 50%. Therefore, the doubling of a single parameter is not su"cient to
greatly change the homeostasis of cycling stem cells. This implies that the regulatory
mechanisms governing the cycling compartment compensate for considerable param-
eter perturbations. It is possible that a combination of parameters could impact the
solution at homeostasis, but before this type of analysis is discussed in section 6.3,
the next section will present a reduced model that e!ectively models tissue after
completed generation.
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6.2 Mathematical Modeling of Homeostatic Tissue
In Chapter V, the ODEMTG model was introduced in Equations 5.7 to simulate
generation of hierarchical tissue. The previous section discussed the sensitivity of
each of the parameters in this three-equation model. It was determined that pertur-
bations in parameters associated with stem-cell transitioning between cycling and
quiescent populations could a!ect the number of cells during the initial stages of
tissue formation, but did not significantly impact tissue homeostasis in the long-
run. This observation suggests that the interplay between quiescence and cycling
does not noticeably alter the composition of the total stem-cell population at home-
ostasis. Consequently, the ODEMTG model can be reduced into a system of two
ordinary di!erential equations by combining the quiescent and cycling populations
into one stem-cell pool, and this model can be used for tissues that have completed
generation.
6.2.1 Model of Homeostatic Tissue Regulation
In this section, the ODEMTG three-equation model is reduced to a system of two
ordinary di!erential equations by combining quiescent and cycling stem cells into





dt . Therefore, according to Equations 5.7,
dS
dt
= ("S " "D " #S) rC(6.3)
dN
dt
= (2"D + "A) rAC " #N ,
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"A = 1" "S " "D " #S.
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By making the substitutions (̄S =
$S
( and k = r+ and dropping the bar on (̄S for
convenience, the final reduced system of equations is
dS
dt
= ("S " "D " #S) kS(6.4)
dN
dt
= (2"D + "A) rAS " #N
with

















"A = 1" "S " "D " #S.
For ease of referral in subsequent discussion, Equations 6.4 is called the Model of
Homeostatic Tissue Regulation (MHTR).
6.2.2 Analysis of Tissue Equilibrium
System equilibrium is achieved when either S = 0 or ("S " "D " #S) = 0. The
elimination state corresponds to a system with zero stem cells and zero di!erentiated
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cells. This steady state has eigenvalues *1 = k(1 " 2#S) and *2 = "#N . Therefore,
the elimination state is stable if and only if #S >
1
2 . In other words, the elimination
state is stable when the probability of stem-cell death is greater than 50%, and
unstable otherwise. In healthy tissue, it is assumed that stem-cell death occurs
with small probability during division, specifically 5% as derived from the suggested
proliferation and death rates of hematopoietic stem cells, rendering the elimination
state unstable [21, 83].
A positive steady state exists when ("S " "D " #S = 0) is satisfied. Under this
condition, the steady state of di!erentiated cells is linearly dependent upon the stem-





By substituting this equality for N into ("S""D" #S) = 0, the steady state of stem
cells can be derived by solving for the roots of the third-degree polynomial
P3S
3 + P2S
2 + P1S + P0 = 0,
where
P3 = "#SKS(1" 2#S)kA" (1" #S)#N(N
P2 = "(1" #S)(1" 2#S)(2SkA" #SKS#N(N
P1 = "2(1" #S)(2S#N(N " (2SKS(1" 2#S)2kA
P0 = (1" 2#S)#N(N(2SKS.
If #S <
1
2 , then according to Descartes’ Rule of Signs, there is exactly one positive so-
lution for tissue homeostasis. Using the parameters presented in Table 6.1, numerical
derivation finds the equilibrium solution to be 1.80% 104 stem cells and 2.62% 1010
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Parameters
Term Value Range Used Value
r 0.002 - 0.6931 (1/day) [1, 21] 0.2310 (1/day)
' 0.05 - 0.25 [21, 90, 104] 0.1528




%N No Information 1% 1010(cells)
"S 0.05 (calculated from [83]) 0.05
KS 15,000 - 1,000,000 (cells) [1, 83] 3% 104(cells)
A No Information 1.1% 108
"N 2.4 (1/day) [9, 13] 2.4 (1/day)
Table 6.1: Parameter values for the Model of Homeostatic Tissue Regulation are from in vivo
hematopoietic cells when possible.
di!erentiated cells. The eigenvalues of this equilibrium solution are *1 = "2.71 and
*2 = "0.02, demonstrating that the solution is stable.
The probability of stem-cell death, #S is the only bifurcation parameter for the
MHTR model presented in Equations 6.4. This implies that stem-cell apoptosis is
the key factor in determining whether a healthy tissue homeostasis may be reached.
If dividing stem cells die with probability greater than 50%, then the stem-cell pop-
ulation declines to zero, subsequently decreasing di!erentiated progeny until all cells
are eliminated. However, if less than 50% of dividing stem cells go through apoptosis,
then the tissue reaches a positive equilibrium state. Figure 6.4 plots the bifurcation
of solution stability as dependent on #S.
This two-equation model of stem and di!erentiated cells provides an appropriate
framework for capturing the important dynamics of a generated tissue in homeosta-
sis. Although parameters involved in transitioning stem cells between quiescence and
cycling are eliminated, these have a small impact on tissue equilibrium as confirmed
by the sensitivity analysis from Section 6.1. Importantly, the MHTR model retains
parameters from the ODEMTG model that had long-term e!ect, particularly the
stem-cell niche and stem-cell proliferation rate. By reducing the number of equa-
tions, there are less parameters, which makes it simpler to now investigate which
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Figure 6.4: The probability of stem-cell death is the only bifurcation parameter for the
Model of Homeostatic Tissue Regulation. When less than half of the stem-cell
division outcomes result in apoptosis, a positive equilibrium solution exists and it is
stable. When the probability of stem-cell death is greater than 50%, the elimination
state is stable.
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combinations of parameters cause significant variations in solutions homeostasis.
6.3 Principal Component Analysis
Principal component techniques are often employed in statistical analysis in order
to highlight important combinations of variables in a system. The theory of prin-
cipal component analysis (PCA) may likewise be applied to a model’s parameter
space to determine solution e!ects based on changes to more than one parameter.
Di!erential sensitivity analysis, as presented in Section 6.1, is useful in identifying
which individual parameters cause the greatest variation. In a dynamical system,
it is possible that alterations in more than one parameter could negate any e!ects
resulting in little deviation from the baseline solution. On the other hand, some
parameter combinations could amplify solution di!erences more when varied jointly
rather than separately. It is therefore beneficial to conduct a principal component
analysis to determine the key groupings of parameters that most significantly alter
solutions.
6.3.1 Theory of Principal Component Analysis
In order to familiarize the reader with PCA theory, an outline of the analysis
is now presented as is relevant to analyze the MHTR model [18]. Let x be the
two dimensional vector x = [S(t, &), N(t, &)] of the solutions of stem cells, S, and
di!erentiated cells, N , evaluated at time t for the parameters &. If &# denotes the




R(&; t)T R(&; t)dt,(6.6)
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R(q; t) = [r1(t, &, &
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Because the solutions of the system are numerically derived, the time interval [t0, tf ]
may be partitioned into , subintervals such that
J(&) ' (tf " t0)
,
(#&)TST& S&(#&)(6.11)
where the sensitivity matrix
ST& = [R
$(&; t1), R
$(&; t2), . . . , R
$(&; t))] .(6.12)
The maximum of J occurs when the change in parameters, that is #&, is in
the direction of the eigenvector corresponding to the largest eigenvalue of ST& S&,
whereas the minimum occurs in the direction corresponding the the smallest eigen-
value. Therefore, matrix ST& S& can be calculated, and its eigenvalues determined
in order to determine the direction in which maximum and minimum change oc-
curs. When the eigenvectors are primarily in the directions of the parameter axes,
it suggests that the parameters act independently of each other. When eigenvectors
are skewed from the parameter axes, however, then it implies that there is some
correlation between the two parameters that leads to maximal change.
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6.3.2 Numerical Results
To determine which parameter pairings can cause the greatest e!ects on model
solutions, a PCA was conducted for each of the potential couplings of the seven
parameters in the MHTR model. When the directions incurring maximum and
minimum change are nearly horizontal and vertical in correlation with the axes,
the parameters act independently of each other, so it is important to identify those
groups of parameters in which the axes are rotated since it implies some level of
dependence. In other words, when there is parameter dependence, a change in one
parameter may be compensated by a corresponding change in the other parameter
in order to maintain the solution derived when using the baseline parameters &#.
Of all the pairings taken from the seven MHTR parameters, only two couplings
exhibit dependence, and the directions causing maximum and minimum e!ect are
plotted in Figure 6.5. The first pair consists of the stem-cell proliferation rate, k,
and the probability of stem-cell death, #S, as shown in Figure 6.5A. Perturbations
local to &# have maximal e!ect in the direction given by the line
k = "1.03#S + 0.299.(6.13)
and minimal e!ect along
k = 0.969#S + 0.199(6.14)
This result may be interpreted by saying that an increase in stem-cell proliferation
accompanied with a decrease in stem-cell death in the direction of Equation 6.13 will
cause the greatest increase of cells in the system. On the other hand, an increase in
stem cell death an increase in stem-cell proliferation combined with an increase of













































Figure 6.5: Significant parameter pairings according to Principal Component Analysis.
Two pairings demonstrate significant correlation: the stem-cell proliferation rate and
stem-cell death rate (A), and the two key parameters involved in symmetric self-renewal
of stem cells (B).
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The second pairing, shown in Figure 6.5B, includes (S and KS, which both con-
tribute to the probability of symmetric self-renewal in stem cells. Perturbations local
to &# have maximal e!ect in the direction of
(S = 0.619KS + 1080(6.15)
and minimal e!ect along
(S = "1.62KS + 68, 100.(6.16)
In other words, maximal e!ect occurs when both (S and KS increase in the direc-
tion of equation 6.15. In contrast, if perturbation increases the size of the niche,
then a decrease of the chemical signaling switch parameter, (S, in the direction of
equation 6.16 may compensate for minimal change.
This principal component analysis suggests that variation to two pairs of param-
eters could significantly alter tissue homeostasis: (i) k, the stem-cell proliferation
rate, and #S, the probability of stem-cell death, and (ii) (S, the parameter deter-
mining symmetric self-renewal based on signaling, and KS, the size of the stem-cell
niche. Specifically, increased stem-cell proliferation coupled with reduced apopto-
sis contributes to maximal change from equilibrium. In addition, the increase of
symmetric self-renewal of stem cells due to increased signaling and niche availability
causes maximal e!ect on the state of the tissue.
It is interesting to note that deregulated proliferation, apoptosis, and self-renewal
have all been implicated in tumorigenesis [50]. Therefore, it is not surprising that
variation in these model parameters greatly disturb tissue homeostasis. In particular,
increased proliferation and decreased cell death cause hypercellularity in di!erenti-
ated cells with little long-term e!ect on stem cells, whereas unbalanced symmetric
self-renewal significantly expands stem cells, which in turn increases the number of
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di!erentiated cells as well. These results are consistent with the findings of Wu et
al. [125]. Specifically, they hypothesize that BCR-ABL increases cell prolfieration
and inhibits apoptosis to cause cancer that exhibits a high ratio of di!erentiated to
immature cells. In contrast, NUP98-HOXA9 deregulates the balance of symmetric
self-renewal, and causes a form of malignancy that is more aggressive because it ex-
pands the number of cancer stem cells. The next chapter will address the acquisition
of these types of mutations and determine the e!ects that stem-cell deregulation has
on tumor initiation.
CHAPTER VII
Deregulation of Tissue-Governing Mechanisms
The Maturity-Structured Model of Mutation Acquisition (MSMMA) presented
in Chapter IV investigated tumorigenesis in hierarchical tissue and predicted that
unbalanced stem-cell division pattern is potentially a main cause of malignancy. In
order to further investigate mechanisms that control the stem-cell division pattern,
the Ordinary Di!erential Equations Model of Tissue Generation (ODEMTG) was
presented in Chapter V. In that model, symmetric self-renewal, asymmetric self-
renewal, and symmetric commitment di!erentiation divisions critically depended on
both stem-cell and di!erentiated-cell populations. Chapter VI discussed the sensitiv-
ity of the ODEMTG model, and simplified the system from three equations to two.
It was argued that the two-equation model, called the Model of Homeostatic Tissue
Regulation (MHTR), could be used to simulate tissue that has achieved homeostasis
following generation. In the present chapter, this MHTR model is used to address
how deregulation of the mechanisms preserving stem-cell homeostasis contributes to
cancer.
7.1 Model Structure
Just as hierarchical structure influences the multi-step process of tumorigene-













Figure 7.1: Mutation acquisition in stem cells and the formation of abnormal progeny.
Stem cells acquire mutations with small probability during each division and pass on
mutations to their progeny. Terminally di!erentiated cells are fully mature, and there-
fore, do not divide and acquire additional mutations.
growth dynamics. In order to investigate the sequential acquisition of mutations
that initiate cancer in regulated tissue, the MHTR model is now extended in order
to incorporate mutated cell populations. Stem and di!erentiated cells with i mu-
tations are denoted Si and Ni, respectively. Specifically, i = 0, 1, 2, 3 because three
mutations are considered: decreased cell death, genetic instability, and deregulated
proliferation. Stem cells mutate with probability mi during division. Stem cells are
the source for di!erentiated cells through asymmetric and symmetric di!erentiation
divisions. Unlike the model presented in Chapter IV, intermediate populations of
progenitors are omitted, and since terminally di!erentiated cells cannot complete
further divisions and mutate, stem cells are the only cells that can acquire additional
mutations. A schematic of the flow of cells from one population to another is shown
in Figure 7.1.
The mathematical model consists of eight ordinary di!erential equations. The
parameters of the non-mutated stem cells, S0, and non-mutated di!erentiated cells,
N0, are as defined in Chapter VI, Table 6.1. Original model equations are presented
in Chapter VI, Equations 6.4. Parameters alter depending on which mutations have
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been acquired; hence, each parameter is also denoted with the subscript i to denote




= [(1" 2m0) "S0 " (1"m0) "A0 " "D0 " #S0] k0S0(7.1)
dS1
dt
= [(1" 2m1) "S1 " (1"m1) "A1 " "D1 " #S1] k1S1
+ [2m0"S0 + m0"A0] k0S0
dS2
dt
= [(1" 2m2) "S2 " (1"m2) "A2 " "D2 " #S2] k2S2
+ [2m1"S1 + m1"A1] k1S1
dS3
dt
= ["S3 " "D3 " #S3] k3S3 + [2m2"S2 + m2"A2] k2S2
dN0
dt
= [2 (1"m0) "D0 + (1"m0) "A0] A0k0S0 " #N0N0
dN1
dt
= [2 (1"m1) "D1 + (1"m1) "A1] A1k1S1 " #N1N1
+ [2m0"D0 + m0"A0] A0k0S0
dN2
dt
= [2 (1"m2) "D2 + (1"m2) "A2] A2k2S2 " #N2N2
+ [2m1"D1 + m1"A1] A1k1S1
dN3
dt
= [2"D3 + "A3] A3k3S3 " #N3N3 + [2m2"D2 + m2"A2] A2k2S2
with the probabilities of stem-cell division defined as
"S0 = (1" #S)
$
(2S
(2S + (S0 + S1 + S2)
2
% $
1" S0 + S1 + S2 + S3
KS
%
"D0 = (1" #S)
$
(N
(N + (N0 + N1 + N2)
% $
S0 + S1 + S2 + S3
KS
%
"A0 = 1" "S " "D " #S.
The functional forms of division probabilities were explained in Chapter V, Sec-
tion 5.3.1. It is assumed that cancer cells with all three mutations, denoted S3, do
not produce signals to inhibit symmetric self-renewal, and thus they are omitted
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from the Hill function in "S. Likewise, cancer di!erentiated cells do not influence
symmetric di!erentiation. Cancer cells do take up space within the stem-cell niche,
and as a result, all stem cells are incorporated in the logistic term. For ease of future
discussion, the model presented in Equations 7.1 is called the Model of Mutation
Acquisition in Regulated Tissue (MMART).
The mutation pathway is the order in which mutations occur. All mutation path-
ways are compared and contrasted in order to determine which sequences generate
cancer cells fastest. As in Chapter IV, three mutations are considered that are be-
lieved to be involved in the initial stages of tumorigenesis. The D mutation decreases
the death rate in both stem and di!erentiated cells. The G mutation increases ge-
netic instability by increasing the rate at which additional mutations are acquired.
The R mutation alters proliferation characteristics of stem cells, by increasing ei-
ther the proliferation rate or the probability of symmetric self-renewal. The various
possibilities for the R mutation will each be examined separately in di!erent cases.
The parameter values for both normal and mutated cells are presented in Table 7.1.
Although values are derived from the hematopoietic system, the model can be easily
applied to other tissues by using appropriate parameter values.
7.2 Increased Stem-Cell Proliferation
The sensitivity analysis conducted in Chapter VI suggested that the stem-cell
proliferation rate is a key parameter in determining tissue generation, and when
combined with changes in stem-cell death, it has a big e!ect on homeostasis. Pro-
liferation is increased in various forms of cancer. For instance, overexpression of the
potassium channel TREK-1, the androgen receptor, and cyclin D1 have each been
implicated in increased proliferation in prostate cancer cells [49, 53, 121]. It has also
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Parameter Value Used Mutated Value
c* 0.1528
r* 7 ln(2)3 (weeks
!1)
k rc = 0.2471 (weeks!1) 2k (weeks!1) @
%S
3e3
c ' 1.96e4 (cells) 2%S (cells) !




"N 16.8 (weeks!1) 0.5"N (weeks!1)
m 10!6 10!4
* parameter from Chapter Six needed to determine parameters
@ only used when proliferation rate increases
! only used when chemical signals are deregulated
$ only used when the niche capacity increases
Table 7.1: Parameter values of non-mutated cells and mutated cells for the Model of Mutation
Acquisition in Regulated Tissue. The D mutation alters death terms, the G mutation
alters the mutation rate, and the R mutation may increase the stem-cell proliferation
rate, or terms increasing symmetric self-renewal.
been suggested that BCR-ABL, which is expressed in CML patients, increases the
rate at which hematopoietic cells divide [125].
According to the sensitivity analysis in Section 6.1.2, increasing the stem-cell pro-
liferation rate alone has minimal e!ect on the homeostasis level of stem cells. Rather,
it increases the number of divisions that stem cells complete, which o!ers more op-
portunity to gain additional mutations. It should be noted that as long as symmetric
self-renewal and symmetric commitment di!erentiation are balanced, then the stem-
cell population reaches equilibrium, even if the rate of proliferation increases. The
number of di!erentiated progeny significantly increases because of the increased num-
ber of asymmetric self-renewal and symmetric commitment di!erentiation stem-cell
divisions, but also reaches equilibrium due to stem-cell homeostasis.
When the R mutation doubles the stem-cell proliferation rate, three sub-cases
may be considered. In the first case, all mutations are advantageous and give the
mutated cell added benefits over normal cells. In the second case, mutated cells
that have acquired G and/or R mutations without a previous D mutation have
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increased cell death. In the third case, cells with G and/or R are penalized without
the D mutation with the added assumption that cancer cells do not retain feedback
regulatory mechanisms. Specifically in this case, the probabilities of stem-cell division
are constant in cells with all three mutations. For each of these sub-cases, the
pathway that causes the fastest emergence of the cancer stem cell population is
determined, and the change in tissue composition over time is discussed.
7.2.1 All Mutations are Advantageous
Consider a case in which every mutation gives advantage to the cell. That is, each
mutation increases the cell’s fitness and cell death does not increase in attempting to
eliminate the mutated cell. Under such conditions, the pathways that acquire G first
are the fastest, concurring with the results from Section 4.2.2. Genetic instability
predisposes the cells to accumulating additional mutations, which quickens the time
in forming the first cancer stem cell. The GDR and GRD pathways are fastest, with
the first cancer stem cell forming in 19 years and the slowest pathway, DRG, is nearly
nine years slower. Cancer stem cells and cancer di!erentiated cells of all pathways
are plotted versus time in Figure 7.2A-B, respectively.
The MSMMA model in Chapter IV did not incorporate feedback regulations gov-
erning stem-cell division, and as a result, the system did not adjust to the increasing
number of mutated cells in the tissue. Normal cells remained in homeostasis, while
all mutated populations expanded without bound. With the inclusion of feedback in
the present model, mutated cells do not grow exponentially for all time, but instead
displace non-mutated cells, until healthy cells diminish from the system entirely.
The tissue composition of the fastest pathway, GDR, is plotted in Figure 7.2C. Non-
mutated cells dominate the tissue for approximately thirty years, after which cancer
cells are the majority. In contrast, when following the slowest pathway, DRG, cells
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Figure 7.2: Comparison of pathways when all mutations are advantageous. The order
in which the G mutation is acquired determines the fastest paths. (A) Cancer stem
cells formed in each pathway are plotted versus time. The GDR pathway has the first
cancer stem cell, followed closely by the GRD pathway. (B) Di!erentiated cancer cells
are plotted versus time for each pathway. The growth of di!erentiated cancer cells
mirrors the growth of cancer stem cells in each pathway. (C) Tissue composition for
the fastest pathway, GDR, versus time. (D) Tissue composition for the slowest pathway,
DRG, versus time.
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with only one and two mutations eventually take over the tissue and cancer cells re-
main a small percentage, as demonstrated in Figure 7.2D. Therefore, not only does
the time to form the first cancer stem cell vary between various pathways, but the
order in which mutations are acquired also determines the dominance of cancer cells
within the tissue.
Model predictions for fastest pathway are consistent with results from Chapter IV.
This implies that the significance of genetic instability is not diminished in tissues
that are regulated by governing mechanisms. There is one important di!erence be-
tween current MMART model predictions in comparison with MSMMA predictions.
Advantageous mutations in tissues that are not governed by regulatory mechanisms,
as in the MSMMA model, automatically cause exponential growth. In contrast,
when regulatory mechanisms are incorporated, exponential tumor growth does not
occur if these governing factors are still in place. Rather, an elevated equilibrium is
approached, and cancer results from the displacement of normal cells. This implies
that exponential cancer growth can only occur in the absence of feedback regulation.
7.2.2 Lethal Mutations
Now a case is investigated in which every mutation does not give the cell added
advantage, but can instead increase cell death as a result of cellular machinery recog-
nizing the mutation and forcing the cell into apoptosis. The D, G, and R mutations
are defined as in Section 7.2.1, but it is assumed that cells that have acquired either
the G and/or R mutation without the D mutation have an increased rate of apopto-
sis such that the probability of stem-cell death is 0.95 during division. For example,
in the GRD pathway, cells with the G mutation only obtain the ability of mutate
faster but they also have a higher death rate. Cells that are able to acquire the next
mutation, R, have both genetic instability as well as increased proliferation, but cell
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death remains high since apoptosis is favored due to the recognition of mutation.
Once D is acquired, then the cell has increased its ability to evade apoptosis, which
lowers the death rate, and the advantages gained in the previous G and R mutations
remain.
Unlike the findings in Section 7.2.1, the order in which genetic instability is ac-
quired is not important in determining the pace in which cancer is initiated. To
illustrate this conclusion, consider the DGR and RGD pathways. Both pathways
acquire G second, but DGR is the fastest pathway while RGD is the slowest. There-
fore, the significance of genetic instability is minimized when it is lethal mutation.
Instead, if the probability of cell death increases in mutated cells that cannot already
evade apoptosis, then acquiring the D mutation first contributes to the fastest emer-
gence of cancer stem cells. Once cells obtain the D mutation, then all subsequent
mutations are advantageous, which is not true if either G or R is acquired first.
Not only does the fastest pathway change under the assumption of advantageous
versus lethal mutations, but the tissue compositions of the fastest pathways are con-
trasting. Figure 7.3 compares the tissue composition between the fastest pathway in
Section 7.2.1, GDR, and the fastest pathway under the assumption of lethal muta-
tions, DGR. In the GDR pathway, cancer cells take over the tissue in thirty years.
In stark contrast, cells with only one mutation, namely the D mutation, eventually
dominate tissue following the DGR pathway. Therefore, it could be argued that the
all-advantageous sequence GDR is a more aggressive form of disease.
The initiation of cancer is delayed 10-20 years in pathways for which D is not
first. Furthermore, the tissue composition for each pathway resembles the pathway’s
composition under the assumption that all mutations are advantageous, but the
dominance of mutated subpopulations is delayed. For example, in the pathway
151




















































Figure 7.3: Comparison of tissue composition in fastest pathways when all mutations
are advantageous versus when some are lethal. (A) The tissue composition of
the fastest pathway, GDR, when all mutations are advantageous. The majority of tissue
is eventually comprised of cells with all three mutations. (B) The tissue composition of
the fastest pathway, DGR, when some mutations are lethal. Its tissue composition is
strikingly di!erent in that the majority of cells eventually have only one mutation and
cancer cells are a small percentage of the tissue.
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GDR in which G is lethal without D, cancer cells still eventually dominate the
tissue, though it is ten years later than when all mutations are advantageous. The
prevalence of cancer cells in the tissue implies that this pathway simulates a disease
that progresses quickly, even though it takes longer to initiate than the DGR pathway.
In contrast, the DGR pathway produces a tumor that primarily consists of cells with
one mutation. The D mutation is the only mutation that can directly increase the
steady state of stem cells, while both the G and R mutations a!ect how quickly cells
move from one mutated population to the next. As a result, when D is acquired
first, stem cells with one mutation outnumber normal cells, and this advantage for
expansion allows the clone with the D mutation to dominate the tissue.
Once again, model predictions are consistent with the results presented in Chap-
ter IV. Specifically, in the event that mutations are lethal without a previously
acquired ability to evade apoptosis, the fastest pathway begins with the D muta-
tion. Similar with the simulations in Section 7.2.1, regulatory mechanisms remain
intact, so cell populations do not grow exponentially. The two cases explored thus
far demonstrate that unrestricted growth is not possible in tissues that maintain
some level of regulation. Hypercellularity can occur, but some level of equilibrium is
achieved, even if it is abnormal. The next section will consider the e!ects on tumor
dynamics when regulatory mechanisms are removed in cancerous cells.
7.2.3 Cancer Cells Lose Regulatory Mechanisms
In the two cases presented thus far, mutations have a!ected death, genetic in-
stability, and proliferation of stem cells, but the regulatory mechanisms governing
stem-cell division pattern have remained intact. As recorded in Chapter IV, without
feedback mechanisms in place that attempt to regain tissue homeostasis, the cancer
population grows exponentially over time. In stark contrast, the results from Sec-
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tions 7.2.1 and 7.2.2 demonstrate that if the stem-cell population does not completely
lose regulatory mechanisms, then even the cancer cell populations can be contained.
In addition, recall that in Chapter IV simulations, non-mutated cells maintained
homeostasis while mutated populations grew exponentially. Cancer dominance was a
result of an increased number of mutated cells that vastly outnumbered non-mutated
cells, not the loss of healthy cells. Conversely, in regulated tissue, non-mutated cells
diminish because mutated cells have a competitive advantage and displace healthy
cells.
Because cancer cells can become independent in providing their own growth sig-
nals, it is not unreasonable to suggest that cancer cells could lose control from reg-
ulatory mechanisms [50]. To investigate this possibility, assume that the D, G, and
R mutations are defined as in Section 7.2.2, so that G and R are not advantageous
without D. In addition, assume that cells that have acquired both the D and R mu-
tations become independent of niche signaling and lose feedback interactions that
dictate the mode of stem-cell division. In other words, the probabilities of stem-
cell division become constant for cells that have acquired both D and R mutations,
equating to some self-reliance in growth signals and evasion of apoptosis.
To determine the constant probabilities of symmetric self-renewal, asymmetric
self-renewal, and symmetric commitment di!erentiation, the functional forms of "S,
"A, and "D are evaluated at the initial starting time, using mutated parameter values.
For example, at t = 0, the initial probability of symmetric self-renewal in cancer
cells to be "SC = 0.21, when using the mutated parameter value #SC . Likewise, the
probability of symmetric di!erentiation in cancer cells would initially be "DC = 0.16.
With the probability of apoptosis as #SC = 0.025 in D-mutated cells, the remainder
of the divisions are asymmetric, giving a probability of "AC = 0.60. Thus, there is a
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slight imbalance in symmetric divisions and death of stem cells, causing exponential
growth of cancer cells that is maintained over time since feedback mechanisms are
not in place to decrease symmetric self-renewal or increase symmetric commitment
di!erentiation. As the cancer population grows without bound, the total stem-cell
population can surpass the size of the niche because cancer cells do not have this
restraint. It is assumed that when the total stem-cell population exceeds the niche
size, the probability of symmetric self-renewal in regulated cells is zero, and the
probability of symmetric di!erentiation is determined by "D = (1"#S) $N$N+(N0+N1+N2)
to ensure that the probabilities of stem-cell division are contained between zero and
one. In other words, the influence of the stem-cell niche on division pattern is removed
in cells with both the D and R mutations.
When the D and R mutations enable unrestricted growth, the initial stages of
tumorigenesis do not greatly di!er from those determined in Section 7.2.2, but over
time, the di!erences between these cases are noteworthy. Figure 7.4 plots the total
number of cancer cells that result from the fastest pathways. Let Case A be the case
in which all mutations are advantageous presented in Section 7.2.1, Case B represents
lethal mutations as in Section 7.2.2, and Case C is for unregulated division in this
section. Recall the GDR pathway was fastest when all mutations were advantageous,
while the DGR pathway was fastest if lethal mutations were considered. When
cancer cells are independent of regulation, the DGR pathway is fastest, and the first
cancer stem cell is formed merely 0.3 years faster than when regulation is maintained.
However, unlike previous cases, the cancer population not only displaces non-mutated
cells, but continues to expand and eventually overtakes the number of cancer cells in
both other cases.
The loss of governing mechanisms is not mandatory for the emergence of cancer
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Figure 7.4: Comparison of fastest pathways for all cases in which stem-cell proliferation
is increased. GDR is the fastest pathway in Case A (blue). DGR is the fastest
pathway in Case B (green). DGR is also the fastest in Case C, but if cancer cells lose
feedback regulation, then cancer stem cells grow exponentially (red).
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stem cells, as confirmed by the results in Sections 7.2.1 and 7.2.2. Cancer dominates
tissue in which governing mechanisms continue to be maintained due to competitive
advantage over healthy cells. In such circumstances, disease can result from the
elimination of healthy cells that have been replaced with mutated cells that do not
properly function. However, when mutated cells are also independent of regulation,
not only do cancer cells displace non-mutated cells, but exponential growth causes
the cancer population to expands uncontrollably. These results imply that tumors
composed of cells that have lost tissue-governing mechanisms are more malignant
than tumors in which some semblance of regulation is maintained.
7.3 Unbalanced Pattern of Stem-Cell Division
It has been suggested that an unbalanced symmetric self-renewal divisions in
stem cells may contribute to certain forms of cancer [4, 12, 20, 23]. For instance, the
Wnt/!-catenin signaling pathway that is important in stem-cell self-renewal has also
been implicated in cancer [23]. Furthermore, mutations that increase the probability
of symmetric self-renewal may even cause more aggressive forms of disease than
those that merely quicken proliferation. For example, consider Chronic and Acute
Myelogeous Leukemia (CML and AML). Patients with CML express BCR-ABL,
which increases proliferation, whereas AML patients express NUP98-HOXA9, which
increases self-renewal in hematopoietic stem cells and causes a more malignant form
of leukemia [125].
Clearly, the mechanisms that govern stem-cell self-renewal are of great interest
when investigating the emergence of cancer stem cells. The mathematical model
in Chapter IV did not account for the dynamic regulation of stem-cell division as
dependent upon tissue status. Now that feedback mechanisms have been incorpo-
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rated, it is possible to examine the impact of mutations that a!ect stem-cell division
properties. Specifically, alteration of (S and KS, will be addressed since these two
parameters determine the probability of symmetric self-renewal. In this section,
the R mutation will increase one of these parameters, thereby increasing symmetric
self-renewal, while the rate of proliferation will remain unaltered. As before, the D
mutation decreases death and the G mutation increases genetic instability.
7.3.1 All Mutations are Advantageous
Again consider the case in which all mutations are advantageous. That is, cell
death does not increase in mutated cells, and mutated cells have competitive advan-
tage over non-mutated cells. The D mutation decreases the probability of stem-cell
death and the di!erentiated cell death rate by half. The G mutation increases the
probability at which mutations are acquired from 10!6 to 10!4. The R mutation dou-
bles the value of (S, which increases the initial probability of symmetric self-renewal
by approximately 10%.
In correlation with the conclusions in Section 7.2.1, the earlier genetic instability
is acquired, the faster cancer stem cells are formed. However, increasing symmetric
self-renewal through the doubling of the parameter (S significantly decreases the
time to the first cancer stem cell in all pathways. The fastest pathway is GRD, with
the first cancer stem cell formed in 8.4 years, nearly eleven years earlier than the
appearance of the first cancer stem cell in Section 7.2.1. In agreement with model
predictions in Chapter IV, genetic instability is less significant when symmetric self-
renewal mutations are considered than when the rate of proliferation increases, as
all pathways develop cancer stem cells quickly.
The growth dynamics of the stem- and di!erentiated-cell populations for the GRD
pathway are plotted in Figure 7.5A-B. As illustrated in Figure 7.5C, the probabilities
158






















0 Mut G GR GRD Total































































Figure 7.5: Growth dynamics for the fastest pathway when the R mutation increases
symmetric self-renewal. When all mutations are advantageous and the R mutation
increases symmetric self-renewal, the GRD pathway is fastest. (A) Stem cells versus
time. The first cancer stem cell is formed in 8.44 years. (B) Di!erentiated cells versus
time. (C) The probabilities for each type of stem cell division versus time. Probabilities
for non-mutated cells are plotted with solid lines, cancer cells with dashed lines.
159
of stem cell-division shift over time to favor symmetric divisions. Doubling (S in-
creases the initial probability of symmetric self-renewal from 0.21 to 0.32, which con-
sequently decreases the probability of asymmetric division. As cancer cells displace
non-mutated cells, the Hill functions in both symmetric self-renewal and symmetric
commitment di!erentiation tend to one. In both non-mutated and cancer stem cells,
the probability of symmetric self-renewal goes to 0.5, the probability of symmetric
commitment di!erentiation goes to 0.475, and the probability of asymmetric division
goes to zero.
An imbalance in favor of symmetric self-renewal causes rapid expansion in mutated
cells and quickly displaces healthy cells. In approximately 15 years, cancer dominates
the tissue. Although the probability of symmetric self-renewal is initially increased in
cells with the R mutation, regulatory mechanisms were not completely eliminated. As
a result, the initial rapid expansion is eventually controlled, preventing unrestricted
tissue growth. This implies that altered regulations may still be capable of mediating
homeostasis, even if it is abnormally controlled.
7.3.2 Lethal Mutations
As in Section 7.2.2, suppose that G and R mutations are not advantageous in cells
that have not previously acquired the D mutation. In stem cells that have either
G and/or R but not D, the probability of death is 0.95. Under these assumptions,
the DGR is the fastest pathway, but the first cancer stem cell forms in 11.7 years,
less than half of the time required by the same pathway when proliferation is altered
rather than symmetric self-renewal. In fact, a cancer stem cell is formed in all
pathways within 18 years. This is remarkable because the slowest pathway initiates





































Figure 7.6: Increased symmetric self-renewal speeds cancer onset more than increased
proliferation rate. The time to first cancer stem cell is faster for increased symmetric
self-renewal when all mutations are not advantageous even when compared to the case
where all mutations are advantageous with increased proliferation rate.
Figure 7.6 compares the time to first cancer stem cell for each pathway when all
mutations are advantageous and R increases the proliferation rate versus those in
which R increases symmetric self-renewal and G and R are lethal. Increasing sym-
metric self-renewal approximately 10% by doubling (S dramatically decreases the
time to first cancer stem cell in comparison with increasing the rate of stem-cell pro-
liferation. It is therefore suggested that increasing unbalanced symmetric divisions
causes malignancies to develop quicker than increasing the rate of division. Fur-
thermore, symmetric self-renewal minimizes the di!erences in cancer initiation when
comparing all pathways. As a result, unbalanced symmetric self-renewal dictates a
faster pace of cancer development, regardless of the sequential order of mutations.
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7.3.3 Cancer Cells Lose Regulatory Mechanisms
The last two cases demonstrate that cancer cells can emerge from increased sym-
metric self-renewal, even if regulatory mechanisms are not completely lost. Based on
the conclusions that unbalanced symmetric divisions speed the onset of cancer more
than increased stem-cell proliferation, one would predict that unregulated symmetric
divisions would be additionally problematic. Indeed, if stem cells with both the R and
D mutations become independent of division regulation and governing mechanisms
are lost, the cancer stem-cell population emerges quickly and grows exponentially.
To emphasize the significance increasing symmetric self-renewal on cancer stem-
cell dynamics, the cancer stem-cell population of the fastest pathways from each
of the six cases discussed thus far are plotted in Figure 7.7. Case 1 denotes all the
simulations in which the R mutation doubles the proliferation rate of stem cells, while
Case 2 denotes the simulations in which the R mutation doubles (S and increases
symmetric self-renewal. All mutations are advantageous in Cases 1A and 2A, G and
R mutations are not advantageous without D in Cases 1B and 2B, and stem-cell
division regulation is lost in cells with D and R mutations in Cases 1C and 2C.
The fastest pathways in which R increases symmetric self-renewal are significantly
faster than the pathways in which R increases the stem-cell proliferation rate. This
only emphasizes our previous results from Chapter IV that predicted aberrant sym-
metric self-renewal can be an important factor in determining cancer initiation. In
addition, when comparing Cases 1C and 2C in which the cancer stem-cell popula-
tion grows exponentially, the rate at which cancer grows is markedly increased in the
latter case. Therefore, deregulated unbalanced symmetric self-renewal quickly initi-
ates tumorigenesis and continues to promote cancer expansion through an elevated
growth rate if regulatory mechanisms are lost.
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Figure 7.7: Complete loss of regulation enables malignant growth. Case One simulations,
in which stem-cell proliferation is increased, are plotted with dashed lines. Case Two
simulations, in which symmetric self-renewal is increased, are plotted with solid lines.
The first cancer stem cell is formed via the GDR pathway when symmetric self-renewal
is increased and all mutations are advantageous. The most malignant growth is formed
through the DGR pathway, when stem cells have increased symmetric self-renewal and
have also lost feedback regulation.
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7.3.4 Increased Stem Cell Niche
It has been suggested that cancer stem cells are not as dependent on the stem-cell
niche as normal stem cells [74, 76]. As a result, cancer stem cells are not as restricted
by the physical carrying capacity of the niche. In Sections 7.2.3 and 7.3.3, all control
from the stem-cell niche was removed, and cancer stem cells grew exponentially. Now
a case is considered in which cancer stem cells are still restricted by the niche, but
the niche controlling mutated cells is larger since it is assumed mutated cells have
more freedom in where they reside. Due to the results of the sensitivity analysis
in Chapter VI, Section 6.1.2, it is predicted that increasing the niche will have a
major impact on tumor growth, since it was the only model parameter that signifi-
cantly altered long-term homeostasis of stem cells. In the following simulations, the
R mutation doubles the size of the stem-cell niche, KS, but does not change the
proliferation rate, k, or (S. As in Sections 7.2.2 and 7.3.2, the D mutation decreases
the death rate, the G mutation increases the mutation rate, and it is assumed that
the G and R mutations are not advantageous unless D has been acquired.
The results of Section 7.3.2 demonstrated that increasing (S increases symmetric
self-renewal, but it is now suggested that doubling KS causes a greater increase in
symmetric self-renewal divisions. In addition, increasing KS also decreases the prob-
ability of symmetric commitment di!erentiation. The combination of the increase in
symmetric self-renewal and decrease in symmetric commitment di!erentiation cre-
ates an even larger imbalance of symmetric divisions than doubling (S. Consequently,
it is not surprising that a mutation increasing the stem-cell niche causes the fastest
cancer onset. The DGR pathway is fastest, forming the first cancer stem cell in 6.65
years, though all pathways have a cancer stem cell in under ten years.
There is an additional interesting aspect of the growth dynamics caused by this
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mutation. The increased niche capacity for R-mutated stem cells give them a signif-
icant competitive advantage other cells. As mutated cells fill up the niche, feedback
regulation forces symmetric self-renewal of normal cells to go to zero since the system
does not want to add more stem cells. In addition, symmetric commitment di!eren-
tiation of normal cells goes to its maximum value of (1 " #S) in order to push cells
out of the niche. In so doing, the normal cell population di!erentiates more than it
self-renews, which in turn causes the forced rapid extinction of normal cells.
Figure 7.8 compares the probabilities of stem-cell division that occur in a system
following the DGR pathway for when symmetric self-renewal increases due to in-
creasing (S, as in Section 7.3.2 as opposed to when it increases because of the niche.
When symmetric self-renewal is increased by doubling (S, all cells continue to be reg-
ulated by the same size niche. As time progresses, non-cancer cells diminish, which
forces the chemical signaling term
$2S
$2S+(S0+S1+S2)
2 to one, and symmetric self-renewal
in both normal and cancer cells goes to 50%, as demonstrated in Figure 7.8A. The
other 50% of divisions result in symmetric commitment di!erentiation and apopto-
sis. In contrast, when the R mutation doubles the niche, the signaling term also goes
to one as time progresses, but because cancer cells fill up the niche and can in fact
surpass the niche, symmetric self-renewal in normal cells diminishes while symmetric
commitment di!erentiation goes to 95%. Cancer cells do not have the same division
probabilities as normal stem cells in the long run due to the increased niche capacity;
cancer stem cells symmetrically self-renew at 50% and symmetrically di!erentiate at
47.5%, as plotted in Figure 7.8B. In summary, a mutation that increases the cell’s
self-reliance apart from the niche, thereby increasing the potential niche capacity
in which the cell may reside, creates a considerable imbalance in stem-cell division
probabilities while also promoting extensive di!erentiation and loss of normal cells.
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Figure 7.8: Comparison of stem-cell division probabilities for mutations that increase
symmetric self-renewal. The fastest pathway of both cases is DGR, but the prob-
abilities of stem-cell division are markedly di!erent. Values for non-mutated cells are
plotted with solid lines, cancer cells are plotted with dashed lines. (A) The probabilities
of stem cell division when the R mutation doubles the switch parameter. Both mutated
and healthy cells approach balanced division patterns in the long run. (B) The proba-
bilities of stem cell division when the R mutation doubles the niche size. Normal cells
are forced to di!erentiate due to crowding from the niche.
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7.4 Conclusions
This chapter focused on investigating mutation acquisition in hierarchical tissue
in which stem-cell division is governed by regulatory mechanisms. The order of mu-
tations that causes the fastest formation of a cancer stem cell was determined under
various conditions. Several results from this chapter coincide with predictions from
the Maturity-Structured Model of Mutation Acquisition in Chapter IV. In particular,
when all mutations are advantageous, the sequential order in which genetic insta-
bility is acquired crucially determines the time to cancer onset. Although pathways
beginning with genetic instability are fastest for both types of R mutations, its e!ects
are significantly diminished when symmetric self-renewal is increased, demonstrating
that aberrant symmetric self-renewal may instigate aggressive malignancies. Over
all, mutations that disturb the balance between symmetric self-renewal and symmet-
ric commitment di!erentiation divisions cause initiate cancer faster than mutations
increasing stem-cell proliferation rate.
Although many of the model predictions in this chapter reflect those discussed in
Chapter IV, there are many aspects of tumor dynamics that can be investigated to a
greater extent with the incorporation of regulatory mechanisms. For instance, with
the inclusion of feedback mechanisms that govern stem-cell division, cancer cells do
not necessarily grow exponentially as seen in the results from Chapter IV. Rather,
if regulation remains in tact, even though it may be abnormal, a new equilibrium
is achieved. Furthermore, unlike the predictions of the MSMMA model in Chap-
ter IV, healthy cells diminish due to the displacement by mutated cells that have a
competitive advantage in the niche.
In the event that all regulation is lost in cancer cells, exponential growth of the
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cancer population occurs in addition to the depletion of normal cells. Therefore, the
model predicts that stem-cell governing mechanisms maintain system homeostasis
under healthy conditions and cancer is easily initiated when they are lost. Con-
sequently, feedback regulation controlling stem-cell self-renewal and di!erentiation
can prevent exponential growth due to perturbations, but complete loss initiates un-
restricted expansion in cancerous populations. In this chapter, the populations of
progenitors were not explicitly modeled, and thus did not determine the e!ects of
deregulation on intermediate populations. The following chapter will more closely
examine the e!ects of tissue deregulation on all tissue cells by incorporating the reg-
ulatory mechanisms outlined in this chapter with the maturity structure defined in
Chapter IV.
CHAPTER VIII
Mathematical Modeling of Homeostatic Deregulation
Instigating Chronic Myelogenous Leukemia
In previous chapters, the process of mutation acquisition was investigated in hier-
archical tissue through the use of two di!erent mathematical models. In Chapter IV,
a maturity-structured model of stem, progenitor, and di!erentiated cells was used
to monitor the initiation of cancer stem cells and the growth of progeny cancer cells,
but this model did not include regulatory mechanisms that preserve homeostasis.
In order to incorporate these tissue-governing mechanisms, an ordinary di!erential
equations model was developed in Chapters V and VI in which stem-cell division
probabilities were dependent on stem and di!erentiated cell populations. This ODE
model was used in Chapter VII to investigate the consequences of acquired mutations
that transform the mechanisms regulating the balance of stem-cell division pattern.
In order to obtain a comprehensive modeling framework for theoretical investigation
of cancer initiation in hierarchical tissue, a model is now presented that incorporates
both the maturity-structure from Chapter IV with the regulatory feedback mecha-
nisms examined in Chapters V, VI, and VII. The tissue of choice is the blood and this
new model is first developed to describe a healthy hematopoietic system. Then, the
model is used to investigate the growth dynamics of Chronic Myelogenous Leukemia
(CML). To our knowledge, this is the first presentation of a cell maturity-structured
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model that incorporates (1) the sequential acquisition of phenotype altering muta-
tions, (2) tissue hierarchy, and (3) internal feedback regulation of homeostasis.
8.1 Mathematical Modeling of Granulopoiesis
The hematopoietic system is composed of stem cells and a variety of progenitor
and di!erentiated cells in the lymph and blood systems. Hematopoietic stem cells
are precursors for cells of both the lymphoid and myeloid lineages. Lymphocytic
progenitors di!erentiate into B cells, T cells, and NK cells, all of which are neces-
sary components of the immune system. Myeloid progenitors di!erentiate to form
platelets, macrophages, etrythrocytes, and granulocytes, which include eosinophils,
basophils and neutrophils [99].
The majority of hematopoietic stem cells reside in the bone marrow, though some
have also been detected in the spleen and blood [9, 71, 91]. The bone marrow is
also the location for the expansion and maturation of progenitors and di!erentiating
cells. Once myeloid cells reach full maturity, they are released into the bloodstream.
Terminally di!erentiated cells in the blood do not complete additional divisions and
have a short half-life. Therefore, the bone marrow is the site of proliferation, ex-
pansion, and di!erentiation, while blood circulation transports fully mature cells to
meet tissue demands throughout the body.
In this chapter, a maturity-structured mathematical model is presented that fo-
cuses on granulopoiesis, that is, the process by which granulocytes are formed. Gran-
ulocytes are crucial for an innate immune response. The primary function of these
cells is to remove pathogens, and their continuous production is characteristic of a
healthy immune system [61]. Hematopoietic stem cells, precursor myeloblasts and
myelocytes, and fully-di!erentiated granulocytes, specifically neutrophils, are con-
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sidered. Unlike the models presented in previous chapters, cells reside in one of two
compartments, namely, the bone marrow or the blood. It is assumed that, under nor-
mal conditions, stem, progenitor, and di!erentiating cells remain in the bone marrow
while terminally di!erentiated cells mobilize into the blood. Although it is true that
stem cells can circulate in the blood, it is assumed that their number is negligible in
comparison with all the other cells. By distinguishing between cells that are in the
blood as opposed to the bone marrow, it is possible to determine the distribution of
cell maturity in each tissue, which will later enable investigation of immature blast
accumulation that is associated with the progression of CML.
8.1.1 Model Structure
The model uses the maturity-structure of Chapter IV while also incorporating the
stem-cell division regulatory mechanisms of Chapters V and VI. Stem cells, S, di-
vide at rate k, and with each division, stem cells either symmetrically self-renew with
probability "S, asymmetrically self-renew with probability "A, symmetrically di!er-
entiate with probability "D, or die with probability #S. Progenitor cells are formed
through asymmetric and di!erentiation divisions. Although it is known that a small
number of stem cells circulate the blood through the process of mobilization [71],
it is assumed that stem cells and immature progenitors reside in the bone marrow,
while fully mature cells are released into the blood, as depicted in Figure 8.1. Cells
of maturity level a at time t in the bone marrow and the blood are denoted w(a, t)
and n(a, t), respectively. The net growth rate of cells in the bone marrow, given by
!(a), the mobilization rate of cells from the bone marrow into the blood, given by
-(a), and the death rate of cells in the blood, given by µ(a), are dependent on cell
















= -(a)w " µ(a)n
with initial and boundary conditions
S(0) = S0(8.2)
w(a, 0) = f(a)
n(a, 0) = g(a)
$w
$t
(0, t) = (2"D + "A) kS
$n
$t
(0, t) = 0.










For ease of referral in subsequent discussion, the model presented in Equations 8.1, 8.2,
and 8.3 is called the Maturity-Structured Model Incorporating Regulatory Feedback
Mechanisms (MSMIRFM).
The functional forms for the probabilities of stem-cell division are as defined in
Chapters V, VI, and VII. Specifically,
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Figure 8.1: Cells are divided into bone marrow and blood compartments. Hematopoietic
stem cells and progenitor cells reside in the bone marrow while terminally di!erentiated
neutrophils are in the blood circulation.
The growth rate and death functions, !(a) and µ(a) are those defined in Chapter IV.
The release of di!erentiated cells into the blood must compensate for the death of
circulating terminally di!erentiated cells. The mobilization entry rate, -(a), is also
switch function, with a maximum rate that is derived from the estimated turnover





















The model terms and parameter values are presented in Table 8.1.
8.1.2 Numerical Simulations of Granulopoietic Homeostasis
Model equations were discretized with the upwind method, and numerical simu-
lations were conducted using MATLAB. The initial condition of 1,000 stem cells and
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Term Biological Meaning Value Used
S hematopoietic stem cells 11,000-22,000 (cells) [1]
W precursors in bone marrow 5" 15% 1011 (cells) [1, 52, 100, 109]
N neutrophils in blood 2" 6% 1010 (cells) [9, 100, 101]
!S(S) probability of SSR 0.20 (from Chapter V) [125]
!D(S, N) probability of SCD 0.15 (from Chapter V) [125]
!A(S, N) probability of ASR 0.60 (from Chapter V) [125]
k stem-cell proliferation rate 0.247 (weeks!1) [21]
%S switch parameter for SSR 19,600 (cells)
KS stem-cell niche capacity 30,000 (cells)
%N switch parameter for SCD 1% 1010 (cells)
"S probability of stem-cell death 0.05 [83]
((a) progenitor net growth rate
b maximum growth rate 9.7 (per week) [100, 109]
#! steepness of ( switch 2
$! maturity at ( switch 2.05 (weeks)
)(a) entry rate into blood
g maximum blood entry rate 4.2 (per week)
#% steepness of ) switch 10
$% maturity at ) switch 4.05 (weeks)
µ(a) di!erentiated-cell death rate
d neutrophil death rate 16.8 (per week) [9, 13, 39]
#µ steepness of µ switch 10
$µ maturity at µ switch 4.10 (weeks) [39]
Table 8.1: Parameter values for the Maturity-Strucutred Model Incorporating Regulatory Feedback
Mechanisms.
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zero progenitor and di!erentiated cells was used to generate the hierarchical tissue
and determine the homeostasis steady states and maturity distributions of the sys-
tem. It should be noted that the model does not segregate cycling and quiescent stem
cells, but instead monitors the total stem-cell population. Following the results ac-
quired from numerical simulations of hematopoietic tissue generation in Chapter V,
it is assumed that approximately 15% of all stem cells are cycling during the entire
generation period. Although tissue generation is more accurately modeled by sepa-
rating cycling and quiescent stem cell populations so the percentage of cycling stem
cells can vary depending on tissue status, reconstitution is not the primary focus
of these simulations. Rather, the purpose is to establish the steady state maturity
distribution of cells in the bone marrow and blood compartments that will be used as
the initial conditions in the mutation acquisition model, because these distributions
cannot be solved analytically.
Figure 8.2 plots the growth of each of the cell populations during generation. The
stem-cell population is plotted in Figure 8.2A. The system begins with 1,000 stem
cells, growing to a steady state of approximately 18,360 stem cells, which is within
the predicted range of 11,000-22,000 hematopoietic stem cells in adult humans [1].
The total number of di!erentiating cells in each the bone marrow and the blood is
plotted in Figure 8.2B. Initially there are no cells in both the bone marrow and blood.
As the system is generated, it reaches a steady state of approximately 7.28 % 1011
cells in the bone marrow and 2.97% 1010 cells in the blood. Neutrophils have a short
half-life and high rate of turnover, but they need a few days to fully mature in the
bone marrow before being released into the the blood. Therefore, the total number
of cells in the bone marrow is far greater than the number of cells in the blood.
Figure 8.2C shows the maturity distributions of cells in the bone marrow as well as
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the blood. The majority of cells in the bone marrow are near full maturity, ready
for release into the blood, while the majority of cells in the blood are fully mature.
The functions determining cell division and death rates are plotted in Figure 8.3.
The probabilities for each type of stem-cell division, shown in Figure 8.3A, change
over time in reaction to the generation of additional stem and di!erentiated cells.
Initially, symmetric self-renewal dominates, but as the system approaches home-
ostasis, asymmetric divisions comprise 60% of stem-cell divisions, while symmetric
self-renewal and di!erentiation account for 20% and 15% of stem-cell divisions, re-
spectively. The maturity-dependent growth, release, and death rates are plotted
versus maturity level a in Figure 8.3B. Myeloblasts have a cycling time of 11-24
hours, thus the maximum rate of proliferation is determined from this doubling
time [100, 109]. Cell cycle times increase as cells mature, thus the proliferation rate
approaches zero as cells mature. Upon completing the final division, cells require
3-4 days to achieve full maturity, after which they are released into the blood. In
the bone marrow, the number of non-proliferating cells of the granulocyte lineage
ranges from 2.7 " 6.6 % 1011 cells, and it is estimated that 1.2 % 1011 granulocytes
are released into the blood every day [39, 109]. Consequently, the estimated release
from the bone marrow occurs at a maximum rate of 0.2-0.6 per day, or 1.4-4.2 per
week. The maximum release rate is approached after bone marrow cells reach full
maturity, which is assumed to occur when - > !; or when baseline parameters are
used, as in this simulation, approximately 3.8 weeks. Cells have a short half-life in
the blood, thus accounting for the high death rate of di!erentiated cells quickly after
release.
The proliferation rate of di!erentiating cells in the marrow, given by the maturity-
dependent function !(a), is helpful in determining the composition of cells in the bone
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Figure 8.2: Hierarchical tissue reaching homeostasis. (A) Stem cells versus time. (B) Total
di!erentiating cells (black) as found in the bone marrow (magenta) and blood (red).
(C) Maturity distribution of cells in the bone marrow (magenta) and the blood (red).
177

























































Figure 8.3: Probabilities of stem-cell division, and rates for proliferation, mobilization,
and apoptosis in di!erentiating cells. (A) Probabilities of stem-sell division versus
time. As the system is generated, symmetric self-renewal, symmetric di!erentiation, and
asymmetric self-renewal approach 20%, 15%, and 60%, respectively. (B) The prolifera-
tion, blood-entry, and death rates of progenitor and di!erentiated cells are dependent
on cell maturity.
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marrow. The estimated doubling time of precursor cells in the bone marrow is 11-24
hours for myeloblasts, 20-42 hours for promyelocytes, and 39-57 for myelocytes [52,
100]. These cycling times correspond with weekly proliferation rates of 4.85-10.6
in myeloblasts, 2.77-5.82 in promyelocytes, and 2.04-2.99 in myelocytes. Therefore,
bone marrow cells of maturity a can be classified based on their corresponding value
of !(a). When the baseline parameters in Table 8.1 are used, there are approximately
1.39% 1010 myeloblasts, 3.03% 1010 myelocytes, and 1.39% 1011 promyelocytes, and
5.44 % 1011 maturing neutrophils, of which 1.83 % 1011 are fully mature. According
to these cell counts, the composition of granulocytic precursors in the bone marrow
consists of approximately 2% myeloblasts, 4% promyelocytes, 19% myelocytes, and
75% maturing cells; approximately 25% of bone marrow cells are fully mature. These
results are comparable with recorded scientific data of bone marrow composed of
2.5-3% myeloblasts, 3-5% promyelocytes, 22-26% myelocytes, and 66-72% maturing
cells [52, 100, 109].
8.1.3 Conclusions
In this section, a mathematical model was presented that incorporated both
maturity-structure and regulatory feedback mechanisms governing stem-cell division
pattern in order to simulate healthy homeostasis of granulocytes and their precur-
sors. To our knowledge, this is the first mathematical model of hierarchical tissue
that incorporates both maturity structure and feedback mechanisms in its framework.
Numerical simulations of tissue generation were conducted, and tissue homeostasis
was investigated to determine the number and maturity-distribution of granulocytic
cells in equilibrium in both blood and bone marrow. Using experimentally measured
parameter values, model predictions were in coherence with recorded cell counts and
tissue composition based on cell maturity.
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The MSMIRFM model presented in equations 8.1 di!ers from the MSMAHR
model presented in Equations 4.1 due to the inclusion of regulatory mechanisms that
govern the balance of stem-cell divisions. The main distinction between the model
predictions is in the dynamics regarding stem-cell division. In the MSMAHR model,
the probabilities of symmetric self-renewal, asymmetric self-renewal, and symmetric
commitment di!erentiation remain constant and do not change, regardless of tissue
dynamics. Stem cells remain in equilibrium as long as the division pattern is bal-
anced. Consequently, the MSMAHR model cannot capture both the expansion that
initially occurs during tissue generation as well as the maintenance of homeostasis. In
contrast, the MSMIRFM model allows the probabilities of stem-cell division pattern
to adjust according to the status of the tissue.
The MSMIRFM model employs the same regulatory feedback mechanisms as the
MHTR model in equations 6.4, but unlike the MHTR model, captures the dynam-
ics of intermediate progenitor populations. The MHTR model accurately simulates
equilibrium of stem cells and terminally-di!erentiated cells, but does not explicitly
model progenitors. Therefore, it is impossible to determine the maturity-distribution
of tissue cells with the MHTR model. The MSMIRFM model, on the other hand,
includes all tissue cells on the maturity spectrum, from the most näıve stem cells to
progenitors to terminally di!erentiated cells.
The mathematical model presented in this section combines the novel features of
the models presented in Chapters IV, V, and VI. By doing so, this inclusive model
captures all aspects of hierarchically structured tissue dynamics. Specifically, this
model integrates tissue hierarchy, regulatory mechanisms governing homeostasis, and
maturity-dependent cell proliferation, mobilization, and death into one comprehen-
sive framework. This model will be utilized in the next section in order to investigate
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the sequential acquisition of deregulating mutations causing the accumulation of im-
mature blast cells that contribute to disease progression in Chronic Myelogenous
Leukemia.
8.2 Mathematical Modeling of Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia (CML) is merely one of the blood and bone mar-
row disorders that deregulates healthy hematopoiesis. Specifically, CML is a myelo-
proliferative disorder in which cells of the myeloid lineage expand [23, 59]. The
National Cancer Institute estimates that 4,830 new cases of CML will be diagnosed
and 450 people will die from the disease in 2008. The rate of incidence in males is
nearly double that of females, with 1.9 per 100,000 men and 1.1 per 100,000 women
having the disease [93]. Although CML a!ects adults and children, the median age of
patients at diagnosis ranges between 45-66 years [45, 93]. Treatment has been more
successful in the last few years with the introduction of Gleevec, the drug specifically
tailored to attack the mutated cells causing this disease, but the overall survival rate
is still poor and approximately 50% of CML patients will die within five years of
diagnosis [93].
One of the obstacles of treating CML is that current chemotherapy regimens
successfully target di!erentiated cells but are unsuccessful in killing cancer stem
cells [22]. By not eradicating cancer stem cells, the source of cancer is able to survive
and continues to proliferate and expand, thereby regenerating disease even after times
of remission. In CML, It is unclear if these cancer stem cells are mutated stem cells
that become deregulated or if progenitor cells have acquired mutations that allow
them to self-renew, though mounting evidence suggests the latter [22, 60]. Either
way, the resulting malignant cells have similar qualities of survival and self-renewal
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as stem cells and are thus termed cancer stem cells.
As demonstrated in Chapter VII, mathematical modeling can be a useful tool
in investigating mutation acquisition contributing to the emergence of cancer stem
cells. Additionally, it is possible to deduce how deregulated cells alter the dynamics
of the whole tissue. In this section, the maturity-structured model presented in Sec-
tion 8.1.1 is extended to include mutation acquisition that instigates CML. First, the
types of mutations found in CML cells are classified and the pathology of tri-phasic
disease progression are reviewed. Next, the mathematical framework is presented.
Finally, the results of numerical simulations are discussed.
8.2.1 Biology of Mutated Cells and Pathology of CML
The Philadelphia (Ph) chromosome, formed from the translocation t(9; 22)(q34;
q11), is detected in 95% of CML patients, which has subsequently made it the trade-
mark mutation associated with the disease [47, 59, 103, 120]. It is unknown how
the Ph chromosome is initially formed, but it is believed that its formation leads
to the chronic phase of CML [47]. The Ph chromosome produces the oncoprotein
BCR-ABL, which is one of few mutations that incurs several e!ects on a cell. BCR-
ABL has been linked to deregulated proliferation, decreased apoptosis, decreased
adherence, and increased genetic instability [27, 47].
The Ph chromosome has been found in cells of the granulocytic, erythroid, lym-
phoid, monocytic, and megakaryocytic lineages, suggesting that the initial mutation
occurs at the stem cell level but manifests itself in progeny downstream, particu-
larly in cells of the granulocytic lineage [59, 103]. Although the Ph chromosome
is used to diagnose CML, it has also been detected at low levels in the blood of
healthy people, suggesting that additional mutations are needed to actually cause
disease [17, 22, 47, 59]. Furthermore, it is believed that Ph-positive progenitors ac-
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quire mutations that promote self-renewal, such as !-catenin, which leads to a more
aggressive form of leukemia and initiates the transition from the chronic to blast
phase [48, 60].
Patients with CML are classified into three phases that are determined by the per-
centage of blasts in the bone marrow or blood. Under normal conditions, myeloblasts
compose approximately 2.5-3% of the bone marrow, and are generally absent from
peripheral circulation [52, 100, 109]. According to the World Health Organization
classification, the chronic phase is when blasts compose less than 10% of cells in
the bone marrow or periipheral blood, the accelerated phase is when blasts compose
10-19%, and the most aggressive phase, the blast phase, is determined when blasts
compose 20% or more [120]. In the chronic phase, mutated cells still di!erentiate,
preventing the accumulation of mutated progenitors. As the disease progresses, it is
believed that additional mutations enable progenitors to self-renew and prevent dif-
ferentiation [48, 60]. The progression through chronic, accelerated, and blast phases
is caused by deregulated proliferation, increased survival, and inhibited di!erentia-
tion of leukemic blasts that expand and displace normal hematopoiesis, eventually
resulting in fatality.
8.2.2 A Mathematical Model of Blast Accumulation in CML Progression
Because the progression of CML is characterized by the accumulation of undif-
ferentiated blast cells, a maturity-structured model of hematopoietic cells is needed
to fully capture the dynamics of this form of cancer. In order to simulate the acqui-
sition of mutations in hematopoietic cells that lead to CML, the MSMIRFM model
presented in Equations 8.1 is now extended such that stem, progenitor, and di!eren-
tiated cells may have zero, one, two, or three mutations. In contrast to the mutation
acquisition models presented in Chapters IV and VII, this model is specifically tai-
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lored to the mutations observed in CML. In particular, BCR-ABL and a mutation
promoting self-renewal in progenitors are considered.
There is little evidence that other mutations occur prior to the formation of the Ph
chromosome, therefore, it is assumed that this is the first mutation [47]. In particular,
BCR-ABL has been associated with deregulated proliferation, increased survival,
and increased genetic instability. Since the Ph chromosome alone is insu"cient to
cause disease, it is assumed that these advantages are not fully manifested until the
second mutation is acquired [17, 22, 47, 112]. However, because BCR-ABL increases
survival, it is assumed that acquiring this mutation is not a lethal mutation, and
therefore, the death rate of cells with only one mutation does not increase. When
the second mutation is acquired, cells are phenotypically altered by a change in
proliferation, decrease in apoptosis, and increase in genetic instability. Thus, cells
with either one or two mutations are BCR-ABL-positive, but it is the cells with two
mutations that initiate the chronic phase of CML. Lastly, it is believed that blast
crisis develops as progenitor cells acquire the ability to self-renew [48, 60]. Self-
renewal in essence freezes the maturation of cells. Consequently, this model assumes
that cells with three mutations do not continue maturation, and thus are removed
from the maturity-structured partial di!erential equation and instead modeled with
an ordinary di!erential equation, similar to the stem cell populations. A schematic
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Figure 8.4: Schematic diagram of the mathematical model for CML. Progenitor and stem
cells first acquire the mutation for BCR-ABL, though it is insu"cient alone to change
cellular characteristics. After a second mutation is acquired, cells have proliferative
advantage, increased survival, and increased genetic instability. Di!erentiation remains
in tact in clones with one or two mutations. The third mutation may only be acquired
in stem cells and early progenitors. It causes unregulated self-renewal and blocks dif-




= ((1" 2m0)"S0 "m0"A0 " "D0 " #S0) k0S0(8.5)
dS1
dt
= ((1" 2m1)"S1 "m0"A1 " "D1 " #S1) k1S1
+ (2"S0 + "A0) m0S0
dS2
dt
= ((1" 2m2)"S2 "m0"A2 " "D2 " #S2) k2S2
+ (2"S1 + "A1) m1S1
dS3
dt
= ("S3 " "D3 " #S3) k3S3 + (2"S2 + "A2) m2S2
where
"Si = (1" #Si)
$
(2Si







"Di = (1" #Si)
$
(Ni






"Ai = 1" "Si " "Di " #Si(8.8)
185
























= (2"D3 + "A3) k3S3 + (2"D2 + "A2) m2k2S2







































= -2(a)w2 " µ2(a)n2
dN3
dt



























(0, t) = (2(1" 2m0)"D0 + (1"m0)"A0) k0S0(8.17)
$w1
$t
(0, t) = (2(1" 2m1)"D1 + (1"m1)"A1) k1S1
+ (2"D0 + "A0) m0k0S0
$w2
$t
(0, t) = (2(1" 2m2)"D2 + (1"m2)"A2) k2S2
+ (2"D1 + "A1) m1k1S1
$n0,1,2
$t
(0, t) = 0
For ease of discussion, this model is now referred to as the Mathematical Model of
Blast Accumulation (MMBA).
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8.2.3 Numerical Simulations for the Onset and Progression of CML
Although it is known that the BCR-ABL fusion gene is the major contributor
in the onset of CML, there are many unanswered questions regarding disease pro-
gression. For instance, it is unknown if both stem cells and progenitor cells acquire
mutations that upregulate self-renewal and cause the accumulation of blast cells [22].
There is also discrepancy in the literature about how BCR-ABL a!ects cellular ki-
netics. Some data suggests that BCR-ABL increases the proliferation rate in both
stem and progenitor cells [83, 125]. In direct contrast, other data implies that BCR-
ABL does not increase the rate of dividing cells, but rather increases the number
of divisions before reaching full maturity [19, 27, 48, 122]. It is also possible that
stem cells can acquire this mutation, but that it does not become advantageous until
inherited in progenitors [22, 103]. In this section, model predictions are presented in
order to address these issues.
To execute numerical simulations, model equations were discretized with the up-
wind method and solved in MATLAB. Two primary sets of parameters were used.
The first, recorded in the Mutated Value (1) column in Table 8.2, assumes a doubled
proliferation rate, halved apoptosis rate, and increased genetic instability in stem and
di!erentiating cells with two mutations. The second, recorded in Table 8.2 under the
column Mutated Value (2), also assumes an increase in genetic instability, but the
kinetics for apoptosis and proliferation are quite di!erent from the first case. In the
second case, the anti-apoptotic quality in cells with two mutations is manifested as a
decreased probability of apoptosis in stem cells and an increased length of survival in
di!erentiating cells, which enables additional progenitor divisions but does not alter
the rate of proliferation.
Cells with all three mutations are blast cells and do not mature. It is assumed
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Term Baseline Value Mutated Value (1) Mutated Value (2)
k (weeks!1) 0.247 0.494 0.247
%S (cells) 19,600 19,600 19,600
KS (cells) 30,000 30,000 30,000
%N (cells) 1% 1010 1% 1010 1% 1010
"S 0.05 0.025 0.025
b (weeks!1) 9.7 19.4 9.7
#! 2 2 2
$! (weeks) 1.7 0.85 2.4
g (weeks!1) 4.2 4.2 4.2
#% 10 10 10
$% (weeks) 3.7 2.85 4.4
d (weeks!1) 16.8 8.4 16.8
#µ 10 10 10
$µ (weeks) 3.75 2.90 4.45
(3 (weeks!1) 4.215 4.215
)3 (weeks!1) 4.2 4.2





Table 8.2: Parameter values for Mathematical Model of Blast Accumulation simulations.
that these cells are leukemic stem cells because they have acquired the ability to
self-renew. The rates of proliferation, mobilization, and cell death are constant in
blast cells because their cell machinery does not respond to regulatory mechanisms.
Because leukemic stem cells do not mature, the model permits blast cells to exit
the bone marrow at a constant rate. The proliferation rate determines how quickly
the blast population expands. In order to estimate the net growth rate of blasts,
the estimated time of disease progression is considered. Specifically, three to seven
years are required for the transition from chronic phase to blast phase, during which
the number of blasts dramatically increases. It is not unreasonable to suggest blasts
increase by a factor of 20 during this time, which translates into a weekly net growth
rate of 0.008 to 0.02 per week. Consequently, the proliferation of blasts is assumed
to satisfy the condition 0.008 < !3 " -3 < 0.02. Finally, blasts die at a rate that is
half the apoptotic rate of non-mutated di!erentiated cells. All model parameters are
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summarized in Table 8.2.
The symptoms of patients with CML is rather vague, and diagnosis sometimes
is made from the results of routine blood tests [45]. In order to identify the time
at which a person might present with CML, the earliest diagnosis time is when
the number of neutrophils in the blood surpasses the maximum normal count of
6% 1010 cells. In all likelihood, this diagnosis estimation is an underestimate, as the
patient can be diagnosed in the chronic phase as long as the bone marrow or blood
compartments have less than 10% blasts. Accelerated phase begins when either the
bone marrow or blood contains 10% blasts, and blast phase is similarly determined
for the composition of 20% blasts. These times are recorded for each of the conducted
simulations in order to directly compare and contrast model predictions.
Tissue Dynamics Resulting from Increased Proliferation Rate
According to the observations in a recent experiment that recorded the division
of immature hematopoietic precursors, BCR-ABL does not influence the division
pattern, but increases the rate at which cells divide [125]. Therefore, the first case
of mutation acquisition contributing to CML is based on the following assumptions:
(1) the first mutation generates BCR-ABL but does not increase cell fitness, (2) the
second mutation doubles the proliferation rates in both stem and progenitor pop-
ulations, decreases the rate of apoptosis by half in all cells, and increases genetic
instability, and (3) the third mutation promotes self-renewal and blocks di!erentia-
tion. Because the proliferation rate is doubled in progenitors, it doubles the number
of divisions that are completed in a certain time; therefore, the maturity at which
the !(a) function switches o! is decreased by half in order to preserve the number
of divisions that occur in the progenitor population. In addition, it should be noted
that this simulation portrays a worst case scenario in the fact that all di!erentiating
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cells may acquire the third mutation that upregulates self-renewal. It is likely that
only early progenitors could acquire self-renewal properties, and this case will be
discussed later. The parameters used in for this simulation are listed in the Mutated
Value (1) column of Table 8.2.
Under these assumptions, the model predicts disease onset and time needed for
progression from chronic to blast phase within the recorded median ranges. Blood
cellularity is doubled in 40.5 years, but at this time bone marrow cells have not yet
doubled. At 51.4 years, the bone marrow and blood each contain approximately 5%
leukemic blasts. The number of cells in the bone marrow is approximately 7.5 times
the maximum number of cells in healthy marrow, while cells in the blood are increased
by 15-fold, which correlates with reported estimates of 5-10-fold increase in total cell
mass during the chronic phase of CML [27]. The accelerated phase begins at 52.1
years and is shortly followed by the blast phase at 52.9 years. Assuming the diagnosis
of chronic phase would occur some time between 40.5-51.4 years, this progression time
is in agreement with the estimated 3-7 years required for the transition from chronic
to blast phase. Figure 8.5 plots healthy and mutated cell populations over time as
well as the composition of cells in the bone marrow and the blood.
It is generally believed that chronic phase CML is initiated by mutations at the
stem-cell level, but it is unknown if the mutation increasing self-renewal in progen-
itors, which is the third mutation in model simulations, must also be acquired in
stem cells [22]. In order to address this issue, consider the case in which stem cells
do not acquire the third mutation so that m2 = 0. Surprisingly, the model pre-
dicts that times for disease onset and progression do not greatly alter from those
in which stem cells do accumulate all three mutations, though there is a di!erence
in tissue dynamics. If stem cells acquire all three mutations, then the final muta-
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Figure 8.5: Tissue dynamics resulting from increased stem-cell and progenitor prolifer-
ating rates. (A) Stem cells with 0, 1, 2, and 3 mutations versus time. (B) Di!erenti-
ating cells with 0, 1, 2, and 3 mutations versus time. (C)-(D) The evolving composition











































































Figure 8.6: Healthy granulopoiesis is displaced less quickly when stem cells do not mu-
tate to form cancer stem cells. (A) Non-mutated stem cells are displaced less
quickly when stem cells do not acquire the third mutation (solid line SC2) than when
stem cells can mutate into cancer stem cells (dotted line SC1). (B) The corresponding
non-mutated populations of di!erentiating cells in the bone marrow and blood depend-
ing on whether or not stem cells acquire the third mutation.
tion enables ungoverned self-renewal, which promotes expansion of cancer stem cells.
These leukemic stem cells take over the niche, forcing non-mutated stem cells into
di!erentiation. Consequently, the tissue is rapidly depleted of non-mutated stem and
di!erentiating cells. In contrast, when stem cells do not acquire the third mutation,
stem cells with two mutations dominate non-mutated stem cells, but the total num-
ber of stem cells does not exceed niche control. Therefore the decline of non-mutated
stem cells and thus healthy granulopoiesis is slower when stem cells do not acquire
the third mutation, as demonstrated in Figure 8.6.
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Model simulations predicting slower displacement of non-mutated cells agree more
with scientific observations. It has been noted that Ph-positive stem cells displace
normal hematopoiesis but do not completely destroy normal stem cells [47]. In addi-
tion, it is thought that the total number of hematopoietic stem cells does not signifi-
cantly increase as disease progresses [22, 60]. Both observations are more accurately
captured by the model when stem cells do not acquire the third mutation. Therefore,
model predictions concur with recent findings that suggest the mutation deregulating
self-renewal in progenitors is acquired in progenitors and not stem cells [22, 60].
It is unlikely that fully mature cells can reacquire the properties necessary for
limitless self-renewal capability because they lose much of their proliferative potential
as they divide. As a result, it is reasonable to assume that di!erentiating cells may
only acquire the third mutation in earlier progenitor phases. Suppose that stem
cells do not acquire the third mutation, and progenitors may only acquire the third
mutation if their maturity level is less than 0.5 weeks, which corresponds to having
completed approximately nine divisions. As predicted, this slows the expansion of the
leukemic blast population, which subsequently delays disease progression. It does not
a!ect the amount of hypercellularity due to expansion of cells with two mutations, as
the blood surpasses the maximum healthy level in 40.5 years. However, accelerated
phase begins at 67.7 years, and blast phase at 68.8 years, approximately 16 years
later than when all di!erentiating cells acquire self-renewal capability. Depending on
when the disease is first diagnosed, the length of progression under these assumptions
may be longer than reported values.
One final scenario is yet considered under the assumption that BCR-ABL in-
creases the rate of proliferation. There are contrasting views as to whether BCR-
ABL acts the same way in both stem and progenitor cells. Suppose that BCR-ABL
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does not alter stem-cell proliferation, but only increases the rate at which progeni-
tors divide. Specifically, stem cells with two mutations die with smaller probability
and have increased genetic instability but have a normal rate of proliferation. In
contrast, di!erentiating cells with two mutations proliferate twice as fast as their
normal counterparts. Furthermore, assume that the third mutation is only acquired
in committed progenitors of maturity less than 0.5 weeks. While the model pre-
dicts that malignancy results from this pathway of mutation acquisition, the tissue
dynamics do not reflect those of CML. In particular, there is no hypercellularity
of the Ph-positive clone, which is shown in Figure 8.7. Under these assumptions,
mutated stem cells gain very little advantage over their non-mutated counterparts.
As a result, very few mutated stem cells exist in the tissue and an increased rate of
progenitor division alone does not increase the number of di!erentiating cells. Cells
with two mutations, namely, the cells that should initiate the chronic phase of CML,
do not even comprise 1% of all cells and are surpassed by blast cells before they
are probably detected. Based on model simulations of this scenario, results suggest
that if BCR-ABL imparts proliferative advantage by way of increasing the prolifer-
ation rate, then the proliferation rate of stem cells must also be increased to reflect
observations of CML.
Each of the model simulations presented thus far has used the assumption that
BCR-ABL increases the rate of proliferation. According to model predictions, this
type of proliferative advantage does give rise to mutated populations of stem and
di!erentiating cells that are similar to those observed in CML, but under certain
conditions. In particular, it is hypothesized that if BCR-ABL increases the rate of
proliferation, then it must do so in both stem and progenitor populations in order
to generate dynamics that correlate with CML. Although malignancy can occur
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Figure 8.7: Increased proliferation in progenitors, but not stem cells, does not generate
tissue dynamics representative of CML. (A) Stem cell populations with 0, 1, and
2 mutations are plotted versus time. Without proliferative advantage, mutated stem
cells do not expand significantly. (B) An increased rate of proliferation followed by
acquisition of self-renewal capability does cause malignancy, but the tissue dynamics
do not reflect those of CML. Hypercellularity is not experienced until the tissue is
dominated by blast cells.
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from self-renewing progenitors, the disease does not resemble CML, and may be
indicative of another disorder. Furthermore, the model suggests that if leukemic
stem cells grow exponentially due to the loss of regulation, normal hematopoiesis is
displaced quicker than if governing mechanisms remain in tact to control the size of
the stem-cell population.
Simulations in which early committed progenitors are the only cells able to acquire
the mutation that upregulates self-renewal exhibit particularly close coherence with
the median times reported for CML diagnosis. The onset of the accelerated phase
occurs more quickly if all di!erentiating cells have equal opportunity to acquire the
ability to self-renew. Consequently, one of the factors that may influence the tempo
of disease progression may lie in the capacity of downstream progenitors to acquire
self-renewal capability.
This section has explored various scenarios of mutation acquisition, under the
assumption that BCR-ABL increases the rate of proliferation, to determine if any
of these cases generate disease that exemplifies CML. There is some disagreement
on how BCR-ABL gives mutated cells a proliferative advantage, however. Next, the
model will be used to investigate the other view, which suggests that BCR-ABL does
not increase proliferation rate, but rather increases survival, thereby increasing the
number of progenitor divisions.
Tissue Dynamics Resulting from Extra Progenitor Divisions
Some researchers believe that the proliferative advantage gained with BCR-ABL
is not due to an increased rate of division, but rather through increased survival that
permits extra divisions to occur in progenitor stages [19, 27, 48, 122]. In order to
consider this possibility, the second scenario of the initiation and progression of CML
is based on the following assumptions: (1) cells with the first mutation are BCR-
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ABL-positive but do not exhibit increased fitness over non-mutated cells, (2) cells
with two mutations have increased survival that decreases apoptosis in stem cells and
permits extra rounds of division in progenitors, and (3) cells with three mutations can
self-renew and do not mature. Specifically, progenitors survive for an additional 0.7
weeks, which enables them to complete six to seven extra divisions before reaching full
maturity. Although the second mutation is acquired in stem cells, the proliferative
advantage is not realized in stem cells but downstream progeny. Furthermore, it is
assumed that stem cells acquire the third mutation and di!erentiated cells can only
accumulate the self-renewal mutation if their maturity is less than a = 0.5 weeks.
The parameters used for this simulation are listed in the Mutated Value (2) column
of Table 8.2.
Based on these assumptions and parameter values, the model predicts that blood
cellularity is doubled in 63.7 years and tissue is composed of 5% leukemic blasts in
70.1 years. It is hypothesized that diagnosis would occur some time in this time
frame. The accelerated phase begins at 71.7 years, followed by the blast phase at
73.5 years. Therefore, it takes an estimated 3.4 to 10 years from the time of diagnosis
for disease to develop into the blast phase. The first mutated di!erentiating stem
cells are formed within weeks, but it is the emergence of the two-mutation stem cell
that truly marks disease onset. Mutated di!erentiating cells continue to mature and
eventually die, but this clone is sustained once mutated stem cells form. The first
stem cell with two mutations is formed in 58.1 years. Six years later, cells with
two mutations dominate the system, which correlates with scientific observations
that estimate Ph-positive cells displace normal hematopoiesis in approximately eight
years [47].
Even though stem cells may acquire the third mutation in this simulation, cancer
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stem cells do not emerge from the stem cell population, which is quite di!erent from
results of the previous section. Stem cells with two mutations have an increased
rate of genetic instability and increased survival expressed through a diminished
probability of apoptosis, but proliferative behavior of stem cells is unaltered. As a
result, stem cells with two mutations have a slight increase of fitness in comparison
to normal stem cells, but the mutated clone does not overtake normal hematopoietic
stem cells. In fact, when 5% of blasts are detected in the blood, only 75 mutated
stem cells exist and all express two mutations. The number of mutated stem cells
increases to 246 by the time blast phase is diagnosed, but all of these only express two
mutations. It has been suggested that non-mutated cells are more frequent in less
mature cell populations than fully di!erentiated cells [48]. The model predicts that
less than one percent of stem cells are Ph-positive throughout disease progression,
even though mutated progeny overtake normal granulopoiesis.
The model predicts hypercellularity results from extra rounds of division in mu-
tated progenitors. Furthermore, each subsequent division compounds on the previous
so that the e!ects are more apparent downstream in the lineage, particularly in the
early stages of disease. Figure 8.8 records the percentage of cells that are proliferat-
ing and those that have completed divisions at four distinct times during progression:
the times at which (A) blood exceeds normal cell counts, (B) 5% of cells are blasts,
(C) the accelerated phase begins, and (D) the blast phase begins. As cells acquire
self-renewal capabilities and the blast population expands, hypercellularity of imma-
ture cells is more noticeable. This prediction is consistent with the observation that
the suppression of normal hematopoiesis by CML cells is more prominent in cells of
greater maturity [48]. Furthermore, the blast population accounts for an increasing






























Figure 8.8: Immature cells increase in frequency as disease progresses. Proliferating
cells include stem cells, myeloblasts, promyelocytes, myelocytes, and blasts. Non-
proliferating cells are those that have completed the final division. The blast column
shows what percentage of proliferating cells are blast cells. (A) The time at which cells
in the blood exceeds normal counts. (B) The time at which five percent of cells are
blasts. (C) The start of the accelerated phase. (D) The start of the blast phase.
proliferative advantage enables additional progenitor divisions, model simulations
closely correlate with recorded diagnosis times and reflect evolving tissue dynamics
commonly observed in CML.
BCR-ABL Alone is Inadequate for Malignancy
Lastly, model simulations are used to confirm that the BCR-ABL mutation is
insu"cient to generate malignancy. Suppose that stem and di!erentiating cells ac-
quire two mutations: the BCR-ABL mutation and another mutation that enables
increased fitness due to BCR-ABL. In this case, progenitors do not acquire stem-
cell like properties, in particular, the ability to self-renew and inhibit di!erentiation.
Two cases are considered. In the first case, stem and di!erentiating cells with two
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mutations have an increased rate of proliferation and a decreased rate of apoptosis.
In the second, it is assumed that BCR-ABL increases survival of all cells, which
enables additional divisions in progenitors and decreases the probability of apoptosis
in stem cells.
The model predicts that hypercellularity ensues from BCR-ABL, but is insu"cient
to promote malignancy. In this simulation, no cells exhibit deregulated self-renewal.
Under the assumption that BCR-ABL does not inhibit the mechanisms governing
stem-cell self-renewal, the total number of stem cells is maintained by the niche, as
shown in Figure 8.9A and C. In Figure 8.9B and D, it is evident that added divisions
increase the total number of di!erentiating cells, but because these cells do not ac-
quire the ability to self-renew, they reach full maturity and eventually die. Therefore,
there is no long-term expansion of mutated cells, so the model predictions concur
with the widely accepted belief that deregulated self-renewal is the key mutation
that drives malignancy and advances disease progression in CML. It should be noted
that fatality could result depending on the magnitude of cell increase, but due to the
success of treating BCR-ABL-expressing cells with the drug imatinib, it is theorized
that this type of hypercellularity could be treated, even if never fully eradicated.
It is hypothesized that expansion of BCR-ABL-expressing cells is due to selective
advantage of Ph-positive stem cells. The Ph chromosome has been detected in various
lineages of hematopoietic stem cells, suggesting that this mutation occurs at the stem-
cell level [59, 103]. In order to determine if hypercellularity results when mutations
only occur in di!erentiating progeny, suppose the stem-cell mutation rate is zero.
The model predicts that BCR-ABL-expressing cells do form as a result of progenitor
mutations, but in the absence of a self-renewing mutated source, these mutated cells
reach full maturity and die so that mutated cells comprise no more than 0.001% of
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the overall tissue, as demonstrated by the dashed line comparisons in Figure 8.9.
Therefore, unless BCR-ABL is able to impart some capacity of self-renewal, disease
does not form if this mutation does not occur at the stem-cell level.
Another potential way in which BCR-ABL could lead to life-threatening disease
is if hypercellularity forces immature cells from the marrow into the blood before
they are terminally di!erentiated. This could result in an insu"cient number of
di!erentiated cells that are needed to perform specific tasks or could problematically
increase blood density. Ph-positive cells do not bind to stromal cells as well as
Ph-negative cells, so it is not unreasonable to assume that the mobilization of cells
with two mutations increases as the bone marrow cavity is filled. There are various
ways in which this could be addressed mathematically in the model. To illustrate
one possibility, suppose that the mobilization rate of cells with two mutations, -2(a)
shifts up by G, where G depends on the fullness of the bone marrow at that time.
Since normal bone marrow cell counts range from 5% 1011 to 1.5% 1012 cells of the
granulocytic lineage, suppose that the marrow capacity is approximately 1013. As
an example, consider G = (W (t)1013 , where W (t) is the total number of cells in the bone
marrow at time t, and + is the factor that determines how much mobilization increases
in mutated cells. Suppose for simplicity that + = 1. At homeostasis, G = 0.08, which
increases the mobilization of BCR-ABL expressing cells by approximately 2% more
than the rate of non-mutated cells. Obviously, mobility could be increased more with
a greater value for +, but this is su"cient for this illustration.
As time progresses and the marrow fills, G increases, which increases the rate
at which cells mobilize into the blood. Whereas non-mutated cells have a negligible
mobilization rate until they reach full maturity, cells with two mutations can mobilize





























































































Figure 8.9: BCR-ABL alone causes hypercellularity but not malignancy. (A)-(B) The
stem- and di!erentiating-cell populations when BCR-ABL increases the rate of pro-
liferation. Solid lines show the in which stem cells acquire mutations, while dashed
lines show what happens when stem cells do not mutate. (C)-(D) Tissue dynamics
when BCR-ABL increases the survival of progenitors, thereby increasing the number of
permitted divisions.
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Consequently, immature mutated cells are released into the blood before they are
fully di!erentiated. Over time, as mutated cells expand and overcrowd the bone
marrow, more and more immature cells accumulate in the blood, which is depicted
in Figure 8.10. The healthy maturity-distribution of cells in homeostasis is shown
in Figure 8.10A. The blood consists of fully mature cells and the majority of bone
marrow cells are in the final stages of di!erentiation. Figure 8.10B plots the maturity
distribution in 35 years, which is not significantly altererd. However, by 70 years,
hypercellularity is accompanied by the appearance of immature cells in the blood,
as demonstrated in the maturity distribution of Figure 8.10C. As time progresses to
100 years, more immature cells are released into the blood, distorting the healthy
distribution even further, which is finally shown in Figure 8.10D.
This illustration suggests that premature mobilization alters the maturity-distribution
of di!erentiating cells in both the bone marrow and the blood. However, in this sim-
ulation, less than 1% of blood cells were in the myeloblast phase. Because BCR-ABL
does not inhibit di!erentiation, fully mature cells are abundant in the system as well,
and this tissue remains in what would be classified as the chronic phase of CML. This
implies that although deregulated mobilization may occur during the progression of
CML due to overcrowding in the bone marrow, another mutation is needed that
promotes self-renewal in progenitors if the percentage of blasts is to significantly
increase.
8.2.4 Discussion
The results of this section demonstrate that a maturity-structured model incor-
porating regulatory mechanisms provides a mathematical framework that accurately
captures the growth dynamics involved in CML. In particular, the maturity structure
facilitates the incorporation of maturity-dependent mutations, such as the acquisition
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Figure 8.10: The maturity distribution of cells in the bone marrow and blood changes
as a result of premature cell release due to bone marrow hypercellularity.
(A) The initial healthy distribution of cells. (B) At 60 years, there is little change in
the maturity distribution of cells in the bone marrow and blood. (C) At 70 years, cells
with two mutations surpass non-mutated cells in both the bone marrow and the blood
and immature cells appear in the blood as they are forced out of the bone marrow.
(D) At 80 years, more mutated cells are in the blood than the bone marrow due to
crowding. Furthermore, many cells have been released prematurely from the bone
marrow into the blood.
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of self-renewal capability in early progenitors, and is useful in simulating the accu-
mulation of immature blast cells that promote disease progression. Although CML
is better characterized than many other forms of cancer, there are still unanswered
questions, and model predictions were made to address these issues.
It is believed that BCR-ABL endows cells with a proliferative advantage, though
there is disagreement in how it is conveyed. Recent experimental data recorded that
BCR-ABL-expressing cells had an increased rate of division in comparison to normal
counterparts [125]. The other opinion is that progenitors with BCR-ABL do not
divide faster but can complete extra rounds of division [19, 27, 48, 122]. The model
predicts that both cases are feasible, though the former requires certain conditions.
If BCR-ABL acts to increase the proliferation rate, then it cannot merely act in
di!erentiating cells. That is, if the rate of division is increases in progenitors but not
stem cells, then the resulting dynamics do not reflect those of CML.
While both scenarios generate CML-like diseases, the contrasts in tissue dynamics
imply that the second more accurately portrays CML. In particular, doubling the
proliferation rate causes mutated stem cells to displace healthy stem cells, which
may not be consistent with scientific observations. For instance, when the disease
is in chronic phase, with blasts comprising only 1% of the bone marrow or blood,
Ph-positive stem cells outnumber Ph-negative cells three to one. This does not agree
with the belief that a small number of BCR-ABL expressing stem cells are responsible
for initiating the chronic phase [103, 48]. However, it cannot be discounted that
an increased rate of proliferation does cause hypercellularity in di!erentiating cells
expressing BCR-ABL, which is often the indicator of a myeloproliferative disorder,
such as CML.
Several parameters influence model predictions for the time it takes to develop
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CML and progress to blast phase. In the case where the rate of proliferation is
increased, the magnitude of change a!ects the time in which normal granulopoiesis
is displaced and determines the amount of hypercellularity, which is due to quickened
rounds of stem-cell division. In the case where increased survival enables additional
progenitor divisions, the degree of expansion in the mutated clone depends on how
many extra divisions are completed. In both cases, the net rate of growth in the
blast population controls the rate at which the disease progresses from chronic to
blast phase. If the blast population expands faster than Ph-positive di!erentiating
cells, then blasts are the cause of hypercellularity and the resulting disease is more
aggressive. In addition, the model predicts that the blast population grows more
quickly when cells of all maturity are capable of acquiring self-renewal capability.
Finally, model predictions agree with the the general consensus that BCR-ABL
alone is insu"cient to cause malignancy. Assuming that BCR-ABL does not com-
pletely transform the mechanisms governing stem cell division or enable self-renewal
in progenitors, there is no cell population in which self-renewal is deregulated to al-
low unlimited expansion. Furthermore, model results suggest the mutation creating
BCR-ABL originates in stem cells, otherwise, there is no expansion of Ph-positive
cells.
8.3 Conclusions
The research of this dissertation is culminated in the mathematical models of
tissue homeostasis and mutation acquisition that are presented in this chapter. Ma-
turity structure captures the dynamics of tissue cells of all maturity-levels, namely,
stem cells, progenitors, and di!erentiated cells. Regulatory mechanisms governing
stem-cell division adapt to promote or inhibit self-renewal and di!erentiation, which
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mediates homeostasis in healthy tissue or can contribute to malignancy when erro-
neously transformed. Lastly, the sequential acquisition of somatic mutations allows
investigation of the pathways that contribute in tumorigenesis. To our knowledge,
this is the first mathematical model that incorporates all of these aspects in its
framework.
In this chapter, the developed mathematical model was specifically applied to
simulate Chronic Myelogenous Leukemia in order to demonstrate the model’s poten-
tial contributions to the scientific community. In particular, the general framework
of this model can be utilized to investigate mutation acquisition in any hierarchi-
cally structured tissue. By using appropriate parameters for the tissue in question,
it is possible to predict the emergence of cancer stem cells, quantify cellularity, and
determine tissue composition. Although many details regarding cancer stem cells
remain unknown, the model provides a useful tool for predicting tissue dynamics in




Several factors make it di"cult to study human cancers in vivo. For example, it is
particularly challenging to investigate the pathways that lead to cancer. Mutations
are often identified in cancer cells long after a patient has developed cancer. As a
result, the sequential acquisition of mutations initiating tumorigenesis is tough to
accurately determine. Furthermore, tumors are composed with cells of di!erent phe-
notypes, even among patients diagnosed with the same type of cancer. Consequently,
it is impossible to generate a prototype that characterizes all tumors. In addition to
these di"culties, there are also experimental limitations to overcome. For instance,
human stem cells are not easily isolated for experimental study, particularly those
in solid tissues. Since various forms of cancer are believed to originate in mutated
stem cells, the inability to monitor stem cells over long periods is an obstacle that
prevents further understanding of how these cells behave.
Although many mathematical models of tumorigenesis have generated insightful
conclusions pertaining to cancer dynamics, none, to our knowledge, have investi-
gated mutation acquisition within the confines of a hierarchically structured tissue
governed by regulatory mechanisms. The modeling approach used in this dissertation
addresses this need and has several novel features. First, it accurately captures the
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unique dynamics of heterogeneous cellular populations, as opposed to other models
that simulate tumor growth in homogeneous tissues. Second, it follows the chrono-
logical order in which mutations accumulate and can predict which sequences initiate
cancer fastest under various assumptions. Third, it incorporates all three modes of
stem-cell division while also including governing mechanisms that mediate homeosta-
sis in healthy tissue and contribute to malignancy when altered.
The presented mathematical model provides a general framework that can be em-
ployed in future cancer investigations. The explicit consideration of tissue hierarchy
reveals useful insight into tumor composition and heterogeneity. As a result, the in-
corporation of maturity structure is an important feature that provides more detailed
and comprehensive information concerning cancer growth in hierarchical tissues. In
addition, the inclusion of regulatory mechanisms more accurately models tissue in
homeostasis. With governing mechanisms intact, mutation does not necessarily re-
sult in exponential growth, a nuance that could be missed in a model that does not
incorporate these regulating factors.
The battle against cancer continues, but there are various ways in which this
modeling approach can supplement experimental research. Two of the obstacles
in cancer research are determining the order in which mutations are acquired and
establishing which transformations are most tumorigenic. If certain mutations are
known to occur in cancer cells of a particular tissue, model simulations of potential
pathways can be compared and contrasted with scientific data in order to predict
which sequences generate the type of tumor that is clinically observed. Moreover,
the model may be used to test hypotheses concerning the cell of origin for specific
types of mutations.
Model simulations can also predict the in vivo dynamics of tumor growth based on
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experimental data. This could benefit clinical research in several ways. If it is known
that a current treatment regimen specifically targets cells of a particular phenotype
but not others, then analysis of the tumor composition may dictate whether that
specific treatment is appropriate. For instance, if the tissue is primarily composed
of mutated cells that are known to respond to chemotherapy, then treatment may
successfully decrease the tumor and prolong survival. On the on the other hand,
if the tissue is dominated by mutated cells that will not be targeted, then the ad-
ministration of chemotherapy will be futile, and may even cause greater damage by
causing unnecessary toxicity to any healthy cells that may be in the tissue.
There are various directions for future research. The most immediate is to incor-
porate treatment and investigate the e!ects on tumor burden and composition. In
particular, imatinib is the first-line of treatment for CML patients in chronic phase.
This drug specifically kills cells expressing BCR-ABL, which makes it successful in
decreasing hypercellarity. Once patients discontinue therapy, however, disease re-
emerges, thereby suggesting that stem cells expressing BCR-ABL are not e!ectively
targeted [83]. A maturity-structured mathematical model can predict response to
this treatment and determine the maturity-distribution persistent cells. In addi-
tion, the development of drug resistance can be simulated, which may be of clinical
assistance.
Since many current methods of chemotherapy are dependent on the cycling status
of cells, it may be appropriate to segregate cycling and quiescent stem cells when
modeling treatment. Stem-cell quiescence is problematic because it prevents mu-
tated cells from being targeted. It would be interesting to examine the composition
of cancer stem cell population to determine the proportions that are quiescent ver-
sus cycling. If the majority are quiescent, this may suggest that cell-cycle specific
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drugs will not e!ectively eliminate cancer stem cells, and other forms of treatment
should be considered. Furthermore, the e!ects of therapies that promote stem-cell
di!erentiation could be investigated to determine if this method of treatment can
successfully eradicate cancer stem cells without sacrificing healthy tissue.
In studying mutation acquisition in this dissertation, various sequential mutation
pathways were considered, but not simultaneously in the same tissue. In reality,
tissue cells may accumulate various mutations concurrently. For instance, three
mutations were previously discussed, namely D, G, and R, that a!ected apoptosis,
genetic instability, and proliferation, respectively. Suppose tissue cells could acquire
any of the mutations at any time. One cell may first acquire G, while another first
acquires D. The cell with G could then acquire either D or R, whereas the cell with
D could acquire G or R, and so forth. All of these clones would co-exist and compete
with each other, which may impact tumor composition and disease progression.
The general framework of the maturity-structured mathematical model could eas-
ily be applied to any type of cancer that evolves in hierarchical tissue. Further com-
plexity could be added by incorporating space variables when modeling solid tumors.
The location of cells within the tissue may also influence cellular behavior, particu-
larly for stem cells in the niche. For example, in the colon, stem cells reside in the
base of the crypt, whereas progenitors and di!erentiated cells rise to the top as they
di!erentiate. The inclusion of a space variable would allow one to determine where
mutated cells are within the colon crypt. Additionally, the incorporation of space to
simulate tumor masses, such as lumps found in the breast, may enable predictions
for tumor aggressiveness, based on the location of cancer stem cells within the mass.
The modeling results presented in this dissertation highlight potential areas of fur-
ther research for experimentalists. For instance, even for the well studied hematopoi-
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etic system, there is a wide range of suggested values that can be used for model
parameters. Better quantification of stem-cell kinetics will improve the accuracy of
model predictions concerning the time required for cancer stem cell emergence and
disease progression. Due to the significance of unbalanced symmetric self-renewal
and genetic instability in promoting tumorigenesis, it would also be useful to classify
any one-hit mutations that advantageously transform cells.
The unique features of the presented mathematical models, particularly the inclu-
sion of regulatory mechanisms and maturity structure, have enabled investigation of
various aspects of tumorigenesis, which in turn has generated additional questions.
For example, in simulating the dynamics of Chronic Myelogenous Leukemia, model
results suggest that under certain assumptions, BCR-ABL may impart advantage
di!erently in stem and di!erentiating cells. In order to e!ectively treat this disease,
it will be important to determine if BCR-ABL a!ects stem, progenitor, and di!eren-
tiated cells in the same manner. In addition, model results predict that the extent to
which progenitors and downstream progeny acquire self-renewal capability influences
the tempo of disease progression. Consequently, it would be of great interest to de-
termine the extent to which progenitors can limitlessly self-renew. For example, how
many mutations, if any, must first be acquired in progenitors before they have the
ability to stop maturation? Is there a threshold maturity after which di!erentiated
cells are incapable of reacquiring stem cell properties?
Unfortunately, at this time there is relatively little quantified data of cancer stem
cells for several reasons. In general, stem cells are di"cult to identify, isolate and
maintain in vitro. Furthermore, it is hard to monitor them in vivo because they are
rare within the tissue and reside in stem-cell niches that o!er protection. There has
been some success in studying malignant cells of the hematopoietic system due to
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the relative ease of accessing blood and bone marrow. Solid cancer stem cells, on
the other hand, are particularly challenging to study in vivo, and di"cult to monitor
in vitro due to the di"culty of experimentally reconstructing the niche. As more
discoveries are made and cancer stem cells are better understood, the mathematical
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